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Abstract 
Brief i ntroduction: There a re l imited studies on CYP1A2 and NAT2 polymorphisms 
among Emirat is .  Aims:  This study aims to determ ine CYP1A2 and NA T2 a l le les and 
genotypes and corre late these genotypes with caffeine metabol ism phenotypes 
among Emi ratis. Methods: After obta in ing informed consent, five hundred and 
eighty one non-smoker subjects were g iven 300ml of caffeinated soft d rink and were 
asked to provide a buccal swab and a u rine sample two hours later. TaqMan Real 
Time PCR, PCR-RFLP,  DNA sequencing were performed to determine CYP1A2 
and NA T2 al le les and genotypes. Phenotyping was carried out by analysing the 
caffeine metabol ites us ing H PLC analysis . Resu lts : We found that 1.4%, 16.3% and 
82 . 3 %  of the recru ited subjects were s low, intermediate and rapid CYP 1 A2 
metabol isers, respective ly .  Only 1.4% of the subjects were homozygotes for 
CYP1A2 mutant a l le les whi le 16.1 % were heterozygotes and 82 . 5 %  were 
homozygotes for the CYP1A2 wild type genotype . Therefore, the frequency of the 
wild type genotype CYP1A2*1A1*1A was 0 .82 5  fol lowed by CYP1A2*1A/*1C and 
CYP1A2*1A1*1K, with frequencies of 0 . 1 02 and 0 . 058, respectively .  The degree of 
phenotype/genotype concordance was 8 1 .6%. The CYP1A2*1C/*1C and 
CYP1A2*31*3 genotypes showed the lowest phenotype status. With regards to 
NAT2, we found that 78 . 5%, 19.1 % and 2.4% of the subjects were slow, 
intermediate and rapid NAT2 acetylators, respectively ,  with 77.4% being 
homozygote or  heterozygote for NA T2 m utant a l le les and 18.4% and 4.2% were 
heterozygote and homozygote for the NA T2 wild type genotypes, respective ly .  The 
most common genotypes found were NA T2*581*78, NA T2*58/*6A, NA T2*78/*148 
and NAT2*4/*58 with frequencies of 0 .255, 0 . 1 35, 0 . 1 05 and 0 .09, respective ly .  The 
degree of phenotype/genotype concordance was equal  to 96. 2 %. The 
NA T2*6A/*6A NA T2*6A/*78 NA T2*78/*78 NA T2*5A/*58 and NA T2*5A/*5A , , , 
viii 
genotypes were found to be associated with the lowest 5-Acety lamino-6-
Formylamino-3-Methy luraci I/1 -Methylxanthine (AFMU/1 X) ratios. Sign ificant 
contri butions: The majority of the studied Emiratis are slow NAT2 acetylators with 
impl ications for the prescription of med ications that are metabol ised by this enzyme. 
In addition ,  a smal l  percentage of Emiratis have slow CYP 1 A2 enzyme activity 
which again should be taken into consideration when prescribing medications that 
are part ia l ly metabol ised by th is enzyme. I n  Em irati populat ion, the frequency of the 
CYP1A2*1A and NAT2*5 a l leles were the h ighest relative to other a l leles 
frequencies.  Moreover, I ndiv iduals who carried NA T2*6A/*6A, NA T2*6A/*7B, 
NAT2*7BI*7B, NAT2*5A/*5B, NAT2*5A/*5A, CYP1A2*1CI*1C or CYP1A2*3/*3 
genotypes mig ht be at h igh risk of toxicity with some drugs and some d iseases 
compared to others as these genotypes a re associated with the s lowest phenotype 
status. Consequent ly ,  genetic testing is recommended prior to prescribing 
medications that are large ly metabol ized by CYP 1 A2 or  NAT2. Gap fi l led: This is 
the first detai led study of CYP1 A2 and NA T2 al le les and genotypes among Emiratis .  
Keywords: Cytochrome P450-1 A2 (CYP1A2) polymorph isms, N-acetyltransferase-
2 (NAT2) polymorphisms, Emiratis genetics, drug metabol ism. 
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List of Glossary 
One of a pair  of genes that appear at a particu lar  location on a 
particu la r  chromosome and control the same characteristic, such 
as blood type or colour-bl indness. Al le les are a lso called 
a l le leomorphs.  
A restrict ion endonuclease enzyme that has specific restrictive 
cleavage s ites and detect mutation at (857G>A) site used to 
identified NA T2* 7  ( rs 1 79993 1 ) . 
A restrict ion endonuclease enzyme that has specific restrictive 
cleavage sites and detect mutations at (34 1 T>C) and (803A>G) 
sites used to identified NA T2*5 ( rs 1 80 1 280) and NA T2*12  (rs 
1 208) respective ly .  
A restrict ion endonuclease enzyme that has specific restrictive 
cleavage sites and detect mutation at (282C> T) site used to 
identified NA T2* 1 3  ( rs 1 04 1 983). 
The I U PAC "I nternational Un ion of Pure and Appl ied Chemistry" 
nomenclature system is a set of logical rules devised and used 
by organic chemists to circumvent problems caused by arbitrary 
nomenclature. Knowing these rules and g iven a structural 
formu la ,  one should be able to write a un ique name for every 
d ist inct compound. 
A restrict ion endonuclease enzyme that has specific restrictive 
cleavage sites and detect mutation at (48 1 C> T) s ite used to 
identified NA T2*1 1  ( rs 1 799929) .  
A restrict ion endonuclease enzyme that has specific restrictive 
cleavage sites and detect mutation at ( 1 9 1  G>A) site used to 
identified NA T2* 1 4  ( rs 1 80 1 279).  
Category g roups of enzymes that use n icoti nam ide adenine 
d inucleotide phosphate (NAOP+ and its reduced form, NAOPH) 
in  redox react ions. 
N atural variat ions i n  a gene, DNA sequence , or chromosome that 
have no adverse effects on the individual and occur with fa i rly 






It is the fluorescence of the reporter dye d ivided by the 
f luorescence of a passive reference dye. I t  is used for 
fluorescence measurement. 
The SOS software plots showed the results of the al le l ic 
d iscrim ination run on a scatter plot of Al lele 1 versus Allele 2 .  
Each we l l  of  the 96-wel l  p late is represented as an  individual 
point on the plot. 
A restrict ion endonuclease enzyme that has specific restrictive 
cleavage s ites and detect mutation at (590G>A) site used to 
identified NA T2*6 ( rs 1 799930) . 
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Chapter 1: Introduction 
1 . 1 Overv iew 
1 . 1 . 1 Backg round 
Drug metabol ism is  part o f  the xenobiotic metabolism processes that involve 
convert ing l ipophi l ic d rugs to more easi ly excretable hydrophi l ic products with each 
drug requ i ring a specific set of enzymes.  The reactions included in these processes 
are c l in ica l ly crucia l  in terms of optima l  therapeutic dose , drug toxicity , cancer 
chemotherapy and some pathogens drug res istance (Mizuno N et al 2003). 
Drug meta bol ism consists of three phases; phase I i nvolves certain enzymes 
which include main ly  the cytochrome P450 (CYP450) oxidases that act by adding 
reactive or polar g roups to the xenobiotic. Usual ly  the modified compound wi l l  be 
less active than the parent compound,  a lthough with some drugs this convers ion 
forms the more pharmacolog ica l ly active agents. In some cases the modified 
com pound can be toxic, teratogenic or even carcinogenic (Meyer JM and Rodvold 
KA 1 996).  These modified compounds will further undergo conjugation process by 
transferase enzymes such as N-acetyltransferase to form polar compounds (phase 
I I  react ion) .  F ina l ly ,  the conjugated xenobiotics wi l l  be pumped out of the ce l l  by the 
phase I I I  efflux  xeno-transporters (F igure 1 )  (Homolya L et al 2003) . 
� Xenobiotic 
� Modifying 







Figure 1 :  The processes of drug metabol ism through phase I ,  I I  and I I I  
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Oxidation ,  reduct ion,  hydrolysis, cyclization ,  decycl ization , and addition of 
oxygen or removal of hydrogen ,  are carried out by m ixed function oxidases 
"CYP450 l ike CYP 1 A2" in phase I reaction (Akagah B et al  2008) .  Acetylation ,  
g lucuronidation ,  g lutathione conjugation ,  g lycine conjugation, methylation and 
su lphation are example of the pathways in  phase I I  reaction (Liston HL et a l  2001 ) .  
1 . 1 .2 Factors Infl uenc ing  Drug Metabol ism 
1 . 1 .2 . 1  Genetic Polymorphism 
Genetic variation is  an  essentia l  factor that contributes to  interindividual 
var iabi l ity in  d rug biotransformation .  Genetics variations, termed genetic 
polymorphism, a rise due to the presence of various combinations of a l leles at the 
same chromosoma l  locus and in  certa in  cases they are l inked to inherited traits. I n  
th is context, the ab i l ity t o  metabol ize a drug is a trait that is  largely determ ined 
genetica l ly .  The definit ion of a polymorphism in pharmacogenetics is the ava i labi l ity 
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of at least genetic 2 g roups with in a population with d istinctly d ifferent abi l it ies to 
metabol ize a d rug (Poulsen H E  and Loft S 1 992, Hedrick P 201 1 ) . 
Genetic d ifferences i n  d rug metabol ism are the result of genetica l ly  based 
variation i n  genes that code for enzymes and proteins responsible for the 
metabol ism or t ransport of the d rug . I n  polymorphisms, the genes show variation 
(contai n  abnormal pairs or mu lti ples or abnormal a l leles) leading to a ltered enzyme 
activity. D ifferences in enzyme activity occur at different rates accord ing to racial 
g roup.  Genetic changes may inactivate or reduce enzyme activity leading to an 
increase in  the level of the substrate d rug . Genetic dupl ication may increase enzyme 
activity result ing in lower levels of the substrate drug concentration .  (Poulsen HE 
and Loft S 1 992). 
Genetic polymorph isms of d rug-metabolizing enzymes g ive r ise to d istinct 
subgroups in  the population that d iffers in  their abi l ity to perform certain drug 
biotransformation react ions.  Polymorph isms are generated by mutations in the 
genes for these enzymes,  which cause decreased,  increased, or absent enzyme 
expression or activity by m ult iple molecular mechanisms. I ndividuals can be 
classified into three ma in  phenotypic g roups: extensive, intermed iate and poor 
metabol izers . Poor metabol izers often have higher risk of adverse effects including 
toxicity ( Meyer J M  and Rodvold KA 1 996). 
General ly, poor metabol izers have two defective a l leles (e.g . :  CYP206*41*5 
and C YP206*41*4) or combination of a l le les including one result ing in no enzyme 
(e.g . :  C YP206*5 and C YP206*4 deletion) .  
I ntermediate metabol izers on  the other hand,  a re heterozygous "having only 
one wi ld type a l le le and one defective a l le le" .  Normal  metabol izers carry wild type 
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a l leles (e.g . :  C YP206*11*1 ) .  Wild type a l leles encode genes for normal enzyme 
funct ion.  
The combination of a l leles encoding the gene determines the activity and 
effectiveness of the enzyme. The overal l  function of the enzyme is the phenotype of 
enzyme funct ion.  Phenotype is  defined as the observable physica l or biochemical 
characteristics determ ined by both genetic makeup and environmental influences 
(Meyer JM and Rodvold KA 1996). 
1 . 1 .2 .2  D iseases 
I nfect ion,  hepatitis ,  a lcohol ic l iver d isease, b i l iary cirrhosis, hepatocarcinoma 
and other forms of i mpaired l iver functions can lead to decreased drug 
biotransformation and the degree of impai rment is a function of the severity of the 
disease (Meyer J . M .  and Rodvold K.A. 1996). 
1 . 1 .2 .3 Age 
The abi l ity to metabol ize a d rug is also inf luenced by the age of the 
individual .  For examples,  very young infants do not have a mature enzyme system.  
I n  addition ,  decreases in  l iver mass,  hepatic enzyme activity and hepatic blood flow 
are more concomitant with the elderly (Meyer J M  and Rodvold KA 1996). 
1 . 1 .2 .4 Concomitant D rugs 
The  most common causes that affect drug biotransformation reactions are 
induction and i nh ib it ion of cytochrome P450 enzymes and thus agents that promote 
these processes have impact on d rug metabol ism as briefed in the fo l lowing 
sect ions (Meyer JM and Rodvold KA 1996). 
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A- I n d uction 
I nduction is an  increase i n  enzyme activity that is  associated with exposure 
to drugs. Th is  can occur when a drug a lters the biotransformation of co-administered 
drugs either by the same enzyme pathway or through an alternative pathway. 
However, inducers are usual ly specific for a g iven cytochrome P450 fami ly.  
Sometimes a d rug can induce its own biotransformation in  addit ion to that of other 
agents (Meyer JM and Rodvold KA 1 996). 
The main factors that affect the t ime course of enzyme induction onset and 
offset are p lasma concentrat ion of the inducer and the half-l ife of enzyme production 
and degradat ion .  The effect of induct ion can be seen with i n  the first few days of 
therapy (Oossing M .  et a l  1 983).  
B- In h ib it ion 
One of the most common mechanisms of inh ibit ion is  competitive inh ibition 
and occurs when two or more drugs compete for the same enzyme, which becomes 
c l in ical s ign ificant based on the relative concentrations of the d rugs,  as wel l  as, a 
variety of other patient specific factors (Meyer J M  and Rodvold KA 1 996) . 
The binding can be either i rreversible or reversible with the heme-binding 
s ite of the enzyme and inh ib its other d rugs from binding , which leads to loss of 
function that activity can only be restored by synthesis of new enzymes, which may 
take several days (Meyer JM and Rodvold KA 1 996). 
More complex mechanisms of inh ibit ion can occur where some drugs 
underg o  metabol ic activation by the cytochrome P450 system to inh ibitory products 
that cou ld resu l t  in re latively stable complexes with cytochrome P450. I n  th is 
scenario the cytochrome is held in  an  inactive state that can be cl in ica l ly s ign ificant. 
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Additional ly ,  the interaction involves narrow therapeutic d rugs which could increase 
the risk of toxicity (Meyer JM and Rodvold KA 1 996).  
U nl ike induction enzyme, inh ibit ion usual ly beg ins with the first dose of the 
inh ibitor. The inhibit ion reaches the maximum level when the inh ibitor reaches 
steady state (four to five ha lf- l ives) .  S imi lar ly, the t ime needed for the interaction to 
resolve depends on the ha lf- l ives of the d rugs involved (Dossing M et al 1 983). 
1 . 1 .3 Cytoch rome P450 (CYP450) 
Cytoch rome P450 enzymes a re composed of a large superfami ly of heme-
thio late proteins monooxygenases responsib le for the metabol ism of a wide variety 
of both exogenous and endogenous compounds (Degtyarenko KN 1 995) .  In 1 955, it 
was d iscovered in rat l iver microsomes and they were characterized by an intense 
absorption band at 450 nm in  the presence of carbon monoxide (Vercruysse A 
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F igure 2 :  S pectrum of  P450 
The cytochrome P450 (CYP) mixed function monooxygenases are located 
on the smooth endoplasmic reticu lum of ce l ls  throughout the body and are present 
7 
at h ighest concentrations in  the l iver (hepatocytes) and smal l  intestine. These 
enzymes are largely responsible for phase I xenobiotic metabol ism (Figure 3) ( Buck 
ML 1 997) . 
Cytochrome P450sp 
POB code : 3AWM 
Figure 3 :  Structure of cytochrome P450 
1 . 1 .3 . 1  Cytoch rome P450 Fam i ly 
Almost 1 2  cytochrome P450 gene fam i l ies have been reported in  the human 
genome. However, on ly 3 fam i l ies ,  the cytochrome P450 1 ,  2 and 3 ( C YP 1 ,  CYP2 
and C YP3) are involved in  the majority of d rugs biotransformations (Meyer JM and 
Rodvold KA 1 996). Based on am ino acid sequence s imi larities the enzymes are 
divided into fami l ies ,  and each fami ly  can be further segregated into subfami l ies, 
which are identified by capital letters fol lowing the fami ly designation (for example 
C YP 1  subfami ly  A is  designated C YP1A) .  The most important and cl in ical ly re levant 
cytochromes are C YP3A4, C YP206, C YP1A2, C YP2C9, C YP2C19 and C YP2E1 
(Martin J and Fay M 200 1 ) .  I n  tota l ,  humans have 57 genes and more than 
59 pseudogenes d ivided into 1 8  fami l ies of cytochrome P450 genes and 43 
subfami l ies as  shown in  table 1 (Ne lson DR et a l  2004) .  
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Table 1 - The summary of the cytochrome P450 prote in  fami l ies 
Family Members 
C YP1 3 subfami l ies, 3 genes, 
1 pseudogene 
C YP2 1 3  subfamil ies, 1 6  genes, 
16 pseudogenes 
C YP3 1 subfamily,  4 genes, 2 
pseudogenes 
C YP4 6 subfami l ies, 1 2  genes, 
1 0  pseudogenes 
CYP5 1 subfami ly ,  1 gene 
C YP7 2 subfami l ies, 2 genes 
C YP8 2 subfami l ies, 2 genes 
C YP1 1 2 subfamil ies,  3 genes 
C YP 1 7  1 subfamily,  1 gene 
C YP 1 9  1 subfamily,  1 gene 
C YP20 1 subfamily ,  1 gene 
CYP2 1 2 subfami l ies, 1 gene,  1 
pseudogene 
CYP24 1 subfamily, 1 gene 
C YP26 3 subfamil ies,  3 genes 
CYP27 3 subfamil ies,  3 genes 
C YP39 1 subfami ly ,  1 gene 
CYP46 1 subfamily, 1 gene 
C YP5 1 1 subfami ly, 1 gene, 3 
pseudogenes 
Gene Names 
C YP1 A 1 ,  C YP1A2, CYP 1 B 1  
C YP2A6, C YP2A 7, C YP2A 1 3, C YP2B6, CYP2C8, C 
YP2C9, CYP2C 1 8, CYP2C 1 9, CYP206, CYP2E1,  CY 
P2F 1 ,  CYP2J2, C YP2R1 ,  CYP2S1,  CYP2U1, CYP2 
W1 
CYP3A4, C YP3A5, CYP3A 7, CYP3A43 
C YP4A 1 1 , C YP4A22, C YP4B1 ,  CYP4F2, CYP4F3, C 
YP4F8, C YP4F1 1 ,  C YP4F 1 2, CYP4F22, CYP4 V2, 
C YP4X1 ,  C YP4Z1 
C YP5A 1 
C YP7A 1 ,  C YP7B 1 
CYP8A 1,  C YP8B 1 
C YP1 1 A 1 ,  C YP1 1 B 1 ,  C YP1 1 B2 
C YP1 7A 1  
CYP1 9A 1 
CYP20A 1 
C YP2 1A2 
CYP24A 1 
C YP26A 1,  CYP26B 1 ,  C YP26C1 
C YP27A 1, C YP27B 1,  CYP27C1 
C YP39A 1 
C YP46A 1 
CYP5 1A 1 
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1 . 1 .4 CYP1 A2 Isoform 
Each of the isoforms has wide substrate specificity, but each has its own 
specific substrate characteristics. These isoforms have differi ng regulatory 
mechanisms to control their activity. The regulatory mechanisms involve chemicals 
wh ich Induce or inh ibit the enzyme. For example, G YP1A2 metabolises some 
carcinogenic tars in cigarette smoke and is  induced by these chemicals .  Members of 
other G YP gene fami l ies are induced by drugs such as barbiturates, anticonvulsants 
and rifampicin (Mart in J and Fay M 200 1 ) . 
As wel l  as showing some degree of substrate selectivity, the i ndividual 
isoforms a lso show selectivity for inh ib itors .  For example, su lfaphenazole is a 
specific inh ibitor of G YP2G9 whereas qu in id ine is  a potent and selective inh ibitor of 
the isoform G YP2D6 (Mart in  J and Fay M 200 1 ) .  
Al l  isoforms wi l l  show some polymorphism . The frequency of these 
polymorph isms d iffers markedly between ethn ic  g roups.  These genetic d ifferences 
mean some people have an enzyme with reduced or no activity. Patients who are 
's low metabolisers' may have an  increased r isk of adverse reactions to a drug 
metabol ised by the affected enzyme (Mart in J and Fay M 200 1 ) .  
Variety of cytochrome P450 enzymes could be found i n  a s ingle hepatocyte . 
An indiv idual enzyme of cytochrome P450 may be able of metabolizing many 
d ifferent d rugs; however, a g iven drug may be primari ly  metabol ized by a sing le 
enzyme (Meyer J M  and Rodvold KA 1 996). 
Drug interact ions involving the cytochrome P450 system may not necessari ly 
be c l in ical ly sig n ificant. There are several factors that help predict whether or not a 
drug interaction wi l l  be c l in ical ly sig n ificant . These include pharmacokinetic, 
pharmacodynam ics, the wide variab i l ity of patient response to the same drug, 
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concomitant medical i l l ness and factors relating to the route and t iming of 
admin istration may a lso be important (Dresser GK et a l  2000). 
C ytoch rome P450 1 A2 ( C YP1A2),  is one of the cytochrome P450 mixed­
function oxidase system and is responsible for the metabol ism of xenobiotics in the 
body and involved i n  the synthesis of cholestero l ,  steroids and other l ipids (Nelson 
DR et a l  2004) .  
I n  humans ,  the CYP 1 A2 enzyme is  encoded by the CYP1A2 gene.  Th is 
cytochrome P450 enzyme is  local ized to the endoplasmic reticu lum and its 
expression is induced by some polycycl ic  aromatic hydrocarbons ( PAHs) , some of 
which are found in cigarette smoke. I t  is of cl in ica l importance due to the huge 
number  of d rug interactions associated with its induction and inh ib it ion .  Crucia l ly ,  i t 
is  ab le to metabol ize some PAHs to carcinogenic intermediates . Other xenobiotic 
substrates for this enzyme include caffe ine,  aflatoxin 8 1 , and acetaminophen 
(Nelson DR et a l  2004). 
Caffeine is considered to be a model substrate for th is enzyme due to its 
common consumption and safety. CYP 1 A2 enzyme activity may be a ltered by 
environmental factors inc luding cigarette smoking , charbroiled meat, vegetables 
such as cabbages, caul iflower, broccoli and cruciferous and a number of drugs 
i ncluding rifampicin,  phenobarbital and omeprazole (Runge 0 et a l  2000). 
1 . 1 .5 Acetylat ion 
I n  the I U PAC ( I nternat ional Un ion of  Pure and Applied Chemistry) 
nomenclature ,  acetylation or ethanoylat ion is "a chemical reaction that describes the 
adding of an acetyl funct ional group into a chemical compound". The process of 
acetylat ion is essential in prote in  formation,  drug biotransformation , regulation of 
deoxyribonucleic acid ( DNA) and other genetiC elements using h istone acetylation .  
1 1  
I n  addit ion ,  acetylat ion mediated b y  acetyltransferase enzymes has been shown to 
be i mportant i n  cancer and other human d iseases (Robert K et al 2003 and Zhao SF 
et a l .  2008). 
N -term inal  Acetylation 
N-term ina l  acetylation is one of the most common co-translat ional covalent 
mod ifications of prote ins in  eukaryotes and it is crucial for the regulation and 
function of d ifferent prote ins (Choudhary C et a l  2009, Fritz KS et a l  201 2) .  N­
term ina l  acetylation plays an  important role in  the synthesis, stabi l ity and local ization 
of proteins (Robert K et a l  2003 and Zhao S F  et a l  2008). About 85% of a l l  human 
proteins and 68% in yeast are acetylated at their No-terminus (Van DP et a l  201 1 ) . 
Acetylat ion is an essential route of xenobiotics metabolism involving an 
aromatic amine (R-NH2) or a hydrazine g roup (R-NH-NH2) ,  which are converted to 
aromatic amides (R-N H-COCH3)  and hydrazides (R-NH-N H-COCH3),  respectively 
as well as for a number of known carcinogens present in the d iet, cigarette smoke 
and the environment (Starheim K et al 20 1 2) .  
N-termina l  Acetylat ion is cata lyzed by a set of enzyme complexes, the N­
termina l  acetyltransferases (NATs) .  The reaction pathway is cata lyzed by two 
cytoplasmic acetyltransferases, N-acetyltransferase Type I (NA T 1 ) and N­
acetyltransferase Type \ I  (NAT2) .  These enzymes are located in the l iver, lung, 
spleen,  g astric m ucosa, red blood cel ls  (RBCs) and lymphocytes and the presence 
of co-factor acetyl coenzyme A is  essential (Liston H L  et al 200 1 ) .  NATs transfer an 
acetyl g roup from acety l-coenzyme A to the a-amino group of the first amino acid 
residue of the protein  as shown in figu re 4 (Starheim K et al 201 2) .  
Polypeptide 0 









N·terminal ace lytated Polypeptide 
Figure 4: I l lustrates the process of acetylation of proteins  
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The genes encodi ng the two NAT prote ins were first identified by Grant et  a l  
( 1 99 1 ) who showed that each component consists of an  intron less Open Read ing 
Frame (ORF) of 870 base pairs.  The two genes are 87% homologous and are 
located at 8p22, a chromosomal reg ion commonly de leted in some human cancers 
(Grant OM et a l  1 99 1 , Starhe im K et a l  201 2) .  
The acetylation polymorphisms in  NA T2 were observed in  tuberculosis 
patients who received isoniazid and reported toxic side effects . This has been 
d iscovered over 60 years ago (Hug hes H B  1 954). I n  fact ,  the polymorphism was 
named the " isoniazid acetylat ion polymorphism" for severa l years unti l  the 
sign ificance of polymorph isms in the metabol ism and disposit ion of other drugs and 
chemical carcinogens was ful ly appreciated (Weber VVW and Hein OW 1 985). 
1 .2 Statement of the Problem 
Cytochrome P450s (CYPs) are responsible for the metabol ism of a wide 
variety of cl in ica l ly, physiological ly and toxicolog ica l ly important compounds 
(Guengerich FP. 200 1 ). CYP fami l ies 1 ,  2 and 3 are responsible for 70-80% of 
phase I metabol ism of cl in ical ly used drugs (E ichelbaum M, et a l  2006) and are 
included in  the biotransformation of a huge number of xenobiotics. Biotransformation 
can turn in bioactivation of pre-carcinogens to carcinogenic and drugs to toxic 
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metabol ites or other toxic effects .  The majority of CYP-mediated xenobiotic 
metabol ism is carried out by polymorphic enzymes (Guengerich FP 2006) .  
Nevertheless, many reports showed that both genetic mutations and 
environmental factors influence the e l imination of d rugs that are metabol ized by 
CYP 1 A2 ( I ngelman-Sundberg M et a l  2007,  Zhou SF et a l  2008, Gunes A and Dahl  
ML 2008 and Zhou S F  et a l  2009a). 
P lasma levels of a drug can vary between individuals ( I ngelman-Sundberg M 
200 1 b and Cascorbi I 2006). I n  fact, genetic factors are one of the main factors that 
play important ro le in the d ifferences between indiv iduals in  the response and 
suscept ib i l ity to d rugs and xenobiotics ( I ngelman-Sundberg M 200 1 a). Variabi l ity 
among indiv iduals in drug metabol ism can resu lt in either reduce drug efficacies or 
i ncrease risk of side effects, which are phenomena that may influence drug therapy 
and development .  
Severa l adverse drug reactions reports re lated to specific drugs metabol ic 
pathways that are catalysed by polymorphic CYP enzymes have been reported. For 
that, the complete understanding of the nature of CYP polymorph isms is crucial to 
ga in  a comprehensive view of the inter- individual  d ifferences in chemical exposure, 
adverse drug effects and toxicity ( I ngelman-Sundberg M 2002) . 
CYP 1 A2 is an important enzyme that bioactivate a number of 
procarcinogens and some natura l  com pounds such as aristolochic acids. In  addit ion, 
th is enzyme also metabol izes a number of essential endogenous compounds (Wang 
8 and Zhou SF 2009) .  Several studies impl icated C YP1A2 polymorph isms in cancer 
suscept ib i l ity (Suzuki H ,  et a l  2008 and Altayl i  E ,  et al  2009) and other d iseases 
(Pruitt KD et al 20 1 2) .  
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On the other hand ,  some studies have recorded that there is a strong 
association between the acetylation status and the risk of many d iseases (Evan DA 
1 984, C lark DW 1 985, Evan DAP 1 993) .  
NAT enzymes polymorph isms have been suggested to be associated with 
risk of cancer, treatment responses and treatment resistance due to their roles in the 
activation or deactivation of xenobiotics. NA T2 enzymes have been impl icated in 
chemical carcinogenesis pathways. For instance, severa l studies had examined the 
widespread occurrence of NA T2 genes polymorph isms in  the population that have 
contributed to i ndiv idual  r isk of having disease (Weber WW and Hein D W. 1 985, 
Sim E et a l  2008, Stan ley LA and Sim E 2008, S im E et a l  201 2,  McDonagh EM et al  
20 1 4) .  
As  mentioned earl ier, NA T2 is a polymorphic enzyme that has  essential roles 
in the deactivation or activation of numerous xenobiotics in humans.  Based on the 
expression of its isoenzymes in the l iver, the genetic variants of NA T2 have been 
corre lated with d rug metabol ism,  response and toxicity. In addition ,  d rug metabol ic 
rates and suscept ib i l ity to d rug toxicity have varied according to acetylation 
phenotypes status which is  conferred by NA T2 genotypes. More studies are crucia l 
to help measure the c l in ical s ign ificant of NA T2 to determ ine the patient's dosage for 
maximum treatment efficacy and to avoid d rug toxicity (Weber WW and Hein 
DW 1 985, S im E et a l  2008, Stan ley LA and Sim E 2008, S im E et al  20 1 2 , 
McDonagh EM et a l  2 0 1 4) .  
U A E  Populat ion 
Woolhouse et a l  ( 1 997) who had conducted one study among Emiratis from 
the eastern reg ion of Abu Dhabi Emirate determined the Polymorphic N­
acetyltransferase (NA T2) g enotypes in  1 06 unre lated Emiratis by PCR-RFLP 
analysis .  This is the first study conducted to overview C YP1A2 and NA T2 
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polymorphism among nationwid e  Emi ratis sample and t o  target the determination of 
the a l leles and genotype frequencies and their correlation with the phenotyping in 
th is population .  
1 .3 Literatu re Review 
1 .3 . 1  CYP1 A2 
1 .3 . 1 . 1  Gene Local ization ,  Prote i n  Structu re and Express ion 
A complete understanding of  the gene location, structure, variation and 
expression of C YP1A2 is crucia l  to gain a comprehensive view of the inter-individual 
d ifferences in chemical exposure, adverse d rug effects and toxicity ( I ngelman­
Sundberg M 2002) .  
1 .3 . 1 . 1 . 1  The CYP1A2 Gene Fam i ly 
C YP1A2 (Cytochrome P450, Fami ly  1 ,  Subfami ly A, Polypeptide 2) is a 
protei n  cod ing gene. Th is gene encodes one of the cytochrome P450 superfami ly of 
enzymes. The transcript from th is gene includes four Alu sequences flanked by 
d i rect repeats in the 3' untranslated reg ion.  I n  l iver microsomes, CYP 1 A2 enzyme 
plays a role in an NADPH-dependent e lectron transport pathway. It oxid izes a 
number of structural ly unre lated compounds, including steroids, fatty acids, and 
xenobiotics. I t  is most active in  cata lyzing 2-hydroxylat ion.  Caffeine is metabol ized 
prima ri ly  by cytochrome C YP1 A2 in the l iver through an in it ia l  N3-demethylation.  
Moreover, it bioactivates the carcinogenic aromatic and heterocycl ic amines.  I t  
cata lyzes the N-hydroxylation of heterocycl ic amines and the O-deethylation of 
phenacet in ( Pru itt KD et a l  201 2) .  
The C YP1A2 gene is  p resented in  a cluster with CYP1A 1 and  C YP1B1  on 
chromosome 1 5  particu larly, in the long a rm reg ion q24. 1 .  (Zhou SF et a l .  2009a) 
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C YP1A2 is one of the major CYPs in human l iver (- 1 3-1 5%) compared to 2% with 
C YP206 (Shimada T et al  1 994) .  
Moreover, 60-fold i nterindividual  variat ion has  been reported in CYP 1 A2 
activity (Shimada T et al 1 994 and Nakagawa K et al 2002). Also, more than 1 5  and 
40-fold variation in  mRNA and prote in expression levels have been detected in  the 
human l iver ( I keya K et al  1 989 and Guengerich FP et al  1 999). 
The genetic component of variation in  CYP 1 A2 activity is a lmost 75% and 
the remain ing is  related to environmental factors, such as smoking ( induction) ,  oral 
contraceptive use in women ( inh ibition) , and others (Rasmussen BB et al  2002) .  
However, in  20 1 0  Klein et a l  provided a pathway-based analysis in human l iver 
samples which demonstrated that the genetic variation of CYP1 A2 activity 
accounted for 42, 38, and 33% of the catalytic activity, prote in expression , and 
m RNA levels ,  respective ly (K le in K et a l  201 0) .  In view of the predominant ro le of 
CYP 1 A2 in  activat ion of toxic xenobiotics compared with its metabolism of 
prescript ion drugs, there are a lot of epidemiological reports testing the ro le of 
variant C YP1A2, metabol ism of procarcinogens, and cancer  risk (Zhou SF et a l  
2009a) .  
1 .3 . 1 . 1 . 2  Reaction Mecha nism,  Structural Features and Functional 
Re leva nce of CYP1A2 
C YP1A2 and C YP1A 1 share a 5'-flanking reg ion of approximately 23 kb, 
which includes shared reg u latory elements, a lthough the genes are positioned back 
to back and transcription occurs in opposite d i rections ( Ueda R et al 2006). The 
CYP 1 A2 gene spans around 7 . 8  kb and comprising seven exons and six introns, the 
first exon 55-bp-long noncoding exon. C YP1 A2 is a 5 1 5-residue prote in with a 
molecular mass of 58 294 Oa (Zhou S F  et a l  2009a) .  
17 
The C YP1A 1 and C YP1A2 genes are spl it by a 23-kb segment that includes 
no open-reading frames (Corchero J et al  200 1 ) . Between C YP1A2 and CYP1A 1 ,  
exons 2 ,  4 ,  6 ,  a n d  particularly  5 are strik ingly maintained in  both nucleotides and 
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Figure 5 :  CYP 1 A2 gene structure (Sachse et al 1 999) 
Exon 
7 
Human CYP polymorph isms i nclude mutations in both non-cod ing regions 
(promoters . introns) and protein-cod ing sequences (exons) .  Mutations in non-coding 
reg ions may result in changes in the expression levels .  whereas mutations in 
protein-coding sequences may resu lt in alteration in the structure and catalytic 
properties of the enzyme (Zhou H. et a l 2004) .  
There are over 1 00 substrates reported for C YP1 A2. including many 
cl in ical ly sign ificant d rugs; such as clozapine. tacrine, procarcinogens (e.g .  
benzopyrene and aflatoxin b 1 ) .  and endogenous substrates (e .g .  steroids and 
arachidonic acid) (Zhou SF. et a l  2009a) . However, compared with other CYPs. 
there have been re lative ly few reports of pharmacogenetics (PGx) relationships. 
This can be explained by the smal l  number  of prescript ion drugs for which CYP1 A2 
is a metabol iz ing enzyme (9% compared with 37% for CYP3A4/5, 1 7% for CYP2C9. 
and 1 5% for CYP206).  I ndeed for several drugs ,  CYP 1 A2 is not the sole 
metabolizing enzyme.  nor is  it active at the rate- l imit ing step (Zanger UM. et al 
2008) .  In addit ion. there are u nder-reported variants that impact CYP 1 A2 activity. 
18 
1 .3 . 1 . 1 .3 CYP1 A2 Reg u lation 
C YP1A2 is markedly expressed in  l iver and is inducible in  the l iver, lung , 
pancreas , gastrointest inal  tract, and bra in  (Jorge-Nebert LF,  et al 201 0) .  Drug 
interactions have been reported many t imes in correlation with polymorphism of 
C YP1A2 that resu lt in a lteration of d rug response (Zhou SF ,  et al 2009a). Smoking, 
dietary cruciferous vegetables, polyamine hydrocarbons from gri l led meat, and 
omeprazole and other proton pump inh ibitors have been shown to increase C YP1A2 
activity (Gunes A and Dahl  M L  2008). Oral contraceptives, fluvoxamine,  and 
fl uoroqu inolone ant ib iot ics i nhibit C YP1 A2 expression (Gunes A and Dahl ML.  
2008) .  
S imi lar  to C YP1 A 1 and 1 8 1 ,  C YP1 A2 is primari ly  regulated by the aromatic 
hydrocarbon receptor (AhR) ,  a l igand-activated transcript ion factor and a basic hel ix­
loop-hel ix protein  belonging to the Per-Arnt-Sim fami ly of transcription factors (Wang 
B and Zhou SF et al 2009) .  
The expression regu lation of  C YP1A 111A2 is complex because gene 
transcription not only includes the AhR but also a number  of transcription factors, 
and is potentia l ly  inf luenced by the actions of transcript ional coactivators and 
corepressors . AhR-mediated signa l ing pathways show a first l ine of defense against 
potentia l ly  tox ic envi ronmental contaminants.  Whi le ,  metabol ic induction procedures 
by the AhR may produce h igh ly carcinogenic metabol ites , generating a l ink between 
AhR activation and chemica l carcinogenesis (Wang B and Zhou SF 2009) .  
1 .3 . 1 . 1 .4 CYP1 A2 Varia nts and its Molecular  Ep idemio logy 
CYP 1 A2 variants have been reported severa l t imes, with some impl ications 
and alteration in  d rug metabol ism (Brown ing SL et a l  201 0) .  
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More than,  1 77 s ing le-nucleotide polymorph isms (SNPs) of human CYP1A2 
upstream sequence have been determined (from which 41 variant a l leles (*1 B to 
*2 1 )  were recorded) ,  i l lustrating the a lterations on DNA sequence levels and in 
some cases their epidemiolog ical frequencies (Browning SL, et a l  201 0) .  Among the 
S N Ps located in seven exons, there are 22 non-synonymous that a lter amino acid 
sequence i n  exons 1 -7 of C YP1 A2 (F igure 6) (Zhou SF et al  2009a) .  
21 7G>,t. 
143.4A>T 
1 36!IC > f  
1 2 1 7G>" 
I 
' 2i f e  T J 
• UTFI 
373T>" 
Figure 6 :  Nonsynonymous S N Ps of the C YP1A2 gene 
The variabi l ity in  l iver expression of the C YP1 A2 gene reach almost 40% and 
60% variabi l ity in  caffe ine metabo l ism;  the most often probe drug used for C YP1A2 
(Gunes A and Dahl  ML .  2008). Only few variants could clearly expla in the 
phenotypic variab i l ity in  C YP1 A2 gene expression contrari ly it is much more with 
other d rug-metabol izing CYPs (Ghotbi R et al  2007) .  Ghotbi et al in 2007 observed a 
very low frequency of the coding sequence variants in  Caucasian and Asian 
populat ions (Ghotbi R et a l  2007).  Brown ing et a l  in 20 1 0  examined C YP1A2 
variation in  Eth iopians, suggested that because of the overa l l  greater incidence of 
variat ion,  includ ing some novel presumable deleterious variants, there could be 
some individua ls  freed from any CYP 1 A2 activity in th is population (Browning SL, et 
al 201 0) .  
] 
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Nevertheless ,  there are several S N Ps reported in the 5'-flanking reg ion and 
intron 1 of C YP1 A2 (Aitch ison KJ et al 2000) .  Aitch ison et al  (20 1 0) recorded several 
S N Ps in the 5'-flank ing region of C YP1A2, inc luding T-3594G and G-3598T. The T-
3594G S N P  has a 1 . 72% frequency in Caucasians (Aitch ison KJ et al  2000) .  In the 
5'-fl anking reg ion ,  identified S N Ps include G-3860A, G-3598T, T-3594G, G-31 1 3A, 
A-3053G, T-2847C, A-2808C, T-2667G, and -2467de1T in Japanese (Chida M et al 
1 999,  Soyama A, et a I 2005).  In intron 1 ,  S N Ps including T-739G, T-729G, G-733C, 
A-587G, C-367T, C-1 63A, a nd C-99T were recorded.  C-1 63A in  intron 1 is present 
with remarkable frequencies in most popu lat ions tested.  G-3860A, A-31 1 3G, _ 
2464de1T, T-739G, and C-729T were observed with d ifferent frequencies in various 
ethnic g roups (Soyama A et al 2005). 
Based on epidemio logica l  studies, it has been clearly observed that there is 
sign ificant ethn ic variabi l ity in the d istr ibution of common and rare CYP1A2 SNPs 
and haplotypes (Zhou SF et a l  2009a). The G-3860A ( * 1 C) SNP has less frequency 
in Caucasians than in Asians (0 . 2 1 -0 .25) (Chida M et al  1 999) .  The frequency of 
* 1 C  is sign ificantly lower in the Turk ish population (0 . 04) (B i lgen T et al  2008) than 
in  Japanese (0 . 2 1 ) (Chida M et a l  1 999) and Chinese (0 .25) ,  whereas it is a lmost 
equal  in the Turkish and Egyptian populat ions (0 .07) (Hamdy S I  et al 2003) . 
The frequency of the -2467de1T ( C YP1A2*10) al lele is lower in Caucasians 
compared with Asians and Africans .  The a l le l ic frequency of the *10 al lele is 4 . 1 -
7 .9% in  Caucasians  (Sachse C et a l  2003, Skarke C et a l  2005). However, the -
2467T deletion appeared at h igher level frequencies of 42. 0-43.8% in Japanese 
(Soyama A et al 2005, Chida M et al 1 999) and of 40% in Egyptians (Hamdy SI et al 
2003). In Turkish ,  the freq uency of C YP1 A2*1  0 is very h igh (92%) (B i lgen T et al 
2008) .  The -739T>G S N P  (a l le le C YP1A2*1E and C YP1A2*1 G) is frequent in 
Ethiopians (0 . 1 0) (Ak l i l lu  E et al 2003), Saudi  Arabians (0. 096) (Akl i l lu  E et al 2003), 
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and Japanese (0 .082) (Chida M et a l  1 999). However, Brit ish (Sachse C et a l  2003), 
German (Skarke C et a l  2005) , Spaniard (Akl i l lu  E et a l  2003), Turkish (B i lgen T et al  
2008), and Egyptian (Hamdy SI et a l  2003) populat ions have a low frequency for this 
al lele (0 .0044, 0 . 0 1 6 , 0 .01 7 , 0 . 0 1 , and 0 .03 ,  respectively) (Table 2). 
Table 2 :  Frequencies of important S N Ps in  Human C YP1A2 Gene among various 
populations (Nakaj ima M et al 1 999,  Ch ida M et al 1 999, Hamdy S I  et a l  2003, 
Tiwari AK et a l  2005, Bi lgen T et al 2008, Zhou SF et al  2009b) 
Ethnic group No. of G-383OA A..:I 1 1 3G -2467de1T T·739G ( 01E. °1G. C-729T C·163A ( 01F. T-5347C (01B. °1H. °1G. 
subjects (O'e) (01D) "1J. and *11<) ( °11<) .'J. and "11<) "3, '8, *15, and ·'6) 
Caucasian 
British 1 1 4 0.009 0 .048 0 004 0.333 0 382 
German 236 0.32 
Italian 9S 0 04 0.24 0.33 
Spanish 1 1 7  0.02 0.005 
Swedish 1 94 0 008 0.023 0. 1 93 0.023 0.003 0.286 
Swedish 1 , 1 70 0.29 
Turkish 1 1 0 0.04 0.92 0.01 0.27 
ASian 
Chinese 27 0.22 0.09 0.50 0 09 0.30 0.20 
Chinese 1 68 0.33 
Japanese 1 59 0.2 1 0 .42 0.08 0.61  
Japanese 250 0.24 0 03 0 . 44 0 .03 0.32 0 . 1 9  
Korean 1 50 0 .267 0.027 0.707 0.027 0 0.373 
Saudi Arabian 1 73 0. 1 0  0 04 
African 
Egyptian 2 1 2  0 07 0 . 40 0 .03 0.68 
Ethiopian 1 73 0 . 1 0  0.03 0 .40 
Tanzanian 71 0.51 
Tunisian 98 0.07 0.075 0. 1 3  0 .44 
Zimbabwean 1 43 0 .43 
The existence of a l le l ic  imba lance in  C YP1A2 expression and the importance 
of epigenetic genetic variation in impact ing C YP1A2 mRNA expression and enzyme 
activity in vitro us ing human l iver were a lso reported (Ghotbi R et al 2007) .  
Epigenetic and  environmental factors play a role in  identifying interindividual  and 
interethn ic variabi l ity in  C YP1 A2 expression and enzyme activity, apart from genetic 
variat ion.  
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Compared t o  other CYP enzymes, the understanding of the 
pharmacogenomic effects of C YP1 A2 variat ion is st i l l  at an early stage .  There is 
also the need to fu l ly evaluate all other variants before assign ing haplotypes 
(Soyama A et al 2005, Ghotbi R et a l  2007, Browning SL et al 201 0). 
I m portant Variants in CYP1A2 
The most frequent ly studied polymorphisms are G-3860A (al le le * 1  C) , _ 
2467deiT ( * 10) ,  T-739G ( *1 E) ,  and C-1 63A located in  intron 1 ( * 1 F) ,  which have 
been in it ia l ly  reported in a Japanese populat ion (Zhou SF et al 2009a) .  These 
polymorphic C YP1A2 a l le les present d ifferences in the promoter region and are 
associated with changed enzyme activity part icu larly ,  a l lele * 1 C, * 10,  * 1 F, and * 1 K 
(Zhou S F  et al 2009a). 
rs762551 , C YP1A2: C-1 63A 
This S N P  is the most wel l-studied genetic variant in C YP1A2. It is the sole 
variant of the C YP1A2*1  F haplotype and found with other variants in several 
haplotypes (CYP1A2*1J, C YP1A2*1  K, C YP1A2*21 ,  and others that have not been 
confi rmed). I t  is located in the intron between the noncoding exon 1 and exon 2 ,  
where the coding sequence begins and causes increase in  enzyme activity (Gunes 
A and Dahl ML 2008). The frequency of rs762551  :C>A varies widely with 
populat ions: the A a l le le (s low) frequencies range from 0 .3  to 0 .39 in Asians,  from 
0 .4  to 0 . 5 1  in B lacks or African Americans,  a nd from 0.29 to 0 .33 in Whites (Gunes 
A and Dahl  ML .  2008). 
rs206951 4, C YP1A2: G-3860A 
The * 1 C  haplotype conta ins G-3860A in  the 5'-flanking reg ion of CYP1A2, 
orig ina l ly  called G-2964A (Obase Y et a l  2003) .  
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I t  was in it ia l ly reported in  Japanese with a frequency of 23.3% (Nakajima M 
et a l  1 999) .  This a l le le showed decrease in  enzyme activity based on the 
measurement of the rate of caffeine 3-demethylation in Japanese smokers , that 
could be due to the decreased inducib i l ity and expression of the enzyme (Nakaj ima 
M et a l  1 999) .  
The C YP1A2*1C haplotype was found at frequencies of 7% in  Blacks or 
African Americans ,  at 6-25% i n  Asians ,  and at 0 .4-1 % in  Whites (Nakaj ima M et a l  
1 999,  Hamdy S I  et  a l  2003, Sachse C et a l  2003,  Tiwa ri AK et a l  2005,  Takata K et 
al 2006, Ojordjevic N et al 20 1 0) .  This variant was associated with a reduced rate of 
caffeine demethylation i n  Japanese smokers but not in non-smokers. The variant 
has changed a transcription factor b inding site in  the gene promoter; however the 
factor was not defined (Obase Y et al 2003). 
rs1 2720461 , C YP1A2: C-729T 
C YP1A2: C-729 T  is a lso cal led C YP1A2: C-730T. This variant was shown in 
vitro to affect b inding of an E-twenty s ix transcription factor (Akl i l lu  E et al  2003) . The 
*1 K haplotype was associated with 40% lower inducib i l ity in vitro, and non-smokers 
heterozygous for * 1 K  had s ign ificantly lower CYP 1 A2 activity compared with the wild 
type (Ak l i l lu  E et a l  2003) .  Alki l l u  et al  (2003) stated that this variant had lower 
i nducibi l ity with 2 ,3 ,7 ,8-tetrachlorod ibenzo-p-d ioxin in human hepatoma cel ls and 
may affect bioactivation and sensitivity to carcinogens. This could i l lustrate the lower 
caffeine metabol ism observed for the *1  K haplotype, which is the only haplotype that 
conta ins  th is variant .  
C YP1A2*1 K was reported to be ra re in  Swedes (0. 3%) and absent in 
Koreans (Ghotbi R et a l  2007) .  However, the effect of allele C YP1A2*1K could not 
be found in these popu lat ions . 
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Other important variants includes rs56276455,  5347T>C (exon 4 ,  causing 
Asp348Asn and the synonymous 5347T>G (Asn5 1 6Asn)) ,  rs725475 1 6, 2499A>T 
(exon 5 ,  leading to I le386Phe) and rs28399424, 5090G>T (exon 7, leading to 
Arg43 1 Trp) which represent al le le C YP1A2*3, CYP1A2*4 and C YP1A2*6, 
respective ly .  Al l  of them are associated with decreased gene expression and 
enzyme activity that has  been identified in the French population with frequency of 
0 . 5- 1 %  (Cheval ier 0 et a 1 200 1 , Al lorge 0 et a 1 2003, Zhou H et a I 2004) .  
Other C YP1A2 Variants 
C YP1A2*1J (C-1 63A; T-739G) and * 1 K  (C- 1 63A; T-739G; C-729T, a l l  
located i n  intron 1 )  have been in it ia l ly identified in  Ethiopian non-smokers (Akl i l lu  E 
et al 2003).  The T-739G had a frequency of 3 .2% in  Japanese; however, the C-729T 
S N P  was not reported in the Japanese population (Soyama A et al 2005). 
C YP1A2*2 (63C>G) ,  mutation that causes a Phe2 1 Leu substitut ion, which 
was in it ia l ly  identified in  one subject out of 1 57 Ch inese subjects with an a l lele 
frequency of 0 .32% (H uang JD et a l  1 999) . Its funct ional impact is unknown . The 
C YP1A2*2 a l le le was not found in  Brit ish (n = 1 1 4) (Sachse C et a l  2003) and Ita l ian 
populat ions (n = 500) (Pucci L et al  2007) .  The *5 haplotype entai ls 3496G>A in 
exon 6 resu lt ing in  Cys406Tyr (Zhou S F  et a l  2009a) .  
C YP1A2*7 (3533G>A) mutation at the spl ice donor site of intron 6 which has 
been reported in a 70-year-old patient who had very high plasma concentrations of 
clozapine when admin istered at normal dose. This SNP caused RNA spl icing defect 
and lead to a loss of CYP 1 A2 activity (Zhou S F  et al 2009a) . 
1 . 3 .1 . 1 .5 CYP1A2 1mportant  HapJotypes 
Almost 4 1  C YP1 A2 haplotypes have been publ ished on the 
Human 
Cytochrome P450 Al le le Nomenclature Committee home page
. Twenty four  
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haplotypes are related to  n ucieotides changes i n  the  non-coding region and 1 7  
haplotypes are related to nucieotides changes i n  the coding reg ion of the CYP1A2 
prote in .  
There a re several studies that  characterize gene polymorphisms in the non­
coding reg ion ,  however, on ly few reports describe non-synonymous protein 
polymorphisms.  M urayama N et a l  (2004),  Saito Y et al  (2005) and Zhou SF et al  
(2004) characterized most of the non-synonymous polymorphisms with a l im ited 
number  of substrates . 
A haplotype can refer to a combination of a l leles or a set of s ingle nucleotide 
polymorphisms (SNPs) .  This set of a l leles is located on one chromosome . Thus, the 
a l leles making up a haplotype can be located in different places on the same 
chromosome but they are inherited together. 
An a l le le is  one of two or  more forms of the DNA sequence of a particular 
gene. Sometimes, d ifferent DNA sequences (a l leles) may resu lt in d ifferent gene 
expression or  have the same result in  the expression of the gene . 
Many studies have focused on certa in a l leles as they alter the gene 
expression. This a lteration results in changing the cata lytic activity of the enzyme 
encoded by th is gene which in turn reflects i nter-individua l  d ifferences in the 
phenotype status. The most relevant a l le les are briefly described in the fol lowing 
section and l isted in table 3. 
CYP1A2*1A 
This is the wi ld-type a l le le to which al l  variants are compared to and it is 
associated with normal  gene expression. 
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CYP1A2*1F 
The *1 F haplotype has been reported i n  many studies with a changed 
phenotype (Ghotbi R et al 2007) .  This haplotype associated with increased gene 
expression wh ich in turn results in i ncreased enzyme activity . However, the 
phenotype effect is  seen only in the avai labi l ity of an inducer, such as smoking or 
heavy coffee consumption ( Djordjevic N et al 2008, Djordjevic N et al  201 0) .  
There are some confl icts in  the l iterature regard ing the designation of this 
haplotype ( I ngelman-Sundberg M et a l  2007) . The variant that defines this 
haplotype , C YP1A2: C-1 63A (rs762551 ) ,  has d ifferent frequencies in different 
populations and the assignment of major and minor al leles therefore varies. Most 
publ ications have l isted * 1  F as C>A ( I ngelman-Sundberg M et al  2007) ,  but others 
have A>C (Cornel is MC et al 2006). 
CYP1A2*1C 
The only s ing le-nucleotide polymorphism (SNP) for th is haplotype is G-
3860A ( rs206951 4) has been wel l-defined and a lso seen in the l iterature as G-
2964A (Obase Y et al 2003). This haplotype is associated with decreased gene 
expression .  
CYP1A2*1K 
There are three variants that define th is haplotype: T-739G (rs2069526) , C-
729T (rs1 2720461 )  and C- 1 63A (rs76255 1 ) . This a l lele was shown fi rstly in  
Ethiopians at  a frequency of  3% (n = 1 73), in  Spaniards at  a frequency of  0 .5% (n = 
1 1 7) ,  and in  Saudi  Arabians at 3 .6% (n = 1 36) (Akl i l lu  E et al 2003) . CYP1A2*1K 
a l le le has s ign ificantly reduced CYP 1 A2 enzyme activity in  non-smokers compared 
with *1A or *1F, using caffe ine as a probe substrate (Akl i l lu  E et aI 2003) . 
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This  haplotype has not been reported in  Japanese (n = 350) (Takata K et  al  
2006) and Koreans (n = 50) and occurs at a very low frequency in  Swedes (n = 1 93, 
0 . 3%) (Ghotbi R et a l  2007). 
CYP1A 2*3 
There are two variants that define this haplotype 2 1 1 6G>A and 5347T>C 
( rs56276455) .  This haplotype is associated with decreased enzyme activity 
(Cheva l ier D et al 200 1 , Zhou H et al 2004). 
C YP1A2*4 
There is one S N P  for th is haplotype 2499A>T (rs725475 1 6) .  This haplotype 
is associated with decreased enzyme activity (Cheval ier  D et a l  2001 , Zhou H et al 
2004) .  
CYP1A2*6 
There is one S N P  for th is haplotype 5090C>T (rs28399424) .  This haplotype 
is associated with decreased enzyme activity (Cheva l ier D et al  2001 , Zhou H et a l  
2004) .  
1 .3 . 1 . 1 .6 CYP1 A2 Al leles Nomenc latu reNa riant An notations 
Table 3 :  C YP 1  A2 a l le les,  their references SNPs and cata lytic activity based on the 
Human Cytochrome P450 Al le le Nomenclature Committee 
CYP1 A2 
Allele 
* 1 A  
* 1 C  





I ntron between the 
noncoding exon 1 and 
exon 2 
I ntron 1 region 
Exon 4 
N ucleotide C hange(s) and rs # 
Reference 
G-3860A (rs20695 1 4) 
C - 1 63A (rs76255 1 ) .  There is 
confusion about the definition of the 
CYP 1 A2 * 1  F al lele in the literature. 
C-729T (rs 1 2 72046 1 )  
2 1 1 6G>A (rs56276455) 










*4 Exon 5 2499A>T (rs725475 1 6) I Ie386Phe Decreased 
expression 
*6 E xon 7 5090C> T (rs28399424) Arg431 Trp Abolished 
expression 
1 .3 . 1 . 1 .7 CYP1A2 Genotype/Phenotype Relationsh i p  
Caffe ine i s  a methylxanthine natural ly avai lable in  some beverages and also 
considered as a pharmacological agent. Its main pharmacolog ical effect is as a 
central nervous system stimulant .  Caffe ine is natural ly occurring xanthine derivative 
l ike theobromine and the bronchodi lator theophyl l ine.  Caffeine biotransformation 
occurs in severa l steps involving hepatic cytochrome P450 1 A2 (CYP1 A2) (figure 7) .  
Caffeine is a lmost complete ly metabol ized with 3% or less being excreted 
unchanged i n  ur ine ( Begas E et al 2007, Marta K and Wadysawa DA 2008a) .  
The main route of metabol ism in  humans (70-80%) is via N-3 demethylation 
to paraxanth ine ( 1 ,7 -dimethylxanthine or 1 7X) (Begas E et a l  2007, Marta K and 
Wadysawa DA 2008a and Benowitz N L et al 1 995) .  This reaction is carried out by 
CYP 1 A2 in  the l iver (Begas E et al  2007) .  Experimental ly, human l iver microsomes 
estimate that N-1  demethylation to theobromine (3, 7-d imethylxanthine) and N-7 
demethylation to theophyl l ine (1 , 3-dimethylxanthine) accounts for approximately 7 to 
8% of caffe ine metabol ism for each (Marta K and Wadysawa DA 2008b). The 
remain ing 1 5% or less of caffeine undergoes C-8 hydroxylation to form 1 , 3 ,7-
tr imethyluric acid (F igure 7)  (Marta K and Wadysawa DA 2008b). 
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Figure 7 :  Schematic representation of caffe ine metabolites. CYP 1 A2 catalyzes the 
3-demethylation of caffe ine to paraxanth ine and NAT2 cata lyzes the acetylation of 
paraxanth in metabol ites to AMFU 
As d iscussed earl ier ,  CYP 1 A2 is responsible for more than 95% of the 
primary metabol ism of caffeine (Kalow W and Tang B K 1 993) .  Therefore caffeine is 
used as a probe drug for CYP 1 A2 activity with the relative ratios of ur inary 
metabol ites used as an ind icator of the fl ux through d ifferent parts of the pathway 
( Begas E et a l  2007) .  As we l l  as paraxanth ine ,  the major metabol ites of caffe ine in 
ur ine are 1 -methylxanthine (1 MX), 1 -methyluric acid ( 1  MU),  5-acetylamino-6-
formylamino-3-methyluraci l  (AFMU)  and 1 , 7 -dimethyluric acid ( 1 7MU) (Begas E et al 
2007) .  
Based on relative ratios of  ur inary metabolites, the  ratio of 
paraxanthine/caffeine ( 1 7MXl1 37MX) has been measured from plasma after 4 hours 
of caffeine consumption to compare C YP1A2 genetiC polymorph ism, enzyme activity 
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and the genotype-phenotype relationship i n  Sweden and Korean (Ghotbi R et a l  
2007) .  
The  ur inary molar ratio o f  ( 1 7MX + 1 7MU)  / 1 37MX, taken a t  4-5 h after 
caffeine ingestion ,  was identified from pharmacokinetic analyses as being better 
correlated for both NA T2 and CYP 1 A2 phenotyping (Butler MA et al 1 992) . 
Evaluat ion of caffe ine as an in  vivo probe for CYP 1 A2 using measurements 
in p lasma, sal iva,  and u rine have been reported by Carri l lo JA et al  (2000) where 
1 00 mg of oral caffe ine has been consumed by subject to estimates CYP1 A2 
activity. They reported that both plasma and sal iva total clearances of caffeine were 
h igh ly  corre lated with each other (Carr i l lo JA et al 2000). 
The ratio 1 7MXl1 37MX restricted to one sampl ing point taken 4 hours after 
dose, where h igh ly  corre lated in plasma and sal iva with the standard reference 
(Carr i l lo JA et al 2000) .  Moreover, the ratio (AFMU + 1 MU + 1 MX + 1 7MU + 
1 7MX)/1 37MX i n  a 0-24 hours u ri ne sampl ing showed the h ighest correlation with 
the standard reference . (Carr i l lo JA et al 2000) 
In conclusion they suggest the use of 1 7X1 1 37X ratio for plasma or sal iva, 
whereas (AFM U  + 1 U + 1 X + 1 7U + 1 7X)/ 1 37X ratio is the recommended one for 
ur ine samples through a sampl ing i nterval of at least 8 hours, start ing at t ime zero 
s ince caffe ine intake (Carri l lo JA et al 2000). 
1 .3 . 1 . 1 .8 C l in ica l  Impact, Drug Metabol ism and Su bstrate Specific ity of 
CYP1A2 Polymorph ism 
CYP 1 A2 i s  an  important enzyme 'together with CYP 1 A  1 and 1 B 1  that 
bioact ivates a number of procarcinogens including polycycl ic aromatic hydrocarbons 
(e . g . ,  benzo(a)pyrene) ,  heterocycl ic aromatic amines/amides (e .g .  2-amino- 1 -
methyl-6-phenyl imidazo (4 , 5-b)pyrid ine) ,  mycotoxins (e.g .  aflatoxin B( 1 ) )  and some 
3 1  
natural compounds such as aristolochic acids present in  severa l Chinese herbal 
medicines.  This enzyme also metabol izes a lot of essential endogenous compounds 
inc luding ret inols ,  melaton in ,  steroids,  uroporphyrinogen and arachidonic acids. 
(Wang B and Zhou SF 2009) 
Several studies have ind icated impl ications of C YP1A2 polymorph isms in 
cancer suscept ib i l ity, namely for pancreatic cancer  (Suzuki H et al  2008),  bladder 
cancer (Altayl i  E et a l  2009) and colorectal cancer (He X et al  201 4). 
Diseases associated with CYP 1 A2 include toxicity or absent response to 
clozapine and porphyria cutanea tarda (Pru itt KD et al 201 2) .  
Huge interindiv idual d ifferences in the e l imination of drugs that are 
metabolized by CYP 1 A2 have been reported, and referred to both genetic mutations 
and environmental factors ( I ngelman-Sundberg M et al 2007, Zhou SF et al  2008, 
Gunes A and Dahl  ML 2008 and Zhou SF et a l  2009b).  
Xenobiotic meta bol ism is varied widely between individuals. P lasma levels of 
a d rug can vary more than 1 000-fold between individuals upon the same drug 
dosage ( I ngelman-Sundberg M 200 1 b, Cascorbi I 2006). These differences can 
result from induct ion or inh ibit ion and genetic polymorph isms of metabolizing 
enzymes, or  from physiolog ica l ,  pathophysiological and environmental factors 
(Cascorbi I 2006). I n  fact, genetic factors are ind icated to be responsible for 20-40% 
of the d ifferences between individuals in the response and susceptibi l ity to drugs 
and xenobiotics ( I ngelman-Sundberg M 200 1 a). Variabi l ity among individuals in drug 
metabol ism can result in  decrease drug efficacies or undesirable toxic side effects. 
There are wide interind ividual d ifferences ( 1 0- to 200-fold) in CYP1 A2 (also 
cal led phenacet in O-deethylase) expression and activity (Gunes A and Dahl M
L 
2008) .  Approximately 1 5- and 40-fold interind ividual variations in CYP 1 A2
 mRNA 
3 2  
and prote in  expression levels have been reported i n  human l ivers ( Ikeya K e t  a l  
1 989) .  These observations ind icate a genetica l ly measured difference in constitutive 
and/or inducible C YP1 A2 gene expression .  Un imodal ,  bimodal ,  and trimodal 
d istri butions of CYP 1 A2 activity when determined by caffeine urinary metabolic 
ratios have been reported in d ifferent studies popu lations (Shimizu T et a l  1 991 ) .  
Pharmacogenetic studies on the  impact of common C YP1A2 polymorphisms 
on d rug clearance and response are sti l l  under investigation .  More well-designed 
studies are important to explore the genotype-phenotype re lationships of C YP1A2 
in terms of d rug clearance and response. Personal ized pharmacotherapy and 
ind ividual ized dosing of d rugs may requ i re incorporation of both genetic and 
environmental  factors .  
Many  c l in ical studies have been establ ished to  test the impact o f  CYP1A2 
polymorphisms on drug clearance and drug response. For example ,  Obase Y et al  
(2003) exam ined the effect of genetic polymorph isms in  the 5'-flanking region to 
intron 1 of the C YP1A2 gene on theophyl l ine metabol ism in Japanese asthmatic 
patients (Obase Y et a l  2003).  
Among asthmatic patients, theophyl l ine clearance was sign ificantly lower in 
patients with the polymorphism at site G-2964A whose genotype was G/A 
( intermediate) or AlA (slow) than in  those whose genotype was G/G (rapid) .  
Therapeutic drug monitori ng may  be  requ i red in patients with the A al lele a t  site 
2964 in the C YP1A2 gene,  due to low clearance level in those patients . Resistance 
to clozapine therapy has been reported in  smoking schizophrenic patients due to 
low plasma drug levels harboring the 1 63 C/C ( C YP1A2*1 F) genotype (Ozdemir  V 
et al 200 1 , Eap C B  et a l  2004) .  
Eap et al. (2004) recorded four smoking patients who d id not respond to 
clozapine therapy at  usua l  dosage and they observed that those individuals were 
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ultra-rapid metabol izers of C YP1 A2 carrying the *1  F al le le (Eap CB et al  2004). On 
the other hand,  h igher plasma concentrations of clozapine and its metabol ite N­
desmethylclozapine have been found in patients carry ing two CYP1A2 variants 
associated with reduced enzyme activity (-3860A, -2467del ,  - 1 63C, -739G, and/or -
729T) com pared with those with one or none (Melkersson KI et al 2007) .  
Subjects with C-1 63C or  C-1 63A genotype had lower plasma melatonin 
concentrations after admin istration of 6 mg melatonin compared with A- 1 63A 
carriers (Hartter  S ,  et al 2006). Another study in patients with rheumatoid arthritis 
(n = 1 05) found that the * I F haplotype (C- 1 63A) affected the risk for leflunomide­
induced organ toxicit ies ( Bohanec GP et a l  2008) .  Patients with A- 1 63A genotype 
had a 9 . 7  -fold h igher risk for overa l l  lefl unomide-induced toxicity compared with 
patients with the C YP1A2*1F CIA or C/C genotype ( Bohanec GP et a I 2008) .  
Porphyria cutanea tarda (PCT) is considered to be genetical ly predisposed 
to development of c l in ical ly overt d isease through mutations and polymorphisms in 
genes associated with known precipitating factors. Christiansen et a l .  (2000) 
elucidated that the frequency of the h igh ly inducible C/C (rapid) genotype at site C-
1 63A was increased in both fam i l ia l  a nd sporadic PCT. The authors presented that 
the C/C genotype was a susceptible factor for PCT (Christiansen et al  2000) . 
Paol in i  M et a l .  ( 1 999) demonstrated that corresponding high levels of CYPs 
in humans would predispose an indiv idual to cancer risk from the widely bioactivated 
tobacco-smoke procarcinogens. No association has been reported between 
CYP 1 A2 activity and sex a nd age based on Bebia Z et al (2004) in bioequivalence 
study when they determ ined to which extent age and sex influence CYP 
activity ( Bebia Z et a l  2004) .  
Acetaminophen as a n  effective analgesic and antipyretic agent, but  causes 
serious hepatic and rena l  toxicity at h ig h  doses by conversion of acetaminophen 
34 
to the toxic intermediate N-acetyl-p-benzoquinone imine (NAPQI)  through CYP1A2, 
C YP2E1,  and C YP3A4 (Sarich T et al 1 997). I n  add ition ,  using CYP 1 A2 enzyme 
inh ibitors, it may increase risk of toxicity of l idocaine due to clearance inh ibition 
(Olkkola KT et a l  2005) .  
The corre lation was reported between caffe ine breath test (CBT) results and 
tacrine blood levels as the first evidence supporting a critical ro le for CYP 1 A2 
activity in  the d isposit ion of this d rug in  vivo (Fontana RJ et al 1 996). 
Mexi let ine is ma in ly cata lyzed by CYP2D6 and partial ly cata lyzed by 
CYP 1 A2 (Kusumoto M et a l  200 1 ) .  Xenobiotics inducing CYP 1 A  1 mRNA expression 
have been found to induce C YP1A2 and C YP 1 8 1 ,  varied only based on the level 
and time course of induction (Krusekopf S et al 2003). 
General ly ,  the 1 5q24. 1 locus, including C YP1A2, is associated with blood 
pressure (BP) .  H igher CYP 1 A2 activity on  the basis of positivity of the CYP1A2*1 F 
al lele was l inearly associated with lower BP after qu itti ng smoking , but not while 
smoking. In non-smokers ,  the C YP1A2 variants were associated with higher 
reported caffeine intake, which in turn was associated with lower BP (Guessous I et 
a I 20 1 2) .  
Some studies have a lso used caffeine a s  a modulator of d isease etiology, 
looking at intake of caffe ine contain ing foods and beverages with respect to d isease 
risk. Two independent genome-wide association studies have examined the effect of 
variants on caffeine intake. They found associated variants in  the regulatory reg ion 
of C YP1A2 ( rs2472304 and rs2472297) and in  its regulator AhR (rs44 1 0790 and 
rs6968865) (Cornel i s  MC et al 201 1 ,  Sulem P et a l  201 1 ) . 
C YP1A2 has been found to be essent ia l  for dosing of several anti psycho
tics 
and for assessing both d rug efficacy and adverse drug reactions. CYP1 A
2 is the 
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main CYP isoform responsible for clozapine metabol ism (Eap CB at el 2004) .  Case 
stud ies presented u ltrarapid metabol izers of clozapine that showed resistant to 
treatment .  I ncreased clozapine doses and co-admin istration with the CYP 1 A2 
inh ibitor fluvoxamine were considered an  alternative way to improve patient 
outcomes (Ozdemir  V et a l  200 1 , Eap CB et a l  2004) .  
CYP 1 A2 also alters the antithrombotic drug clopidogre l  (Wang Z et al  201 5).  
Smoking elevates clopidogrel-mediated platelet inh ibition (B l iden KP et al  2008, 
Gremmel T et a l  2009). This is related to induction of CYP 1 A2 ,  which can play a 
sign ificant role in  colpidogre l  activiat ion. 
Like many of other CYPs, CYP 1 A2 is subjected to induction and inh ibition by 
a number  of compounds. Particu larly ,  antofloxacin ,  carbamazepine, d ihydralazine, 
furafy l l ine ,  isoniazid, rofecoxib ,  clorgyl ine ,  th iabendazole, and zi leuton are 
mechanism-based inh ibitors of CYP1 A2 . Reversible and i rrevers ible inh ibition of 
CYP 1 A2 that may g ive an i l lustration of some cl in ica l d rug-drug interactions. 
The process of d rug interact ions is a complex process because the 
medication interacts with one substrate of a specific cytochrome P450 pathway, 
does not mean it i nfluences a l l  substrates of that isozyme. Genetics, age, nutrit ion, 
stress, l iver d isease, hormones, and other endogenous chemicals also influence 
drug metabol ism.  
S ubstrate Spec ific ity of Human CYP1 A2 
Phenacetin O-deethylation ,  caffeine 3-demethylation and ethoxyresorufin 0-
deethylation are a commonly used marker reactions for CYP 1 A2.  Part icularly, 
phenacetin O-deethylat ion is the most common marker reaction for CYP 1 A2 activity 
in the in vitro study. (Yuan R et a l  2002) . 
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To a less extent,  tacri ne ( 1 ,2 ,3 .4-tetrahydro-9-aminoacrid ine,  1 -
hydroxylation) ,  melatonin (6-hyd roxylat ion) and tizan id ine (oxidation) are also used 
as probes for CYP 1 A2 in vivo. For in vitro studies, phenacetin (O-deethylation),  7-
ethoxycoumarin (O-deethylat ion), and 7-ethoxyresorufin (O-deethylation) are also 
used probes for determ in ing CYP1 A2 activity (Waxman OJ and Chang TK 2006) . 
1 .3 .2  N-acety l transferase-2 (NA T2) 
1 .3 .2 . 1  Gene Location , Structu re and Express ion 
Almost 22 NAT- l ike genes have been reported in 1 4  d ifferent prokaryotic and 
eukaryotic species ( Butcher NJ et a l  2002). The genes invariably have an intronless 
coding sequence that encodes for a protein  between 254 and 332 amino acids in 
length (Butcher NJ et a l  2002) .  
1 .3 .2. 1 . 1 N-acety ltra nsferase Gene Fami ly  
H uman NA T1 , NA T2 as wel l  as  NA TP1 (pseudogene) were local ized to  the 
short arm of chromosome 8 ,  more specifica l ly in  region 8p22. Both NA T1 and NA T2 
genes show pronounced a l le l ic  variat ion (H ickman 0 et al  1 994, Blume M et al  1 990, 
Butcher NJ et al 2002, Stanley LA and Sim E 2008, Hein OW 2009). The NAT loci 
are segreg ated by 1 70-360 kb only and are in the orientation 
NA T1 -? NA TP1 -? NA T2, with NA T1 being on the centromeric side of marker 
08S26 1 and NA T2 co incid ing with marker 08S21 (Figure 8) (Matas N et aI 1 997). 
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Figure 8 :  Chromosomal location  and structure of N-Acetyltransferase (NA T2) gene 
The two funct ional NAT genes possess an 87 . 5% nucleotide identity, which 
reach up to 81 % homology at the amino acid level and around 80% with the 
correspond ing sequence in  NA TP (B lume M et a l  1 990). The whole transcript of 
NA T1 is derived from a s ingle exon ;  whereas NA T2 is derived from the protein  
encoding exon together with a second noncoding exon of  1 00 bp located about 8 kb 
upstream of the translation sta rt site (B lume M et al 1 990, Ebisawa T and Oeguchi 
1 99 1  ) .  
1 .3 .2. 1 . 2  Reaction Mechan ism,  Structu ra l Featu res, Variation and 
Fu nctiona l  Releva nce of NAT2 
The react ion is composed of two steps. I n it ia l ly ,  acetyl coenzyme A binds to 
the enzyme and the acetyl moiety is sh ifted from the cofactor to a cysteine (Cys68 
for the human isoforms) of the prote in .  The second step occurs when the binding of 
substrate to the acetylated enzyme where the acetyl moiety is transferred to the 
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substrate . F ina l ly ,  the acetylated product is separated from the enzyme (see 
aforementioned Figure 4) (Minchin RF et al 1 992, Oelomenie et al  2001 ) .  
S incla ir  (2000) reported the first crystal structure of an ary lam ine N­
acetyltransferase.  A cyste ine-h istid ine-aspartate cata lytic triad was recorded in  the 
N-term inus of the protei n  (Sincla ir  JC 2000). In this regard ,  the protein  has been 
d ivided into three domains.  The first consists of a hel ical bundle,  located from amino 
acid 1 to approximately 90 ,  which forms one side of a cleft in  which the cyste ine 
involved in  acetyl transfer resides . 
The second domain consists of residues from approximately 90 to 2 1 0  amino 
acids and is located on the other side of the cleft. I t  mostly consists of l3-sheet 
structures. The last domain at the carboxyl terminus is a combination of l3-sheets 
and a-hel ices , which represents the b iggest variation between species (Sinclair JC 
2000) .  
N ine missense mutations where the a lteration is in an amino acid (C-1 90T, 
1 9 1 G>A, 34 1 T>C, 434A>C ,  499G>A, 590G>A, 803A>G, 845A>C, and 857G>A), 
and four s i lent where it occurs in the noncod ing reg ion ( 1 1 1 T>C, 282C>T, 481 C>T, 
and 759C> T) have been recorded in d ifferent studies (Grant OM et al  1 991 , Vatsis 
KP 1 995,  Hein OW et al  2000) .  The NA T2 gene has one non-coding exon around 
8.6kb upstream of the intron less ORF (F igure 9) (Ebisawa T and Oeguchi T 1 991 , 
Boukouvala S and Sim E 2005, H usain A et a l  2007) .  
EXOtl 1 lntn>n 1 EXOt. 2 
865"'1 bp 
_ _ _ _ _  -11 _ _ _ _ _ _  _ 
Figure 9 :  Structure of human NA T2 gene 
Leff et a l  ( 1 999) studied several d ifferent human NA T2 al leles in a yeast 
expression system .  They observed that three novel a l leles, namely NA T2*50 
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haplotype (34 1  T>C),  NA T2*14G haplotype ( 1 9 1 G>A, 282C> T, and 803A>G) ,  and 
NA T2*60 haplotype ( 1 1 1  C> T, 282C> T, and S90G>A), expressed prote ins that had 
N- and O-acetylat ion capacities simi lar to the expressed protein  of the commonly 
occurring slow NA T2*58 a l le le ,  and sign ificantly less than that of the wi ld-type 
NA T2*4 al le le .  
The expression of NA T2*58 and NA T2*50 haplotypes was reported to be 
signif icantly l ower than that of the wi ld-type prote in ,  suggesting that the base 
substitution at posit ion 34 1 ,  which is common to the NA T2*5 cluster, is sufficient for 
reduction in NA T2 prote in expression . This was not observed to be the case for 
NA T2*60 and NA T2* 1 4 G  hap/otypes, which were expressed at levels comparable 
to wi ld-type. Contrar i ly ,  NA T2*60 and NA T2*14G haplotypes were observed to be 
s ignificantly less stable than the wi ld-type. 
1 .3 .2 . 1 .3 NAT2 Regu lation 
N-acetyltransferases (NATs) are xenobiotic metabolizing enzymes for which 
three d istinct enzymatic activities have been described . One is includes the acetyl 
coenzyme A (CoA) dependent N-acetylation of arylamines and arylhydrazines, a 
reaction usual ly  associated with xenobiotic detoxification (Hein DW 2009). 
The second one is also acetyl-CoA dependent and involves O-acetylation of 
N-hydroxyarylamines (He in  DW 2009), typica l ly  generated through N-oxidation of 
a ry lamines by cytochrome P4S0 enzymes. 
The th i rd one is an acetyl-CoA independent N, O-acetyltransfer performed on 
N-ary l hydroxamic acids, generating h igh ly reactive mutagenic compounds that bind 
to DNA. NATs have essential roles in the metabol ism and detoxification of 
xenobiotics and therapeutic drugs, and are impl icated in cancer risk because of their 
role in the activation or detoxification of carcinogens and their interaction with 
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environmental chemicals (Sim E et a l  2008, Stanley LA and Sim E 2008, Sim E et a l  
20 1 2) .  
1 .3 .2 . 1 .4 NAT2 Variat ion and its Ep idemiology 
NA T2 is  a polymorphic gene with a lmost 88 NA T2 al leles which have been 
assigned offic ia l  symbols by the Ary lamine N-acetyltransferase Gene Nomenclature 
Committee ,  accord ing to consensus gu idel ines (Hein DW et al 2008) .  NA T2*4 is the 
reference (or "wi ld type") a l le le for the respective gene, and the other variant a l leles 
d iffer from this by one or more single nucleotide polymorph isms (SNPs) .  
The NA T2 gene has a h igh frequency of functional variat ion,  which varies 
amongst populat ions that are ethn ical ly d ifferent, and has high levels of haplotype 
variat ion ( Patin E et al 2006b, Mortensen HM et al  201 1 ) . SNPs within 
the NA T2 gene cause several changes in  NAT2 function by a ltering enzyme 
stabi l ity ,  altering affin ity for substrate, or a protein  that is targeted for proteasome 
degradation (Walraven JM et al 2008, Hein DW 2009) .  
NA T2 genotypes have been classified into three d ifferent phenotypes: "slow 
acetylator" (two slow a l le les) ,  " intermediate acetylator" (1 s low and 1 rapid al le le) ,  
and "rapid" acetylator (2 rapid a l leles) (Stanley LA and Sim E 2008) . Some papers 
report rap id as any genotype conta in ing NA T2*4 and slow as any non-carriers 
of NA T2*4 acetylators (Soej ima M et al  2007) .  However, other rapid a l leles that 
have been found apart from NA T2*4 are NA T2*1 1 A, NA T2*12A-C, NA T2*13A, 
NA T2 *1B. I n  addition ,  within the slow acety lator genotype group there is 
heterogeneity in phenotype due to variation in enzyme activity conferred by d ifferent 
a l le les (He in OW et al 1 995, Cascorbi I et al  1 999, Hein OW 2009, Ruiz JO et a l  
201 2) ,  which may affect the a bi l ity to identify s ign ificant associations (Sel inski S et  al  
20 1 3b). 
4 1  
The frequency of  the  slow acetylator phenotype differs markedly among 
ethnic groups (Evans DAP 1 984), and this is referred to the differing frequencies of 
the polymorphisms that correspond to the slow acetylator a l le les. I n  Caucasian and 
Afri can populations, the frequency of the slow acetylation phenotype varies between 
40 and 70% , whereas it ranges from 1 0  to 30% in  Asian populations , such as 
Japanese, Ch inese, Korean ,  and Thai (Meyer UA and Zanger UM 1 997). Caucasian 
and African populat ions have h igh frequencies of NA T2*5 haplotypes (>28%) and 
low frequencies of NA T2* 7  haplotypes « 5%),  whi le Asian populations have low 
incidences of NA T2*5 haplotypes « 7%) and higher incidences of NA T2*7 
haplotypes (> 1 0%) .  Moreover, NA T2* 1 4  haplotypes are almost absent from 
Caucasian and Asian  populations « 1  %) ,  but are present in African populations at 
comparably h igher frequencies (>8%). 
Several studies examin ing the variation of NA T2 haplotypes between 
d ifferent populat ions and ethn icities support the hypothesis suggesting the NAT2 
slow acetylator phenotype was positively selected for the transit ion to an 
agricultu ral! pastoral l ifestyle from a hunter-gatherer/ nomadic l ifestyle,  leading to 
changes in d iet and thus exposure to d ifferent xenobiotics (Patin E et al  
2006a, Magalon H et a l  2008, Sabbagh A et al  2008, Luca F et a l  2008). 
For example,  slow acetylator status is higher among Taj ik populations 
(agriculturists) compared to Kirg h iz populations (nomads) in  Central Asia (Magalon 
H et a l  2008), and a high frequency of rapid or intermediate status is observed in 
hunter-gatherer  populat ions in  Western/ Southern Africa (Kung San,  Bakola Pygmy, 
B iaka Pyg my populat ions) (Pat in E et a l  2006b, Mortensen HM et al  20 1 1 ) . In I ndia, 
the frequency of slow acetylators (based on genotype) was higher than rapid 
acetylators in areas where a vegetarian diet dominates, and the opposite was found 
in  areas where non-vegetarian d iet is more frequent (Khan N et a l  201 3). 
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Yul iwulandari et al  (2008) detected 23 d ifferent variants in  the promoter and 
coding regions of the NA T2 gene among 2 1 2  I ndonesian individuals and they found 
that phenotypes for rapid, intermediate and slow acetylators were 1 3 .6%, 50.8%, 
and 35 .6%, respective ly .  The frequency of slow acetylators was simi lar to that 
recorded for other Southeast Asian populations.  
Magalon et a l .  (2008) genotyped 1 38 individuals from 6 populations in 
central Asia ,  they found that the Taj iks and Kazakhs showed the h ighest frequency 
of the s low acetylator haplotype *58, ranging from 22 to 26%. The *6A haplotype 
was exhibit at h igh frequencies in the Taj ik  populations (39 to 45%), whereas it was 
at the lowest frequency in Kazakhs ( 1 3%).  The Kazakhs exhibited the highest 
frequency (23%) of *78, which is  main ly  restricted to East Eurasian popu lations. The 
'rapid' haplotype *4 was observed at h igh frequency in the Kirgh izs (46 to 48%) and 
in  the Uzbeks (42%) ,  but at nearly 2-fo ld lower frequencies in the Taj iks (23 to 26%), 
and intermediate frequency in  the Kazakhs (38%). Overa l l ,  the Taj iks showed 
sig n ificantly h igher proportions of s low acetylators (55% to 63%) as compared to the 
Uzbeks, Kirgh izs, and Kazakhs, where the proportions of slow acetylators ranging 
from 26 to 35% (Table 4 and 5) (Magalon H et a l  2008). 
Table 4: Frequency of important SNPs in human NA T2 gene (Guaoua S et a1 201 4) 
Ethn ic  g roups NA T2*5 NA T2*6 NA T2*7 NA T2*14  
Caucasians 0 .46 0 .285 0.029 0 .00 
Germans 0 .425 0.278 0. 0 1 3  0 .001  
Americans 0 .437 0.266 0 .01 9 0 .001 
Southern Korean 0 . 0 1  0 .224 0 . 1 32 0 .00 
Spanish 0 .47 0 .25 0 .006 0 .004 
Southern Brazi l 0 .289 0 . 1 04 0.02 1 0 .0 14  
Egyptian 0 .497 0 .26 0.028 
Argent ine 0 . 37 0 .256 0.08 0 .01 3 
Omanis 0 .44 0 .27 0 .04 0 .00 
Senega lese 0 . 322 0 . 1 88 0 .00 0 .084 
Tun isians 0 . 3 1 5 0. 1 75 0 . 1 5  0.05 
South Africa 0 .361  0 . 1 7  0.067 0. 1 03 
Japanese 
I nd ians 
Moroccans 
0 .0 1 9  
0 .33 




0 .01 1 
0.03 
0.02 0 .04 
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Table 5 :  Frequency of other S N Ps in  human NA T2 gene (Luca F et a l  2008) 
Haplotype Dendi Amha Orom E gyptla Italian G ree 
ra 0 ns s ks 
"4 0 0 06 0 08 0. 1 2  0 24 0 2 1 
'5 0 0 0 04 0 01 0 0 0 1  
"58 0 23 0 53 0 33 0 49 0 32 0 38 
*5C 0 05 0 0 .04 0 01 0 03 0 04 
'50 0 05 0 0 0 0 0 
*5G 0 05 0 03 0 0 0 0 
*5J 0 0 0 0 0 0 
*6 0 27 0 27 0 2 1 0 27 0 34 0.29 
*68 0.09 0 0 0 0 0.01  
*6C 0 05 0 0 0 0 0 
'7 0 0 0 0 0 0.01 
?8 0 0 03 0 1 7 0 0 1 0.03 0.03 
*11 0 0 0 0 0.01  0 
*12 0 05 0 03 0 08 0.01 0 0 
*128 0 05 0 0 0 0 0 
*12C 0 0 0 0 0 01 0 01 
*13 0. 1 4  0 03 0 04 0 07 0.01 0 01 
I mportant Variants 
Czee 
hs 

















Mordvin RusSI Khanty 
an MansI 
0 2 1 0 33 0. 1 4  
o 0.04 0 
0 50 0.33 0 29 
o 0 0.07 
o 0 0 
o 0 0 
o 0 0 
0. 1 1  0.08 0. 1 1  
o 0 0 
o 0 0 
o 0 0 
0.07 0 04 0. 1 8  
o 0 0.1 1 
o 0 08 0.04 
o 0.04 0 
0 07 0 0.04 






































NA T2 al le les conta in ing the 1 9 1 G>A (rs 1 80 1 279), 34 1 T>C (rs 1 80 1 280) , 
590G>A (rs 1 799930), and/or 857G>A (rs 1 799931 )  m issense substitutions are 
associated with slow acetylator phenotype(s). Strik ing ethnic d ifferences in the 
frequencies of these missense substitutions (Grant OM et al  1 997) play an important 
role in ethnic d ifferences in frequency of s low acetylator a l leles (Cascorbi I et a l  
1 999) and phenotype(s) (Weber WW and Hein OW 1 985). For example, the 
1 9 1 G >A substitution commonly represents the NA T2* 1 4  gene cluster that is 
ava i lable in g reater extent in African Americans and native Africans, but it is v irtual ly 
absent in Caucasian populat ions. 
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Lin et a l .  ( 1 994) detected 4 mutations 1 9 1 G>A, 481 C>T, 590G>A, and 
857G>A accounted for nearly al l  s low acetylator a l leles among blacks, whites, Asian 
I nd ians ,  H ispanics ,  Koreans,  Japanese, Hong Kong Ch inese , Taiwanese , F i l ipinos, 
and Samoans. 
Cascorbi et a l .  ( 1 995) found 7 d ifferent a l leles of the NA T2 gene coding for 
the 's low' phenotype . They observed a slow acetylation genotype in 58.9% of the 
844 unre lated German subjects studied (Cascorbi et al 1 996) . In vivo acetylation 
capacity of homozygous wi ldtype subjects was sign ificantly h igher than in  
heterozygous genotypes . Al l  mutant a l leles showed low in vivo acetylation 
capacit ies ,  and the term 's low' genotypes differed significantly among each other, as 
reflected in  lower acetylation capacity of some a l leles as compared with others. 
Other I m portant Varia nts 
Other NA T2 a l le les that have been reported to be associated with slow 
acetylator phenotype a re those conta in ing the A-434C (rs 7255461 6) and C-1 90T 
( rs 1 8051 58) (Oai  Z et al 2008) .  However, t i l l  now there are no reports which detect 
S N P  rs725546 1 6  inf luence on drug metabol ism or any d isease so it may not have 
any cl in ica l impact.  On the other hand, on ly one report of isoniazid side effect has 
been detected with S N P  rs 1 8051 58 (Fuse l l i  S et al 2007). 
Other Variants 
Other variants include G-499A (rs 725546 1 7) which represent haplotype *10, 
shows slow cata lyt ic activ ity but substrate dependent. Variant 803A>G (rs 1 208) 
presented in a l le le * 1 2, variant 282C> T (rs 1 041 983) presented in a l le le * 13  and 
variant A-845C (rs 56054745) presented in  a l lele * 18  have shown to have rapid 
catalytic activities that is a lso included in the metabolism of certain drugs l i ke 1 , 7-
d imethylxanth ine ,  antivirals for treatment of H IV  infections, drugs for treatment of 
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tuberculosis, hydralazine , su lfamethoxazole and trimethoprim (Weber WW and Hein 
OW 1 985,  Stan ley LA and Sim E 2008, Sim E et a l  201 2 , McDonagh EM et al  20 1 4) .  
1 .3 .2 . 1 .5 NAT2 I m porta nt Hap lotypes 
NA T2*4 is  considered the wi ld-type a l le le because of the absence of any of 
these substitut ions and based on many stud ies in many ethnic groups, NA T2*4 is 
not the most common a l le le (He in  OW et a l  1 994 , Hein OW et a l  1 995 ,  O'Neil WM et 
a I 2000) .  
NA T2* 5, NA T2* 6, NA T2* 1 4, and NA T2* 7 al leles have low catalytic activity 
associated with the s low acetylator phenotype, whereas NA T2*12  and NA T2*13  
al le les associated with h igh  catalytic activities that show rapid acetylator phenotype 
s imi lar  to NA T2*4 (He in OW 1 994, Hein OW et al 1 995,  O'Nei l  WM et al 2000). 
1 .3 .2 . 1 .6  NAT2 Al le les Nomenclatu reNa riant  Annotations 
Since 1 995 many a l le les and their nomenclature have been identified and 
publ ished (Vatsis KP et a l  1 995) .  The Human Gene Nomenclature Committee has 
agreed that the symbol NAT be assigned to the arylamine N -acetyltransferase 
genes. NA T2 a l le les *1 ,  *2 and *3, have been found but these are non-human NA T2 
a l le les . Based on th is ,  h uman NA T2 a l le les sta rt with al le le *4 (wild type) (table 6) 
(He in OW et al 2008) .  
Tab le 6 :  NA T2 a l leles and i ts  references SNPs and cata lytic activity 






N ucleotide Change(s) and rs # 
Reference 
34 1 T>C (rs 1 80 1 280) 
48 1 C> T (rs 1 799929) 
34 1 T>C (rs 1 80 1 280) 
481 C>T (rs1 799929) 
803A>G (rs1 208) 




1 1 1 4T 
L 1 6 1 L 
(synonymous) 
1 1 1 4T 
L 1 6 1 L 
(synonymous) 
K268R 












* 1 4A 
*148 
*14C 
803A>G (rs 1 208) 
282C>T (rs 1 04 1 983) 
590G>A (rs1 799930) 
590G>A (rs1 799930) 
282C> T (rs 1 04 1 983) 
590G>A (rs1 799930) 
803A>G (rs 1 208) 
857G>A (rs1 79993 1 )  
282C>T (rs 1 04 1 983) 
857G>A (rs1 79993 1 )  
282C>T (rs 1 04 1 983) 
803A>G (rs1 208) 
857G>A (rs 1 79993 1 )  
1 9 1 G>A (rs 1 801 279) 
1 9 1 G>A (rs 1 801 279) 
282C>T (rs 1 04 1 983) 
1 9 1 G>A (rs 1 80 1 279) 
34 1 T>C (rs 1 80 1 280) 
481 C> T (rs 1 799929) 




R 1 97Q 
R 1 97Q 
Y94Y 
(synonymous) 















1 1 1 4T 












1 .3 .2. 1 .7 NA T2 Genotype/Phenotype Relationsh ip 
The caffeine metabol ite Paraxanthine can  undergo acetylation by  NAT2 to 
form 5-acetylam ino-6-formylamino-3-methyluraci l (AFMU) (Thorn CF et al 20 1 2) .  
Caffeine can  be  uti l ized as a non-toxic probe drug in  vivo for examin ing the 
acetylat ion phenotype status;  by determin ing metabol ite ratio AFMU/1 -methyl 
xanthine ( 1  MX) in u rine after caffeine consumption ,  a bi- or tri-modal pattern in  a 
g iven populat ion is  determined (Grant OM et al 1 984, Grant OM et al  
1 990, Kaufmann GR et al  1 996). AFMU/AFMU+1 X+1 -methyluric acid (1 U) ,  
AFMU+5-acety lamino-6-amino-3-methy luraci l  (AAMU)/AFMU+AAMU+1 MX+ 1 MU or 
AAM U  / AAM U+ 1 X+ 1 U metabol ite ratios can also be used to measure acetylation 
phenotype status (Jetter A et al  2004, Begas E et al  2007, Ojordjevic N et a l  201 1 ,  
Ojordjevic N et a l  201 2) .  
Therefore , most commonly used probe drug for NAT2 phenotype 
measurement is caffe ine (Grant OM et al 1 984, Lorenzo B and Reidenberg MM 
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1 989 , Leyland-Jones B et al 1 999) and excel lent NA T2 genotype/phenotype 
correlat ions h ave been recorded (Cascorbi I et al 1 995, Grant OM et al  1 997).  
Although admin istration of caffe ine is a relatively noninvasive method for measuring 
NAT2 acetylator phenotype, the method used involves determ ination of the quantity 
of other metabol ites . Thus ,  genetic and environmental factors may influence the 
levels  of the metabolites used in the phenotype determination. For example,  NAT1 
phenotype affects the urinary caffeine ratio uti l ized for determination of NAT2 
phenotype (Cribb AE et a l  1 996) . 
No association has been reported between NAT2 acetylation activity and 
sex, race, age, education , smoking , physical activity, weight, vitamin E supplements, 
alcohol and d ietary intakes of red meat, processed meat or cruciferous vegetables 
or use of menopausal estrogens (Le Marchand I et al  1 996). 
In one study, up to 54% of the d ifferences in acetylation activity measured by 
caffeine test could be demonstrated by NA T2 genotype (homozygous wildtype, 
homozygous variant or heterozygous determined by PCR-RFLP),  although it was 
found that use of phenotyping had some advantages in sensitity over genotyping (Le 
Marchand L et a l  1 996). 
The orig ina l  method for determin ing the NAT2 genotype used Southern blot 
analysis of genomic DNA from leukocytes but soon afterwards, a PCR-based RFLP 
method was described (Mashimo M et a1 1 992, Abe M et al  1 993). I n  addition, use of 
the u rinary molar ratio of AFMU/1 -methylxanth in  to determ ine NAT2 phenotype it 
was described and va l idated at around the same t ime (Butler MA et al 1 992) .  
48 
1 .3 .2 . 1 .8 C l i n ica l  I m pact, Drug Metabol ism and Su bstrate Specific ity of 
NAT2 Polymorph ism 
The association between acetylator status and the risk of various diseases 
has been extensive ly  recorded,  and reviewed in deta i l  (Evans DAP 1 984, Clark OW 
1 985,  Evans DAP 1 993) .  
Altered r isk with e i ther the slow or rapid phenotype has been reported for 
severa l d iseases including b ladder, colon and breast cancer, systemic lupus 
e rythematosis , d iabetes , G i lbert 's d isease, Parkinson's d isease (PO) and 
Alzhe imer's d isease. Humans are exposed to many toxic NAT substrates including 
the food-derived heterocycl ics present in  the d iet as well as a rylam ines such as 4-
am inobiphenyl and l3-naphthylamine present in  tobacco smoke (Nagao M et al  
1 996, Smith CJ et a l  1 997 ,  Besarati NA et a l  2000, Sram RJ and Binkova B 2000). 
Their infl uences cause several adverse effects with a lot of drugs l ike d ipyrone, 
d rugs for treatment of tubercu losis,  hydralazine, isoniazid, pyrazinamide, 
su lfamethoxazo le ,  su lfapyrid ine,  su lfasalazine and caffe ine (Weber WW and Hein 
OW 1 985,  Stanley LA and Sim E 2008, S im E et al  20 1 2 , McDonagh EM et al  201 4) .  
I n  cancer, NAT2 phenotype/genotype may  be a risk factor. NAT2 has  been 
impl icated in chemical carcinogenesis pathways. Un l ike the relatively rare but h ighly 
penetrant genes incl uded in  fami l ia l  cancers, those genes responsible for metabolic 
polymorphisms have low penetrance and cause only a moderate increase in cancer 
risk. Nevertheless, their widespread occurrence in  the general population suggests 
that they are a sig n ificant contributor to individual r isk (Weber WW and Hein OW 
1 985, S im E et a l  2008, Stan ley LA and Sim E 2008, Sim E et al 201 2 , McDonagh 
EM et a l  20 1 4) .  
For that ,  polymorphisms in  the NA T2 genes have been examined for an 
association with cancer risk ,  however the find ing s  are inconsistent; th is may be due 
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to the com plex nature of cancer etiology and the mult iple factors that contribute to 
susceptib i l i ty (Weber WW and Hein OW 1 985, S im E et al 2008, Stan ley LA and Sim 
E 2008, Sim E et al 201 2 ,  McDonagh EM et a I 2014) .  
I n  1 986, Lang et a/  first i l l ustrated an association between the slow acetylator 
phenotype and bladder cancer whi le the rapid acety lator phenotype was suggested 
to have an i ncreased risk factor for colon cancer (Lang et al 1 986, l Iett et al 1 987, 
Wohl leb JC et a l  1 990). Other studies have been unable to confirm these findings 
(Welfare MR et a l  1 997,  Chen J et a l  1 998, Brockton N et a l  2000). 
Cartwright et a l  ( 1 982) d ivided the ratio that used to measure the phenotype 
status i nto 4 g roups: 0 .3  and greater correspond to rapid acetylators, and the other 
three (0 . 0 1 -0 .09;  0. 1 -0 . 1 9 ;  and 0 .2-0.29) correspond to d ifferent levels of s low 
acetylator phenotype. U rinary bladder cancer risk is markedly elevated in  NAT2 slow 
acetylator phenotype , particularly with the slowest NA T2 phenotype (Cartwright RA 
et al 1 982) .  Th is same conclusion has been reported by d ifferent stud ies including 
some recent large genome-wid association studies (Brockmol ler J et al 1 996, 
Okkels H et al  1 997, F i l iad is I F  et a l  1 999, Hamdy SI et al  2003, Lubin JH et al  2007, 
Garcia-Closas M et al 201 1 ,  F igueroa JD et al  2014) .  
Another study showed an  enhanced effect for smoking intensity and bladder 
cancer in  NAT2 s low acetylators which increases with intensity (Lubin JH et al 
2007) .  
Severa l stud ies have been reported that rapid N-acetylation phenotype was 
associated with an increased r isk of co lorectal cancer, part icularly, in patients with 
r ight-sided cancer. However, the frequency of the *7 A haplotype associated with the 
slow acety lator status, was increased among colorectal cancer patients on the left 
side and a long the s igmoid/rectal reg ion (Lang N P  et al 1 986, l Iett KF et al 1 987, 
Lee EJD et al 1 998). 
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Women with very s low acetylator genotype (homozygous for NA T2*5) who 
smoked for 20 years showed an increased breast cancer risk when they were 
compared to ind iv iduals with rapid NA T2 genotype (Vander H L  et al 2003). 
Some other studies showed no association between NA T2 acetylator 
phenotype and breast cancer (Webster OJ et a l  1 989, Ladero JM et al  1 991 ) .  
Contrar i ly ,  rapid acetylator phenotype was associated with breast cancer r isk in 
other stud ies (Bulovskaya LN et a l  1 978, Phi l ip PA et al  1 987,  Sardas S et a l  1 990). 
In yet other studies,  the association between NA T2 acetylator genotype and 
breast cancer has been examined in  relation to diet .  I t  was observed that red meat 
consumption and NA T2 genotype were not associated with breast cancer risk 
(Ambrosone C B  et al 1 998, Gertig OM et a I 1 999). However, in another study, rapid 
/ intermediate NA T2 genotypes were associated with breast cancer risk in women 
who consistently consume very wel l-done meat (Deitz AC et al 1 999) . 
The corre lat ion between NA T2 genotype and breast cancer among smoking 
women has produced inconsistent results (Ambrosone CB et al  1 996, Hunter OJ et 
al 1 997, M i l l i kan  RC et al 1 998, Huang CS et a l  1 999). Mixed results were observed 
for NA T2 genotype and risk  of breast cancer (Zgheib NK et al 201 3,  Fernandes MR 
et al 201 3) and a lso oesophageal cancer  (Jain M et al  2007, Mal ik  MA et al  2009, 
Wang L et al 20 1 4) .  
The studies that investigate the r isk association between NA T2 phenotype 
and the suscept ib i l ity to lung cancer were either negative (Burgess EJ et a l  1 985) or 
showed a s l ight overrepresentation of rapid acetylators ( Roots I et al  1 988, Phi l ip PA 
et al 1 988, Martinez C et al 1 995, H i rvonen A et al 1 995, Cascorbi I et al  1 996, 
H i rvonen A et al 1 996, Nyberg F et al 1 998, Bouchardy C et al 1 998). 
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Rapid NAT1 and/or NAT2 acetylators activate N-hydroxy-heterocyclic amine 
carcinogens with in  the colon to their u lt imate carcinogenic forms,  thereby 
predisposing them to colorectal cancer ( Kir l in WG et al  1 991 , Turesky RJ et al  1 991 , 
Bel l  OA et al 1 995) .  Several stud ies have observed an association between rapid 
NAT2 acetylator phenotype and colorectal cancer (Lang NP et al  1 964, I lett KF et al 
1 987 ,  G i l  JP and Lechner MC 1 998), whereas other studies did not (Ladero JM et al 
1 99 1 , Rodriguez JW et al  1 993,  Sh ibuta K et al 1 994 , Probst-Hensch NM et al  1 995,  
Spurr NK et a l  1 995,  H ubbard AL et a l  1 997) .  Some studies have recorded an 
association between rapid NAT2 acetylator phenotype and colorecta l cancer for 
Ind ividuals consuming wel l-done meat and,  presumably ,  h igher levels of heterocycl ic 
amine carcinogens (Lang NP et a l  1 994, Skog K et al  1 995, Roberts-Thomson IC et 
a l  1 996, Welfare MR et al  1 997,  Chen J et al  1 998, Kampman E et al  1 999). 
Consistent with that ,  rapid NA T2 acetylators who consumed pan-fried meats 
had h igher leve ls  of u rinary mutagen icity than slow acety lators (Marin i  OM et al 
1 997) .  Whereas it is on ly l im ited to homozygous rapid ( *41*4) acetylators (Gil JP and 
Lechner MC 1 998) , th is fi nd ing was a lso observed for lung (Cascorbi I et al  1 996) 
and laryngeal (Henn ing S et al 1 999) cancers . Bel l  OA et al 1 995 recorded an 
association  between the NA T1 * 1 0  al le le and colorectal cancer, and the risk were 
hig hest among NAT2 rapid acetylators. Another study a lso found a h igher risk for 
colorectal cancer in i nd iv iduals who consumed well-done meat and possessed both 
the NA T1 * 1 0  a l le le and rapid acetylator NA T2 genotype (Chen J et al 1 998). 
In a nother study, the homozygous slow acetylator NA T2 genotype was 
correlated with an increased risk of oral/pharyngeal cancer, but not laryngeal cancer 
(Jourenkova-Mi ronova N et al 1 999). However, the homozygous rapid acetylator 
( *41*4) genotype was strongly correlated with laryngeal cancer in a German study 
(Smelt VA et al 1 998). 
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Several studies conducted to examine the associations between acetylator 
genotypes and prostate cancer found no re lat ionship between NA T2 genotype and 
prostate cancer (Agundez JAG et a l  1 998, Wadel ius M et al  1 999). Additional ly ,  
aromat ic amine N-acetyltransferase activity levels in  human prostates were 
independent of NA T2 genotype (Agundez JAG et al 1 998). 
Head and neck cancers are strongly correlated with smoking , and several 
studies have investigated the role of NA T1 and NA T2 polymorph isms and the risk of 
head and neck cancer in smokers .  The slow NAT2 acetylator phenotype was 
observed to be associated with the development of head and neck cancer in 
Caucasians (Or6zdz M et al 1 987,  Gonzalez MV et al  1 998) and with the 
development of oesophageal cancer in Japanese (Morita S et al  1 998) . 
Another study showed that NA T2 slow acetylator genotype can be a smal l ,  
low penetrance risk factor for head and neck cancer (Zhang L et al  201 4) .  Seeking 
further studies is  i mportant to have clear picture about the associations 
between NA T2 variants and susceptibi l ity to other cancers (Boukouvala S and Fakis 
G 2005, Sim E et al  2008, Butcher NJ and Minchin RF 20 1 2) .  
Chan et a l .  (2003) found that the frequency of the slow acety lator genotype 
for NA T2 was s ign ificantly h igher in Parkinson's d isease (PO) patients than in a 
control g roup after adjust ing age, sex, and smoking history in Hong Kong Chinese . 
A s ign ificant associations with PO for NAT2 was also reported in a meta analysis 
(Tan EK et a l  2000) . S imi larly, Bandmann 0 et al  (2000) stated that "the slow 
phenotype appears to increase risk of PO" .  
I ncreased r isk of the late-onset Alzheimer's d isease has been observed with 
the rapid NA T2 phenotype in non-a poE epsi lon 4 carriers (Ogawa M 1 999) . 
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NA T2 polymorph isms and acetylator phenotype may affect risk of other 
complex mult ifactoria l  d iseases ( inc luding asthma and diabetes), however, the 
results are confl ict ing and further studies are needed (Ladero JM 2008, Batra J and 
Ghosh B 2008). 
The development of molecular epidemiologica l studies exploring the 
relationsh ip between the acetylation polymorphisms and cancer are sti l l  i ncomplete 
but there has been considerable progress recently due to the avai labi l ity of genome-
wide association studies (Chung CC et a l  201 0). The inconsistency in  the human 
epidemiological stud ies may be re lated to d ifferences in carcinogen exposures, 
genotype and/or phenotype methods, insufficient sample sizes , and/or other 
susceptib i l ity genes and factors . 
The drug adverse effects re lated to NA T2 phenotype mostly occurred as the 
result of a sh ift in  the metabol ic pathways responsible for the activation and 
detoxification of the d rug .  This is best demonstrated by the amine-contain ing 
su lphonamides, such as sulphamethoxazole,  that undergoes hydroxylation to a 
reactive N-hydroxy metabol ite capable of covalently binding to macromolecu les and 
g iving rise to id iosyncratic adverse reactions (F igure 1 0) (Spielberg SP 1 996) . 
Hydroxyl.don 
• 
Covalendy bind to 
Macromolecules leading 
to Idlosyne de 
Adverse Reaction 
Figure 1 0 : The metabol ic pathways responsible for the activation 
and detoxification 
of the drug 
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These drugs can a lso be acetylated by NAT2 to non-reactive N-acetyl 
metabol ites. I n  s low acetylators , a h ig her proportion of the drug is N-hydroxylated 
and based on that i ndivid uals with slow acetylation status are at a greater risk of 
sulphonamide-ind uced toxicity (Das KM and Dubain R 1 976, Shear NH et al 1 986 , 
C ribb AE et al 1 996). 
The major focus of NA T2 pharmacogenetic stud ies are on the association of 
anti-tuberculosis (anti-TB) d rugs and drug-induced hepatotoxicity, l iver injury (D il l ) ,  
or hepatitis .  
Su lfamethoxazole is acetylated to N-acetylsu lfamethoxazole,  or oxid ized to 
su lfamethoxazole hydroxylamine (a reactive metabolite that is responsible in  
toxicity) by CYP450 enzymes (Davis CM and Shearer  WT 2008). The association 
between NA T2 genotypes and su lfamethoxazole pharmacokinetics (PK) have also 
been supported in  renal  transplant patients treated with an immunosuppressive 
reg imen ,  sign ificantly h igher su lfamethoxazole concentrations in  s low acetylators 
(defined as homozygotes or compound heterozygotes for *5, *6, or *7 variants) are 
seen compared to rapid acetylators (homozygous *41*4) (Kagaya H et al 20 1 2) .  
NAT2 is important pathway in  the metabol ism of ison iazid ( I NH) ,  mediating 
its biotransformation to the metabol ite acety l- I NH ,  which is hydrolyzed to isonicot in ic 
acid or acetyl-hydrazine and subsequently to the non-toxic diacetylhydrazine, or 
hydrolyzed to hydrazine (Preziosi P 2007, Tostmann A et al  2008, Metushi  IG  et al  
201 1 ,  Mahapatra S et al  201 2 , Da ly AK and Day CP 20 1 2) .  L iver toxicity of I N H  
treatment derives from I N H  itself (a hydrazine derivative) and its metabolites, 
including acety l-hydrazine ,  hydrazine and ammonia, and is thought to include the 
formation of reactive oxygen species that can cause necrosis and autoimmunity 
(M itchel l  J R  et al 1 975,  Preziosi P 2007, Tostmann A et al  2008, Fukino K et al 
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2008,  Metush i  I G  et a l  20 1 1 )  and may also involve epigenetic effects (Murata K et al  
2007). 
Consequently, NA T2 slow acetylators have been associated with an 
increased r isk of hepatotoxicity / l iver injury / hepatitis induced by anti-TB drug 
treatment when compared to rapid acetylators (Bose PO et al 201 1 ,  Chamorro JG et 
al 20 1 3  and Gupta VH et al 201 3) .  
NA T2 variants 590G>A and 857G>A were independently observed at a 
s ign ificantly h igher frequency in  chi ldren with co-trimoxazole induced adverse drug 
react ions (AO Rs) compared to those without (Zie l iriska E et al  1 998). 
In another study on Japanese patients who were treated with co-trimoxazole ,  
i t  was found to have h igher r isk of  adverse events with slow acetylator status 
(determ ined in th is study by NA T2 genotypes *6A/*6A, *6A1*78, *781*78) compared 
to rapid acetylators (genotypes *41*4, *41*58, *4/*5E, *4/*6A, *41*78) (Soej ima M et 
aI 2007) .  
The increased risk of developing side effects such a s  neurotoxicity or 
haemolyt ic anaemia ,  to dapsone therapy is very s imi lar  to that e lucidated for the 
su lphonamides (May OG et al 1 990). The most severe incidence of toxicity found in 
indiv iduals with a s low acety lator phenotype who are rapid hydroxylators (B luhm et 
a l  1 999). 
Whi le slow acetylators a re at a greater risk of toxicity from sulphonamides 
and dapsone, amonafide wh ich is d rug used for treatment of various cancers it is an 
arylam ine that show e levated incidence of adverse reactions in  rapid acetylators 
after being g iven standard dose compared to the slow acetylators. The d
rug 
undergoes N-acetylation to an active metabol ite that contributes to system
ic toxicity 
(myelosuppression) .  Based on that, d ifferent doses for the tw
o groups were 
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recommended. However, the d rug displayed variable and unpred ictable toxic effects 
fai led to reach phase I I I  c l in ical tria l  pr imary end points (Rata in MJ et a1 1 99 1 , 1 993, 
1 995 ,  1 996, I nnocenti F et al  200 1 , Freeman CL et a l  201 2) .  
One study found a reduction in the antihypertens ive activity of hydralazine in 
the rapid acetylators which requ i red a 40% higher dose to show simi lar therapeutic 
effect compared with slow acetylators . This variation appeared to be due to 
a lteration in the bioavai lab i l ity of the drug which reduced from 33% in s low 
acetylators to less than 1 0% in  rapid acetylators (shepherd AM et a l  1 980). 
Stud ies revealed that rapid acetylators show lower hydralazine plasma 
concentrat ions and area under the concentration-time curve compared to slow 
acetylators ( I sra i l i  ZH and Dayton PG 1 977,  Weber WW and Hein OW 
1 985,  Gonzalez-Fierro A et a l  201 1 ,  Spinasse LB et al 201 4) .  
Su lfasalazine consists of su lfapyrid ine that metabol izes to N-acetyl­
su lfapyrid ine which is sign ificantly d imin ished in s low acetylators (carriers of two 
variant a l le les NA T2*58, NA T2*6A, NA T2*78 or NA T2*5, NA T2*6 and NA T2*7) 
compared to both intermediate (one variant and one NA T2*4 haplotype) and rapid 
acetylators (NA T2*41*4) (Yamasaki Y et al  2008, Ma JJ et al  2009). Slow acetylators 
have h igher concentrat ions and e l imination ha lf-l ife of su lfapyrid ine (based on 
genotyping NA T2 SNPs rs 1 04 1 983, rs 1 80 1 280, rs 1 799929, rs 1 799930 and 
rs 1 79993 1 )  (Kuhn UD et al  201 0) .  
A supported prospective study of  female rheumatoid arthrit is (RA) patients 
treated with sulfasalazine detected 4 patients who had reported adverse effects to 
su lfasalazine in a one year period - none had the NA T2*4 haplotype, each carrying 
two variant a l le les in Japan  (Soej ima M et al  2008) . 
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In summa ry ,  the examples d iscussed above have highl ighted the essentials 
of NA T2 as a genetic inf luence on drug pharmacokinetics and pharmacodynamics 
(Table 7) (Ratai n  MJ et al  1 996, I nnocenti F et al  200 1 ) . 
Table 7 :  Effect of acetylator status on drug response and toxicity (Butcher NJ et al  
2002) 
Drug P henotype Effect 
Dapsone Slow Neurotoxicity 
Sulphamethoxazole Slow Hypersensitivity 
Hydralazine Slow Systemic lupus erythematosus 
Rapid Decreased therapeutic effect 
I soniazid S low Interaction with phenytoin 
I nteraction with rifampicin 
Cotrimoxazole Slow Various adverse reactions 
S u lphasalazine Slow Various toxicities 
Hepatotoxicity. nausea /vomiting 
Amonafide Rapid Leukopenia 
Procainamide Slow Systemic lupus erythematosus 
Phenelzine Rapid Decrease therapeutic effect 
Some studies demonstrated that bacterial NAT from the gut flora has a role 
in the activation and detoxification of xenobiotics in the host organ ism and may play 
an essential role in  the metabol ism of ant i- inflammatory drugs, such as 5-
aminosal icy l ic  acid (Trepanier LA et a l 1 997, Delomenie C 200 1 ) . 
Su bstrate S pecific ity of Human NAT2 
There is no specific substrate structure that is un iform for the different 
isoforms of NAT, a lthough ,  p-aminobenzoic acid (PABA), p-aminobenzoyl g lutamate 
and p-am inosa l icyl ic acid ( PAS) are identified as specific substrates for human 
NA T1 . These substrates can be featured by the avai labi l ity of re latively smal l  
hydrophi l ic substitut ions in  the para posit ion of the aromatic r ing. On the other hand, 
su lfamethazine,  procainamide and dapsone are acetylated primari ly by human 
NA T2. Other com pounds such as 2-aminofluorene are excel lent substrates for both 
human NA T1 and NA T2 (M inchin RF et al 1 992 , Delomen ie C et al  2001 ). 
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Endogenous substrates for human NA T2 are not well known , a lthough ,  in 
rodents N -acetyltransferases metabol ize a number of aromatic and heterocycl ic 
amine carcinogens that form tumors (Layton OW et al 1 995). Aromatic amines and 
hydrazines (N-acetylat ion) and N-hydroxy-aromatic and heterocycl ic  am ines (0-
acetylat ion) are both examples of acceptor substrates that are deactivated (N­
acetylat ion) or activated (O-acetylation) by NAT2 (Hein OW 1 988) . 
1 .4 Potentia l  Contri bution and  Limitation of the Study 
Time constra ints have been the main chal lenge that we have faced during 
this study.  Molecular and epidemiological research involving human subjects 
requ i res obta in i ng the appropriate ethical approvals which involved numerous 
communicat ions with managers and admin istrators in severa l institutions. This was 
an absolute pre-request before sample col lection. 
Moreover, our study requ i red volunteers who had to drink  caffeinated drinks 
and come back after 2 hours for sample collection which was inconven ient for some 
ind ividua ls who refused to participate . Additiona l ly ,  not a l l  the places were 
considered appropriate for sample collection which l imited the number of centers 
that we could use for subjects recru itment. 
I nterest ingly ,  the level of consanguin ity in  the UAE varies with more than 
50% of marriage are consanguineous. This clearly may influences the genotypes 
frequencies and may result in their deviation from Hardy-Weinberg .  
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Chapter 2 :  Aims and Objectives 
2 . 1  Aims 
This  study has been conducted to  determine CYP1A2 and NA T2 genotypes 
and their  frequencies and correlat ions with the corresponding phenotypes in 
Emiratis. 
2.2 Spec ific  Objectives 
./ Literature evaluation of C YP1 A2 and NA T2 polymorphism and its association 
with d iseases, d rug response and toxicity . 
./ Recruitment of a sample of volunteers that is genetica l ly  representative of 
Emiratis and wi l l i ng  to go through phenotyping and genotyping analysis . 
./ Measurement of CYP1 A2 phenotyping status of the recru ited samples . 
./ Determin ing the polymorphic C YP1 A2 a l leles and genotype frequencies of the 
recru ited samples and examine if they fol low or deviate from the Hardy­
Weinberg equ i l ibrium . 
./ Defin ing the corre lat ion between C YP1A2 genotyping and phenotyping . 
./ Measuring the NAT2 phenotyping status of UAE population samples . 
./ Determin ing the NA T2 genotype frequencies of UAE population, and their 
deviations from Hardy-Weinberg equi l ibrium . 
./ Defin ing the corre lation between NA T2 genotyping and phenotyping . 
./ Discovering new mutat ions, identify ing and classifying them if present. 
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Chapter 3 :  Methods 
This study was approved by the Research Ethics Committee of the Faculty 
of Medicine and Health Sciences of UAE Un ivers ity (AI-Ain Medica l District Human 
Research Ethical Committee, AAMD/HREC No: 2 1  M059) . No deviation from the 
protocol was implemented without the prior review and approval .  
3.1 Researc h  Des i g n  
3 . 1 . 1  Type o f  Study 
Randomized , open labeled and mUlt i-center study of the CYP1A2 and NA T2 
polymorphism and their phenotyping and genotyping corre lation in  Emirati 
population ,  from the period of September 20 1 2  t i l l  September 201 6. 
3 . 1 .2  Sett ing 
Al l  the  7 emirates of  UAE were involved ; subjects were UAE National 
volunteers. 
3 . 1 . 3  I nc lud i ng C riteria 
Healthy subjects of more than 1 2  years of age. 
3 . 1 .4 Exc lus ion Criter ia 
Subjects who were smokers, not Emirati or aged less than 1 2  years were 
excluded. 
3 . 1 .5  Place of Study 
The study was conducted in  the Un ited Arab Emirate
s. 
6 1  
3 . 1 .6  Study Duration I Period of  Study 
The period of this study started from September 201 2 and ended in 
September 20 1 6  du ring the PhD study period . 
3 . 1 .7 Eth ics and Eth ica l  Approva ls 
Ethical approval for the research was taken by the Research Eth ics 
Committee of the Facu lty of Medicine and Health Sciences of UAE Un iversity 
(Appendix 1 and 2: AI-Ain Medical District Human Research Ethical Committee , 
AAM D/H REC No:  2 1  M059).  
Commun ication letters were prepared and submitted for a l l  the places that 
we were plann ing to visit for samples col lect ion.  Approval letters were collected from 
that places that had been vis ited (Appendix 3: UAEU Approval ,  Appendix 4: Abu 
Dhabi Education counci l (ADEC) Approva l ,  Appendix 5 :  Dubai Education zone 
Approval and Append ix 6: Ras AI Khaimah Education Zone Approval ) .  The 
volunteers signed a written consent form that their part icipation is voluntary 
(Appendix 7 :  Consent Form).  
3 . 1 .8  Sampl ing  
I ndividua ls  with U nited Arab Emirates national ity had been chosen who were 
above 1 2  years o ld ,  non-smokers and had been assigned randomly in a systemic 
way, from multicenters including a l l  of the Emirates of UAE. 
The assigned number of ind ividuals who participated from each Emirate was 
defined based on UAE National Bureau of statistics of UAE (Emiratis) population 
(Table 8) .  
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Sample S ize Ca lcu lation 
The sample size calculation was carried out to ensure the precision of 
confidence interva l  to be 5%. Although ,  the frequencies of a l leles were d ifferent from 
region to region we used sample size calculation assuming the maximum variabi l ity 
in data. By doing so,  the sample size requ i red for this prevalence study was around 
500 subjects .  The volunteers signed a written consent form that their participation 
was voluntary .  To ensure that this number was achieved we recru ited 581 subjects 
( 1 6% more subjects) to make up for incomplete data and withdrawals .  
Sample Col lection  
Based on UAE populat ion (Em iratis) d istribution between the  Emirates, the 
expected d istribution of our samples was shown in  fo l lowing table (Table 8): 
Table 8 :  The expected d istribution of our samples based on the distribution of UAE 
populat ion (Emiratis) between the Emirates 
UAE e m i rates 
Abu Dhabi  (AD) 
Duba i  
Sharjah 
Ras AIKhaimah 
F uja irah 
Ajman 
U m  A I  Q uwain 
Tota l 
3 .2  Data Co l lection 
Population 
400000 = 42% 
1 7 1 000 = 1 8% 
1 52000 = 1 6% 
95000 = 1 0% 
66500 = 7% 
47500 = 5% 
1 9000 = 2% 
950000 = 1 00% 
Samples expected to be col lect 






1 0  samples 
500 samples 
Data co l lect ion form was fi l led by each volunteer who agreed to participate 
and sig ned the consent form only (Appendix 8: Data Col lection Form).  This was 
fol lowed by samples col lection and treated as anonymous since no names were 
disseminated. F ina l ly ,  codes were assigned for each volunteer that had been used 
in tracing the data in data col lection and analysis .  
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3 .2 . 1  Sample Col lection 
Five hundred and eighty one subjects were enrol led in  this study. The 
subjects were asked S imply to consume 300ml of a caffeinated cola d rink or a cup of 
strong tea or coffee and then to provide a spot urine sample 2 hours later. No 
restrict ions whatsoever regarding food intake or caffe ine consumption are requ i red 
of our  subjects prior to their taking part in the study. However, volunteers were 
asked not to consume any of these beverages during the two hours period . 
I n  addit ion ,  each volunteer had to provide buccal swab at the time of urine 
sample col lect ion using I sohel ix SK1  buccal swabs with Isohel ix dri -capsules for 
sample col lection (F igure 1 1 ) . This bucca l swab had a unique swab matrix that 
g reatly improves DNA yie lds , it is an a lternative to blood collection method , suitable 
for human ,  easy to handle and qu ick to use. 
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Figure 1 1 :  I n struction of I sohel ix SK1  buccal swabs use 
3 .2 .2  Storage and  Arrangement for U rine Samples and Buccal  Swabs 
Urine samples were placed on ice immediately after voiding and the pH of 
each sample was adjusted to <3 .5  with in  1 to 2 hours of collection to prevent loss of 
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5-acety lamino-6-formylami no-3-methylu racil (AFMU) ,  a key metabol ite of caffeine 
and other caffeine metabolites .  After adjustment of pH,  al iquots of urine were stored 
at -200 C unt i l  analysis .  Sample ana lysis was done as described by Grant et al 1 984 
and Woolhouse et al 1 997 as deta i led in the fo l lowing sections.  
The col lected buccal swab which consisted of Isohel ix SK1  buccal swabs 
and I sohel ix d ri-capsule for each subject was placed immediately on ice after 
col lect ion and then was stored at -200 C unt i l  analysis.  
3 .2 .3  Determ i nation of Phenotypes 
3 .2 .3 . 1  The Extraction Protocol of Caffe ine Meta bol ites from U rine 
The u rine samples were thawed to  room temperature and vortexed 
thorough ly  for 1 m inute, u ltrason icated for 1 5  minutes and vortexed again for 5 
seconds.  Then,  0 .2m l  of uri ne and 1 20mg ammonium su lfate were added into a 
labeled clean 1 5m l  centrifuge tube and vortexed for 30 seconds. This was fol lowed 
by the addit ion of 6ml of chloroform :  isopropanol (95:5)  and vortexed for 1 minute. 
The solut ion was centrifuged at 3000g for 5 minutes; the supernatant 
aqueous phase was carefu l ly removed and dried in N2 flow at 42 °C . Final ly ,  when 
the dryness of the solut ion was assured 0 .5  ml of acetic acid (0.05%) was added to 
dissolve the contents. 
3 . 2 .3 .2  Us ing HPLC Method 
The m ixture was fi lte red throug h  0.22u filter, 1 00 u l  of the final product was 
injected into the column of H PLC. Each sample took one hour to complete the cycle 
on the H PLC. 
High performance l iquid chromatography (HPLC) was performed by 
separating the metabol ites using a reversed-phase 4 .6x 250 mm column (u ltra-
6S 
sphere ODS-35uM ,  H ichrom,  U K) and eluted with mobile phases A (0.045% acetic 
acid) and B ( 1 00% methanol) using a gradient profile starting 1 ml/min ,  1 8% B at 0 
minute and increasing to 50% B at 27 minute; increasing to 90% B at 32 minute; 
90% B at 37 minute; reduced to 1 8% B at 42 minute t i l l  the end of 50 minute for re­
equ i l ibrat ion.  
The standards included AFMU,  1 MU, 1 MX, 1 7MU,  1 7MX and 1 37MX. 
S pectra l conformation of caffeine metabol ite peaks was performed routinely, using a 
programmable mult ip le wavelength detector (Waters 2998PDA, Waters Corp. , 
M i lford MA). Us ing th is methodology,  recovery of caffeine,  paraxanthine, AFMU and 
1 -methylxanthine ranged from 91 to 1 03%. 
Subsequent ly ,  the levels of caffe ine metabol ites including caffeine, AFMU, 
1 7MX,  1 7M U ,  1 M U and 1 MX were determined by H PLC. 
Based on Butler et a l  ( 1 992), caffe ine 3-demethylation activity (CYP1A2) was 
assessed by determ in ing the ratio ( 1 7MX + 1 7MU)/1 37MX. This molar ratio 
correlates wel l  with the rate constant for hepatic 3-demethylation of caffe ine based 
on a pharmacokinetic study ( r= 0 .73,  P value = 0.007) compared to other urinary 
metabol ism ratios 1 7MXl1 37MX, (AFMU+1  MX+ 1 MU)/1 7MU and 
(AAMU + 1  MX+1 M U )/ 1 7MU (Butler MA et a l  1 992) .  Since other studies had used this 
molar rat io,  this measure was calculated and compared in this study, the frequency 
d istri bution of ( 1 7 MX + 1 7M U)/1 37MX in  our data ind icated a trimodal distribution 
with specific cut points that represented slow, intermediate and rapid acetylators. 
The ratio of ( 1 7MX+ 1 7MU)/1 37MX was calcu lated to determine the 
phenotype status of CYP 1 A2 activity in each subject as described by Tang B et al 
1 994 and Joshua EM et al 2008; the following table was used to identify the 
CYP1 A2 status (Table 9). 
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Table 9 :  Classification of CYP1 A2 enzyme activity based on the ratio of ( 1 7MX+ 
1 7M U)/1 37MX 
( 1 7MX+ 1 7M U )/1 37MX ratio E nzyme activity status 
0 .7  2 .5  
2 .5 1 -6.5 
6 .5 1 - above 
Slow CYP 1 A2 enzyme activity 
I ntermediate CYP1 A2 enzyme activity 
Rapid CYP 1 A2 enzyme activity 
Caffeine 3-demethylation activity (NAT2) was assessed by determining the 
ratio of AFMU/1 MX. This molar ratio correlates well with the rate constant for hepatic 
3-demethylat ion of caffe ine based on a pharmacokinetic study (Butler MA et al 
1 992) .  Th is ratio typical ly fa l ls into three phenotypes (s low, intermediate or rapid) 
( Butler MA et a l  1 992) .  The ratio of AFMU/1 MX was ca lculated to determ ine the 
phenotype status of NA T2 activity in each subject as described by Grant OM et al 
1 984 and Woolhouse NM et al 1 997 .  Table 1 0  was used to identify the acetylator 
status by calculat ion of AFM U/1  MX ratio. 
Table 1 0 : The acetylator status of NA T2 activity was class ified based on the ratio of 
AFMU/1 MX 
A F M u/1 M X  ratio 




Slow NA T2 acetylator 
I ntermed iate NA T2 acetylator 
Rapid NA T2 acetylator 
3. 2.4 Determi nation of Genotypes 
3. 2.4. 1 The Extraction Protocol of DNA from the Isohel ix SK1 Buccal  
Swa bs 
DNA isolat ion protocol ( ref: http ://www. isohel ix. com/documentation) was 
carried out using I sohel ix Buccal DNA I solation Kit. Isohel ix Bucca l DNA Iso lation 
Kits were specifica l ly  formu lated to produce h igh DNA yield and purity from buccal 
swabs. The kits were fully opt imised at ce l l  projects LTD company (UK) for use on 
buccal cel l  samples and offer reduced handl ing t imes, increased DNA yields and 
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many other Important tech nical benefits for their use in manual ,  96-wel l  or other h igh 
throughput formats . 
Part 1 :  DNA Sta b i l ization 
Five hund red microl iter Lysis buffer (LS solution) and 201-11 Proteinase K (PK 
solut ion) from kit were added to the tube contain ing the buccal swab and vortexed 
briefly .  At th is point the DNA was stabil ized to proceed for DNA isolation or store the 
stabi l ized swab in a sealed tube at room temperature which can be stored for at 
least 3 � years .  
Part 2 :  DNA I solation 
After DNA stabi l ization , the tube conta in ing the swab, LS solution and PK 
solut ion was placed in  a 60 °C water bath for 1 hour and vortex briefly .  Then,  the 
l iqu id in the tube (approximately 4001J1)  was transferred into a 1 . 5ml centrifuge tube 
using a steri le p ipette t ip .  Then,  4001J1 of Capture buffer (CT solution) was added to 
the tube and vortexed briefly and the tube was then placed in  a micro-centrifuge 
(with h inge posit ioned outwards so the l iqu id can be removed from the opposite 
side) and spun at maximum speed ( 1 3 .4K rpm/1 2,000 x g)  for 7 minutes to pel let the 
DNA. Subsequently, a l l  the supernatant were careful ly removed with a pipette t ip 
taking care not to d isturb the DNA pel let. The tube was re-spun briefly and any 
remain ing l iqu id removed as  it was important to do this.  Then, a smal l  volume of re­
hydration buffer (TE solut ion) "-701J1" was added to the tube to d issolve the DNA. 
The solution was left for at least 1 0 minutes at room temperature and vortexed 
briefly for the DNA to re-hydrate . F ina l ly, the tube was re-spun for 1 5  minutes at 
max imum speed ( 1 3 .4K rpm/1 2 ,000 x g) to remove un-d issolved debris .  The 
supernatant was transferred to a steri le 1 . 5ml  tube, be ing careful not to d isturb the 
pel let . 
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The DNA sample at th is stage was ready for use in ampl ification. The 
storage of the D NA sample was at 4 °C for short term storage or at -20 °C for long 
term storage.  The expected yield from a buccal swab was on average 1 to 1 0IJg 
DNA (5  to 70ng/lJ l )  from an adult .  
The purity and concentration of the DNA was ascertained by measuring the 
optical density of the D NA samples using Nano Drop Spectrophotometer. 
At this stage and before starting PCR and during PCR,  care was taken to 
avoid contam ination as PCR assays requ i re special laboratory practices to avoid 
fa lse posit ive ampl ifications.  
3.2 .4 .2  TaqMan Rea l Time PCR (Polymerase Cha in  Reaction)  
TaqMan genotyping assays genotype s ingle nucleotide polymorphisms 
(SNPs) using the 5' nuclease assay for ampl ifyi ng and detecting specific SNP 
al le les in  purified genomic DNA samples. Each assay a l lows to genotype individuals 
for a specific SNP .  Each TaqMan genotyping assay contains two primers for 
ampl ifying the sequence of interest and two TaqMan Minor Groove Binder (TaqMan 
MGB) probes for detecting a l le les.  The presence of two probe pairs in each reaction 
a l lows genotyping of the two possible variant a l le les at the SNP site in a DNA target 
sequence. The genotyping assay determines the presence or absence of a SNP 
based on the change in  fl uorescence of  the dyes associated with the probes. 
The TaqMan® MGB Probes consist of target-specific ol igonucleotides with: 
f irst a reporter dye at the 5' end of each probe (VIC dye is l inked to the 5 '  end of the 
Al le le 1 p robe and FAM dye is l inked to the 5' end of the Al le le 2 probe) (Table 1 1 ) . 
Second, a MGB increased the melt ing temperature (Tm) without increasing probe 
length (Afon ina L et al 1 997) , thereby a l lowing the design of shorter probes; shorter 
probes resu lted in  g reater d ifferences in  Tm values between matched and 
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mismatched probes, resu lt ing in accurate al lel ic discrimination. Th ird , a non­
fl uorescent quencher (N FQ) was at the 3 '  end of the probe. Because the quencher 
did not fl uoresce, Appl ied Biosystems Real Time PCR system could measure 
reporter dye contribut ions with great sensitivity. 
The assays are suppl ied by Life Technolog ies "Applied Biosystems" , USA. 
The deta i led procedure can be checked by TaqMan® SNP genotyping assays 
protocol booklet provided by Applied Biosystems.  
Table 1 1 :  F luorescence s ignal  corre lations 
Fluorescence Increase 
VIC dye F luorescence only 
6FAM dye F luorescence only 
F luorescence s ignals for both dyes 
I nd ication 
Homozygosity for al lele 1 
Homozygosity for a l lele 2 
Heterozygosity for a l lele 1 and al lele 2 
Basics of the 5 ' N uc lease Assay and d u ri n g  peR 
Genomic DNA was introduced into a reaction mixture consisting of TaqMan 
Genotyping Master Mix, forward a nd reverse primers and two TaqMan MGB Probes. 
Each TaqMan MGB Probe annealed specifica l ly  to its complementary sequence, if 
present, between the forward and reverse primer sites. When the probe was intact, 
the proximity of the reporter dye to the quencher dye resulted in quenching of the 
reporter fluorescence primari ly by Forster-type energy transfer (Lakowicz JR 1 983) . 
The primers bounded to the template were extended by AmpliTaq Gold DNA 
Polymerase which in  turn cleaved the probes only that were hybridized to the target .  
The cleavage separated the reporter dye from the quencher dye, which resu lted in 
increased fluorescence signa l  by the reporter. Thus, the fluorescence signal 
generated by PCR ampl ification ind icated which a l leles were presented in  the sample 
(Figure 1 2) .  
sa Componen and D A em pIa e 
3. Signa Geoer c n 
70 
Figure 1 2 : Complementary TaqMan probe fl uorescenes after it anneals to the 
template and after cleavage by Ampl iTaq Gold DNA Polymerase U P  
C YP1A2 genotyping of a l l  subjects was determined b y  TaqMan Real Time 
PCR analysis to detect the five major observed C YP1 A2 mutations responsible for 
the phenotype (slow) of the correspond ing a l lele described as smal l  subset of G-
3860A, C-729T, 2 1 1 6G>A, 2499A> T and 5090C> T substitutions.  
The G-3860A substitution was found in  the C YP1 A2*1 C gene. I t  was located 
in the Sf-flank ing reg ion of human C YP1 A2 gene a ltering guanine (wi ld type) to 
adenine (mutated type) at posit ion 2964 in the gene. The C-729T substitution was 
found in C YP1 A2*1  K gene.  it was located in the intron 1 region of the gene 
e 
F ,":a r: € 
7 1  
changing cytosine (wi ld type) t o  thymine (mutated type) a t  position 873 in the gene 
as metioned earl ier  in  table 3. 
The 2 1 1 6G>A missense sUbstitution was found on C YP1 A2*3 gene cluster. 
I t  was located in exon 4 causing Asp348Asn .  The 2499A> T missense sUbstitution 
was found on the C YP 1  A2*4 gene cluster. I t  was located in exon 5 leading to 
l Ie386Phe.  The 5090C> T missense substitution was found on the CYP1 A2*6 gene 
cluster. It was located in exon 7 lead ing to Arg431 Trp. The WT al lele was formerly 
defined as the absence of G-3860A, C-729T, 2 1 1 6G>A, 2499A>T and 5090C>T 
nucleotide substitutions as metioned earl ier in  table 3. 
The presence of these mutations "G-3860A, C-729T, 2 1 1 6G>A, 2499A>T 
and 5090C> T" were determined by specific designed assays. Each assay was able 
to genotype ind ividuals for a specific SNP .  Each TaqMan genotyping assay 
conta ined two primers for ampl ifying the sequence of interest and two TaqMan Minor 
Groove Binder (TaqMan MGB) probes for detecting al leles. The presence of two 
probe pairs in each reaction defined the genotyping of the two possible variant a l leles 
at the S N P  site in a DNA target sequence. The genotyping assay determ ined the 
presence or absence of a S N P  based on the change in fluorescence of the dyes 
associated with the probes. 
In our assay, TaqMan genotyping assays were used to identify the important 
S N Ps that we investigated in C YP1A2 gene (rs20695 1 4, rs 1 2720461 , rs56276455, 
rs725475 1 6  and rs28399424). The assays with their I Ds had been defined by the 
manufacturer company (Thermo Fisher Scientific) for each dbSNP with their specific 
primers that wou ld  detect a specific s ingle nucleotide changes. Particularly, G-3860A, 
C-729T, 2 1 1 6G>A, 2499A> T and 5090C> T that represented the major 
S NPs/alterations responsible for the slow phenotype of the corresponding *1 C, *1 K, 
*3, *4 and *6 haplotypes, respectively (Table 1 2). 
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Table 1 2 : Assay 10  or design that has been used for each SNP 
Forward and Reverse VIC dye- FAM dye-
Assay 10 dbSNP Haplotype 
Primers Context Sequence fluorescence fluorescence Allele 
[VIC/FAM)" signal generated signal generated Nomenclature 
G 
TGGCTCACCGCAACCTCC 
Wild type allele 
rs20695 
At poSItion A 
C 1 585 3860 GCCTCTC[G/A]GA TTCAAG 
Mutant allele 
9191_30 1 4  CAATTGTCATGCCCCAG 
CYP1A2'1 C  
C 
At position GGCTAGGTGTAGGGGTC 
Wild type allele 
T 
C -3063 rs12720 729 CTGAGTTC[CfT]GGGCTTT 
Mutant allele 
4 1 46_10 461 GCTACCCAGCTCTTGACT 
CYP1A2'1 K 
G 
At position GTACATGGGGGCCCCCA 
Wild type allele 
• A 
C -3063 rs56276 21 16  ACCCTATA[G/AjACAGAGG 
Mutant allele 
4247_20 455 AAGATCCAGAAGGAGCTG 
CYP1A2'3 
A • 
At position ACACTCCTCCTTCTTGCC 
Wild type allele 
T 
C -3063 rs72547 2499 CTTCACC[AfT]TCCCCCAC 
Mutant allele 
4246_1 0  5 1 6  AGGTGAGGCCTGCCGGT 
CYP1A2'4 
GGACCCCTCTGAGTTCCG C • Wild type allele 
At position 
GCCTGAG[CfT]GGTTCCT 





4244_20 424 C CYP1A2'6 
Dote represent no signal has been generated 
Storage a n d  Sta b i l i ty 
TaqMan Genotyping Master Mix is stable when stored at 2 to 8 °C. 
S pecific G u i de l i nes 
Particu larly  for TaqMan rea l  t ime PCR,  defin ing the method for adding DNA 
is important.  Wet DNA del ivery was selected where the al iquot genotyping rea
ction 
m ixed to an optical react ion plate and del ivered genomic DNA to the fi n
al reaction 
mix. 
Nevertheless, proper selection of the instrument and reaction
 plate is a lso 
essentia l  in  order to detect and record the fluorescent s
ignals generated by the 
cleavage of TaqMan probes. For that, Applied B
iosystems Thermal Cycler 
QuantStudio 7 Flex (278870068) with MicroAmp ™
 Optical 96-wel l  reaction plate; 
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react ion volume 20uL was used throughout the experiments . F igure 1 3  summarizes 
the procedures for performing a genotyping experiment. 
F ina l ly .  quantify ing genomic DNA by adding 1 to 1 0  ng of DNA template per 
reaction wel l  to have a un iformed DNA concentration with al l the samples and along 
the experiment .  Quantitate genomic DNA has been done using Nano Drop 
Spectrophotometer machine for DNA quantificat ion. 
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Figure 1 3: Overv iew of a genotyping experiment using Real Time pe
R 
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P repar ing the Reacti on M i x  G u idel i nes 
For opt imal  PCR performance: first, al l  TaqMan reagents were kept 
protected from l ight unt i l  they were ready to use as excessive exposure to l ight may 
affect the f luorescent probes. Second,  freeze-thaw cycles were min imized . Third ,  
prior to use: the TaqMan Genotyping Master M ix was mixed thoroughly by  swir l ing 
the bott le ,  thawing any frozen TaqMan reagents by placing them on ice and when 
thawed , the samples were re-suspended by vortexing then centrifuging the tubes 
briefly. F ina l ly ,  the PCR reaction mix was prepared for each assay before 
transferri ng it to the optical reaction plate for thermal cycl ing and fluorescence 
analysis .  
The number of reactions were calcu lated to be performed for each assay 
with one extra reaction for each ten to provide excess volume for the loss that occur 
during reagent transfers . Then , the volume was calcu lated of each reaction mix 
com ponent needed for each assay "20ul reaction for each sample using 96-wel l  
standard plate". 
The react ion p late was prepared using wet DNA del ivery method by pi petting 
the reaction mix into each wel l  of a reaction plate , inspecting each well for vo lume 
un iformity, noting which wel ls do not conta in the proper volume,  covering the plate 
with MicroAmp Optical Adhesive F i lm ,  centrifug ing the plate briefly to spin down the 
contents and e l im inat ing any air bubbles from the solutions, d i lut ing 1 to 1 0  ng of 
each purified genomic DNA sample into DNAase-free water, pipetting samples into 
the plate, covering the plate with M icroAmp Optical Adhesive F i lm or M icroAmp 
Optica l Caps and centrifug ing the plate briefly to spin down the contents and 
e l iminate a i r  bubbles from the solutions. 
Later, ampl ificat ion of genomic DNA was performed by the Sequence 
Detect ion System (SDS) using the thermal cycl ing condition that specified and 
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optim ized to  be used with Taq Man genotyping assay on ly  (F igure 1 4) where 1 cycle 
denaturation at 60°C in it ia l ly for 30 sec, then held at 95°C for 1 0min ,  then 40 cycle 
(denature at 95°C for 1 5  sec and anneal/extend at 60°C for 1 min) ,  then 1 cycle at 
60°C for 30. Standard mode thermal cycl ing setting was selected in the plate 
document (F igure 1 5) ,  the reaction volume was settled accordingly and the reaction 




Figu re 1 4: The thermal cycl ing condit ion specified for our TaqMan genotyping 
assays for C YP1A2 
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Figure 1 5 : The Standard mode thermal cycl ing settin
g 
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Al le l ic  D iscr imination Plate Read and Analysis 
After peR ampl ificat ion,  an endpoint plate read was performed on a Real 
Time peR instrument ( ppl ied Bio y terns Thermal Cycler Quant tudio 7 Flex 
mod I no. 278870068) using the fluorescence measurements (Rn) made during the 
plate read and the SOS software plots Rn values based on the fluorescence signals 
from each wel l .  
The  plotted fluorescence signals ind icated which a l leles were in each sample 
"The SOS software plots showed the results of the al lel ic d iscrimination run on a 
scatter plot of Al le le 1 versus Al le le 2 .  Each well of the 96-wel l  plate was 
represented as an individual  point on the plot" (Figure 1 6) .  The al leles were 
determ ined in each sample as fo l lowing :  first, the al le l ic discrimination plate read 
documents were created and set up (F igure 1 7) .  Second , post-peR a l le l ic 
d iscrim ination plate read was performed on a real t ime peR instrument (Figure 1 8) .  
Th i rd ,  the plate read documents were ana lyzed. F ina l ly ,  an automatic or manual 





2 3  
1 6  








Homozygous for Alle.e 
0.3 
0 1  0 3  
• 
o Templa: e Control 
0 5  0 7  0 9  
AI Ie C) R 
1 . 1 1 3 
Figure 1 6: Variat ion in  c lustering due to the genotype of the target a l lele 
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Figure 1 7 : The a l le l ic  d iscrim ination plate read document 
F igure 1 8 : RT -peR plate layout during sample runn ing in the system 
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The C YP1A2*1A haplotype represented the wild type al lele whereas 
C YP1A2* 1 C, C YP1A2*1K, C YP1A2*3, C YP1A2*4 and CYP1A2*6 genotypes 
represented the mutant a l le les.  I nd ividuals who were homozygote for CYP1A2 
polymorphisms ( * 1  C, * 1  K, *3, *4 and *6) were classified as slow phenotype. 
I nd iv iduals who were heterozygote for C YP1A2 polymorph isms had an intermediate 
phenotype. I ndividuals who lacked C YP1A2 polymorph isms had a extensive or 
normal phenotype. 
3 .2.4.3 Polymerase Cha in  Reaction - Restriction Fragment Length 
Polymorphism ( PCR - RFLP) 
3 .2 .4. 3 . 1  Polymerase Chain Reaction (PCR) 
Ampl ificat ion of  genomic DNA was performed by the polymerase cha in 
react ion (PCR) us ing the pair of forward and reverse ol igonucleotide primers of 
NA T2, master mix that is specified for NA T2 ampl ification and to be ampl ified at 
certain condit ions as described by H ickman & Sim ( 1 99 1 ) . 
Reagents for pe R 
Tenfold PCR buffer concentrate, including magnesium chloride ( 1 5mM) ,  was 
suppl ied by the manufacturer Bio l ine of the DNA Taq polymerase, the Q solut ion, 
Deoxynucleoside tr iphosphates (dNTPs) ,  restriction enzymes: Msp l ,  Dde l ,  Fok l ,  
kpn l ,  Taq l and Bam H I ,  restrict ion enzyme buffer 1 0-fold concentrate supplied by  the 
manufacturer of the restrict ion enzymes, steri le water for the ampl ification and 
themostable DNA Taq polymerase supplied by the manufacturer. 
The reagents were stored at -20 °C and the work was done on ice through al l  
the procedures, the PCR tubes were kept on ice unti l  placed in the thermal cycle
r. 
The Q solut ion faci l i tates ampl ification of templates that have a h igh d
egree of 
secondary structure or that are GC-rich by modifying the melting b
ehavior of DNA. 
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The PCR buffer provides a fina l  concentration of 1 . 5mM MgCI2 in  the fi nal reaction 
mix which provided satisfactory results. 
Am pl ifi cation of 442b p  and 559bp Segments of NA T2 Gene Sequence 
Genomic DNA was obta ined from the buccal swab samples of subjects by 
specific proced ure for extract ion.  DNA ampl ification was performed by thermocycler 
GeneAmp® PCR system 9700 version 3 . 1 2  using 0 . 1 -0 .5 IJM of ol igonucleotide 
primers (forward primers ;  5/-GTC ACA CGA GGA M T CM ATG C-3' and 5/-ACA 
CM GGG TTT A TT TTG TTC C-3/) 1 8 .6nmol/1 00ul and (reverse primers; 5/-ACC 
CAG CAT CGA CM TGT M T TCC TGC CCT CA-3' and 5/-M T T AC A TT GTC 
GAT GCT GGG T-3/) 1 1 .03nmol/1 00ul described by Hickman and Sim ( 1 99 1 )  in a 
20 IJ I  m ixtu re of 2u l  of 1 0X solut ion (PCR buffer contain 1 5mM MgCI2, 4ul of Q 
solut ion (5X), 0 .2u l  of dNTP solut ion 200uM,  1 1  ul H20 (sterile water for 
ampl ificat ion) ,  0 .2u l  of Taq DNA polymerase 2 .5  un its/reaction, 0 .8ul of each primer 
and 1 ug of the sample DNA. Reagents and mixture were kept on ice during 
preparat ion .  Negative control (DNA not added) was used for qual ity contro l .  
The 1 0X buffer, dNTP mix ,  primer solut ions, Q-solution , sterile water for 
ampl ificat ion and Taq DNA polymerase were thawed on ice and the master mix was 
kept on ice after complete thawing and mixed thoroughly before use to avoid 
loca l ized d ifferences in salt concentrat ion. The reaction mix was prepared 
accord ing ly and mixed gently but thoroughly by p ipetting up and down a few times. 
Then, the template DNA ($ 1 ug/reaction) was added to the individual PCR tubes 
contain ing the react ion mix. F ina l ly ,  ampl ification was done using GeneAmp® PCR 
system 9700 vers ion 3. 1 2 . Ampl ificat ion conditions were denaturation 1 cycle at 
94°C for 5 m in ,  then 35 cycles (94°C 30 sec, 56°C 1 min,  72°C 2 min) ,  then 1 cycle 
72°C 7 m in ,  then cool ing at 4°C (F igure 1 9) .  
Figure 1 9 : The thermocycler program for the NA T2-PCR 
Reagents for Aga rose Gel Electrophoresis 
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Agarose ,  bromophenol b lue,  ethid ium bromide "store in dark p lace" , Boric 
acid (H3B03) ,  ethylenediaminetetraacetic acid d isodium salt dehydrate (EDTA) and 
tr is-hydroxymethylaminomethane (TRIS) .  The last three were used to prepare the 
TBE buffer concentrate (Table 1 3) .  The agarose gel was prepared by dissolving 
agarose in TBE solut ion in  d ifferent concentrations based on the needs.  One 
percent gel concentration was prepared to run the control PCR before digestion. 
One percent, 1 . 5% and 2 .5% gel  concentration were prepared to run PCR after 
d igestion with certa in  enzymes. Then ,  the gel was placed in electrophoresis 
mach ine with addit ion of Eth id ium bromide (0 .5ug/m l)  5uL.  
The 1 00bp DNA ladder (supplied by Promega Corporat ion, USA) was 
composed of bands where the fragments of DNA samples would be compared to. It 
cons isted of e leven double-stranded DNA fragments with sizes of 1 00, 200, 300, 
400, 500, 600, 700, 800, 900, 1 000 and 1 500bp. The intensity of these fragments 
appeared to be equal  on the ge l  with an exception of the 500bp band which showed 
triple the intensity of other fragments. Accordingly,  the DNA ladder and DNA 
samples were added into specific wel ls  to be run in  the gel for certain t ime (60-90 
minutes) under 80- 1 00 V cm-1 . 





2L 1 L  500mL 
1 1 0g 55g 27 .5g 
2 1 6g 1 08g 54g 
E ?TA 1 4. 8g 7 .4g 3 . 7g 
Dissolve T R I S  and EDTA first then add Boric acid . Make up to volume with d istilled water 
3 .2.4.3 .2  Restriction Frag ment Length Polymorphism (RFLP) 
8 1  
I n  molecular biology, restrict ion fragment length polymorphism (RFLP) i s  a 
technique that exploits variat ions in homologous DNA sequences. It refers to 
a d ifference between samples of homologous DNA molecules from different 
l ocat ions of restrict ion enzyme sites.  I n  RFLP analysis, the DNA sample was broken 
into pieces (d igested) by restrict ion enzymes and the result ing restriction 
fragments were separated accord ing to their lengths by gel e lectrophoresis. NA T2 
genotyping of a l l  subjects was carried out by PCR-RFLP analysis as described by 
Vatsis KP et al ( 1 995),  Woolhouse NM et a l ( 1 997) and Chida M et al ( 1 999). 
NA T2 genotype of a l l  subjects was determ ined by PCR-RFLP analysis to 
detect the four commonly observed NA T2 mutation associated with slow acetylation 
usual ly described as minor a l lele of 1 9 1 G>A (rs 1 80 1 279), 34 1 T>C (rs 1 801 280), 
590G>A (rs 1 799930) and 857G>A (rs 1 79993 1 ) . The 34 1 T>C (rs 1 80 1 280) 
substitution is found in NA T2*5 gene cluster. The 590G>A missense substitution is 
found in NA T2*6 gene c luster. The 857G>A missense substitution is found on 
NA T2*7 gene cluster. The 1 91 G>A missense substitution is found on the NA T2*14  
gene cluster (Vats is K P et  al  1 995). The WT al le le was formerly defined as  the 
absence of 341 T>C, 590G>A, 857G>A and 1 9 1 G>A nucleotide substitutions. 
The presence of these mutat ions "34 1  T>C, 590G>A, 857G>A and 1 9 1  G>A" 
were determined by restriction endonuclease d igestion us ing Ddel ,  Taq l ,  BamH I  and 
Mspl , respective ly. Then , the presence of 282C>T, 481 C>T and 803A>G were 
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determined by restrict ion endonuclease d igestion using Fok l ,  Kpnl and Ddel 
respectively  to identify the gene cluster or subtype. After amplification of DNA, 
d igestion of the PCR product ( 1  ug - quantitate genomic DNA has been done using 
Nano Drop Spectrophotometer machine for DNA quantification . )  was carried out in a 
total volume of SOul  using the appropriate d igestion buffer (Table 1 4) .  The PCR 
product obta ined using aforementioned primers was digested in separate 
experiments for 6hrs at 37° with Kpn l ,  Dde l , Fok l ,  BamHI  and Mspl and for 8hrs at 
6S0 with Taq i .  Digested DNA ( 1 0ul)  then was separated by electrophoresis on 1 %  
for Mspl  restrict ion enzyme, 1 . S% for Dde l ,  Fok l ,  Kpnl and BamH I  restriction 
enzyme and 2 .S% for Taq l  restrict ion enzyme agarose gel under 80-1 00 V cm-1 
(Table 1 4) .  DNA bands were visual ized with ethid ium bromide and UV 
trans i l l uminat ion.  
Table 1 4 : The restrict ion cleavage for the ampl ificates of the PCR product 
Volumes for one sample 
Kpnl  Taq l BamHI  Mspl Dde l Fokl 
PCR product 1 ug 1 ug 1 ug 1 ug 1 ug 1 ug 
Master mix 
Restrict ion enzyme 1 u l  1 u l  1 u l  1 u l  1 u l  1 u l  
1 0X N E  Buffer Su i  Su i  Su i  Su i  Su i  Sui 
Total Rxn Volume SOul  SOul SOul SOul SOul SOul 
I ncu bation 37° C 6So C 37° C 37° C 37° C 37° C 
Temperature 
I ncubat ion Time 6hrs 8 hrs .  6hrs 6 hrs. 6 hrs.  6 hrs.  
Can a lso be used overn ight with no star activity 
Agarose ge l  to run the 1 . S% 2 .S% 1 .S% 1 %  1 .S% 1 . S% 
samples 
P rimers 
The pa i rs of forward and reverse ol igonucleotide primers were (forward 
primers ;  S'-GTC ACA CGA GGA M T CM A TG C-3' and S'-ACA CM GGG TTT 
ATT TTG TTC C-3') and (reverse primers; S'-ACC CAG CAT CGA CM TGT MT 
TCC TGC CCT CA-3' and S'-M T TAC ATT GTC GAT GCT GGG T -3') as described 
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by H ickman & Sim ( 1 991 ) respectively were used to ampl ifying 442bp and 559bp 
segment of NA T2 gene sequence. The 442bp fragment was used for 1 9 1  G>A, 
282C> T, 34 1 T>C and 481 C> T mutations detect ion,  whereas the 559bp fragment 
was used for 590G>A, 803A>G and 857G>A mutations detection . 
The primers were d issolved in  steri le water so that concentrations of 
1 00pmol/u l were avai lab le .  They were stored at -200 C. The primers were stable for 
approximately 1 to 2 years under these condit ions. 
DNA Seq uenci ng 
DNA sequencing was done uSing Applied Biosystems 31 30xl Genetic 
Analyzer machine for certa in  a l leles that were not analyzed based on the designed 
eval uation sheet described below (Table 1 6) .  DNA sequencing was done for certa in 
samples randomly as a confirmation of the accuracy of our technique. The gene 
accession number  is NG_0 1 2246 . 1  and the transcript accession number is 
NM 0000 1 5 .2 .  C DS 1 3760 - 1 4632. 
Nomenc latu re 
Using RFLP analysis ,  the presence/absence of polymorphism(s) in each 
DNA sample was identified.  Accord ingly ,  the genotype was determined as per the 
last u pdate of NAT nomenclature scheme publ ished by The Arylamine N -
acety ltransferase Gene Nomenclature Committee accord ing t o  consensus 
gu idel ines (http://nat .mbg.d uth .gr/Human%20NAT2%20a l le les 201 3 .htm) .  
Al le l ic  L in kage Analys is  - Restriction Map of NA T2 and Restriction C leavage 
S ite 
On completion of electrophoresis ,  the wet gel was placed on the UV trans
­
i l lum inator and the eth id ium bromide interca lated in the DNA was exc
ited to cause 
fluorescence emission at 3 1 2  nm.  The band pattern was pho
tographed with the 
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camera of the evaluation device and pri nted out. The results for the investigated 
sample were recorded by marking the pert inent field in an evaluation sheet (Table 
1 6) for each a l le le variation detected in the DNA fragments (Table 1 5) .  The al lele 
combinat ion in  the samples can be determ ined by superimposing the evaluation 
scheme (Table 1 6) of the same scale .  The evaluation is complete, when the 
variations specified on the scheme can be assigned to al i points (reference 
sequence = wild type or sequence variation = mutant) . I f  only one row on the 
eva luat ion scheme showed a match with the entries in the evaluation row, the 
person was a homozygous al le le carrier. I f  two rows of the evaluation sheet 
matched with the evaluation scheme rows, the person was a heterozygous al lele 
carrier .  I f  it was impossible to determine which of the al leles concerned was real ly 
present, DNA seq uencing was done to identify these al le les. 
DNA fragment lengths from the restrict ion cleavage has been i l lustrated by 
the fol lowing table (Table 1 5  and F igure 20) where the reference sequence (RS) = 
wi ld type , sequence variat ion (SV) = mutant and the control peR = 442bp and 
559bp. 
Table 1 5 : The restrict ion cleavage site and its DNA fragment lengths from the 





K p n l  
Taq l  
Odel  
Ba m H I  
F i rst  P C R  = 442 
M utation s ite 
1 9 1  
282 
34 1 




Sequence - fragment lengths ( b p )  
RS - 1 8 1 , 1 68 ,  9 3  
S V  = 2 7 4 ,  1 68 
RS = 337, 1 05 
SV = 442 
RS = 22 1 ,  1 63,  58 
SV = 1 89 , 1 63, 58, 32 
RS = 424, 1 35 
SV = 559 
RS = 226, 1 70, 1 42, 2 1  
S V  = 396, 1 42, 2 1  
R S  = 345, 1 24, 90 
SV = 345, 97, 90, 27 
RS = 5 1 5, 44 
SV - 559 
Second PCR 559 
E xon 1 
1 00bp 
5!U TR 
Intron1 E xon 2 - 1 2 1 5bp 
NAT2 
\ 3' U TR 
1 91 G>A 282C >T 341 T>C 481 C >T 690G>A B03A>G 857G>A 
Figure 20: NA T2 gene structure with the mutation sites 
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The *4 a l le le represents the wild type al lele whereas *5, *6, *7 and *14  
haplotypes represent the  mutant a l le les.  I ndividuals who were homozygous for 
NA T2 polymorph isms (NA T2*5, NA T2*6, NA T2*7 and NA T2* 1 4) were classified as 
slow acetylator phenotype. I ndividuals who were heterozygous for NA T2 
polymorphisms had an  intermediate acetylator phenotype. I ndividuals who lacked 
NA T2 polymorphisms had a rapid acetylator phenotype. 
Al le l ic  L inkage Ana lys is  - Restriction Enzymes 
Evaluation sheet ( = fragment length combination found) and restriction 
enzymes with mutation sites and fragment length for NA T2 have been documented 
in the fol lowing table (Table 1 6) where the control peR = 442 bp and 559 bp to 
show how we assig ned NA T2 a l leles. Nevertheless, examples of fragment lengths 
found for 1 5  samples have been clearly i l l ustrated as guidance. 
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Table 1 6: Eva luation sheet ( or · = fragment length combination found) of the 

























1 0  
1 1  
1 2  
1 3  
1 4  
1 5  
First peR = 442 Second peR = 559 
Mspl( 1 9 1 )  Fokl (282) Ddel (34 1 )  Kpnl (481 )  Taq l (590) Ddel (803) 9amHI 
(857) 
WT 
1 8 1  
1 68 
93 
Mu WT Mu WT Mu WT Mu WT Mu WT Mu WT Mu First peR = 442 bp 
274 337 442 221 1 89 424 559 226 396 345 345 515 559 Second peR 559 
bp 
168 105 163 1 63 1 35 1 70 1 42 1 24 97 44 
58 58 1 42 21 90 90 
32 21 27 
Examples of fragment lengths 
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.J '781"78 (mu/mu) 
homozygote 
v '781'148 (mulmu 
heterozygote 
' 1481*148 (mulmu) 
homozygote 
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3 . 3  Data Ana lys is  
T h e  C YP1A2 haplotype construction and analysis was performed using 
QuantStudioTM 6 and 7 Flex Real Time PCR System Software v1 .0  thorough 
Thermo F isher Cloud Scientific Analysis,  instrument type: QuantStudio 7 Rea l-Time 
PCR S ystem .  Slow and rapid CYP 1 A2 genotypes were reported according to the 
H uman CYP-Al le le Nomenclature Committee .  
The NA T2 haplotype construction and analysis was performed with the 
PHASE v2 . 1 . 1  program (Stephens M et al 200 1 , Agundez JA et a l  2008 and Sel inski 
S et a l  20 1 3a) us ing the default model for recombination rate variation (Li  N and 
Stephens M 2003) . Seven independent runs with 1 000 iterations,  500 burn-in 
iterat ions,  and a th inn ing interva l  of 1 .  The run that showed the maximum 
consistency of resu lts across a l l  runs was selected to be the best run,  as described 
by Agundez et a l .  2008. Slow and rapid NAT2 genotypes were reported accord ing to 
the consensus NAT2 gene nomenclature (Hein OW et al 2008) . 
Data entry analysis SPSS (Statistical Package for the Social  Sciences) 
vers ion 1 9  was used for data entry and analysis .  Kruska l-Wal l is test, Spearman's 
rho and other statistical tests were used for ana lysis l ike Paired sample T test, 
Pearson Chi-Sequare ,  L ikel ihood Ratio, Regression, Ph i ,  Cramer's V, Odds Ratio 
and Relative Risk tests. A p va lue of 0 .05 was considered statistica l ly significant. 
The deviation from Hardy-Weinberg Equi l ibr ium was also calcu lated for each 
genotype to determine whether observed genotype frequencies are consistent with 
Hardy-Weinberg equ i l i br ium using Chi-Sequare test. 
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Chapter 4: Results 
4.1  Popu lation Data 
The study was carried out on 556 non-smoker Emirati males ("95% - mean 
age 1 8  years") and 25 females ("5% - mean age 25 years"). F ive of the recruited 
(-1  %; 3 males and 2 females) had been assigned to standard ize the procedures 
and protocols before proceeding with the study samples and 576 subjects (99%; 
553 males and 23 females) were assigned as study samples. 
The age ranged from 1 6  - 51 years old;  the vast majority of the recruited 
subjects were between 1 6  and 1 9  years of age. (F igure 2 1 ) . 
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Figure 2 1 : The age d istribution of the recru ited subjects 
2 1- 30  >�o 
All of our subjects were from UAE population who were orig inal ly from this 
reg ion . Out of al l  subjects, 269 (46 .3% of the tota l recruits) were from Abu Dhabi 
Emirate (96.6% of them were males and 3 .4% females), 1 1 3 ( 1 9 .4%) were from 
Dubai Emi rate (95 .5% ma les a nd 4 . 5% females) and 1 99 (34 .3%) were from 
Northern Emi rates (94.4% males and 5 .6% females) .  
The d istr ibution of subjects who were enrol led in th is study
 and the areas 
where samples were co l lected represented almost the same d istribution of UAE 
populat ion (Emiratis) between the Emirates. There is no significant d ifference i n  
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sample d istri bution between the Emirates compared to the data provided by UAE 
Nat ional Bureau of statistics of UAE (Emiratis) population (P = 0 .262; using 95% 
confidence interval of d ifferences) us ing Paired Samples T test. 
4.2 Descri ptive Ana lysis of the Rec ru ited Sample 
Out of a l l  sample subjects 290 (50.3%) were chi ldren of consanguineous 
marriages reflect ing the h igh of consanguin ity among Emiratis .  Out of those 290 
subjects ,  1 85 subjects (63.7% " 1 8 1 males and 4 fema les") had th ird degree related 
parents and 1 05 (36.3% " 1 0 1 males and 4 females") had the same tribe or fami ly 
name. On the other hand , 286 subjects (49.7%"27 1 male and 1 5  females) were 
chi ldren of non-relative parents. 
Out of a l l  sample subjects 520 (90% "499 males and 21 females") were 
healthy whereas 56 ( 1 0% "54 ma les and 2 females") had medical i l lness. Out of 
those with h istory of i l l ness 3 subjects (0.6%) had al lerg ic condit ions, 4 subjects 
(0 .8%) had cardiovascular d isease, 23 subjects (4%) were with asthma, 2 subjects 
(0 .4%) had epi lepsy, one subject (0 .2%) had hypercholesterolemia,  one case (0.2%) 
had vertebra l d isc disease, 4 subjects (0. 8%) had diabetes mel l itus, 1 6  cases (2 .9%) 
had Sickle-ce l l  d isorder, one (0. 2%) was with migraine and (0.2%) had thyroid 
disease. 
Out of a l l  sample subjects ,  555 (96 .3% ;  532 males and 23 females) reported 
no sensitivity to medications whereas 2 1  (3 .7%; "; 21 males) subjects had reported 
sensit ivity to med ications.  Out of them 2 cases (0. 3%) had antibiotics a l lergy (not 
specified by the participants), 6 subjects ( 1  %) had sensitivity to G6PD deficiency 
re lated drugs, 2 cases (0. 3%) were sensitive to ibuprofen and 1 1  cases ( 1 . 9%) had 
a l lergies of unknown cause. 
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4.3 H PLC Ana lysis 
H igh performance l iqu id chromatography (H PLC) was performed by 
separating the metabol ites included AFMU,  1 M U , 1 MX, 1 7MU,  1 7MX and 1 37MX, 
and their levels were determ ined based on the area under the curve that has been 
specified through specific retention time for each metabol ites peak (AFMU = 3 . 1 82 ,  
1 M U = 4 .868,  1 MX = 5 .8 1 2 , 1 7MU = 8 .279 ,  1 7MX = 8 .588 and 1 37MX = 1 2 .440) 
measured by specific standards (F igure 22). 
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Figure 22:  Representative chromatogram curves that are specific for caffe ine 
metabolites with their retention t ime 
The standards included AFMU,  1 MU, 1 MX, 1 7MU,  1 7MX and 1 37MX. 
Spectral conformation of caffe ine metabol ite peaks was performed routinely, using a 
programmable mult ip le wavelength detector (Waters 2998PDA, Waters Corp . ,  
M i lford MA). U sing th is methodology, recovery of  caffeine,  paraxanth ine, AFMU and 
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Figure 23 :  Standard Spectral conformation of 1 37MX, 1 7MX, 1 7MU,  1 MU ,  1 MX and 
AFMU.  The amount on X axis is in  ug/ml 
92 
4.4 Statisti cal  Analys is 
4.4.1  C YP1A2 
4.4 .1 . 1  C YP1A2 Genotype 
Genetica l ly ,  we were able to genotype all cases for the selected 
polymorph ism using TaqMan Real Time peR analysis. We found out of 576 
subjects 8 ( 1 .4%) subjects were homozygote for mutant a l le les, 93 ( 1 6 . 1  %) were 
heterozygote and 475 (82 . 5%) homozygous for the wild type al lele genotyping 
(F igure 24) .  
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Figure 24: The genotype frequencies of the studied sample.-0 .0 14  of our subjects 
were homozygote for mutant a l le les , 0 . 1 6 1  were heterozygote and 0 .825 were 
homozygous for the wi ld type genotyping 
The overa l l  mutant a l leles' frequency was 0 .095 with a l le le CYP1A2*1 C  
frequency = 0 .0636, a l lele C YP1A2*1 K = 0 .0287, a l lele CYP1A2*3= 0.0027, al lele 
CYP1A2*4= 0 and a l le le CYP1A2*6 = 0 while the wild type a l lele frequency was 
found to be 0 .905 (F igure 25). 
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Figure 25 :  Al lele frequencies- a l lele CYP1A2*1C frequency = 0 .0636, a l lele 
CYP1A2*1K = 0 .0287 , a l lele CYP1A2*3= 0 .0027, a l lele CYP1A2*4= 0 and al lele 
C YP1A2*6= O.  The wi ld type a l le le frequency was found to be 0 .905 
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The fol lowing figure (26) shows an  example of a l le l ic discrim ination plot that 
demonstrates a variation in  c lustering due to the genotyping of the targeted al le le 
(CYP1A2*1 C) us ing QuantStudio™ 6 and 7 Flex Real Time peR System Software 
v 1 .0 .  
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Figure 26: An example of a l le l ic d iscrim ination plot that demonstrates a variation i n  
c lustering d u e  t o  the genotyping of the targeted a l lele (CYP1 A2*1 C) 
We are able to identify six different CYP1A2 diplotypes. Out of the 576 
subjects ,  568 (98.6%) subjects were homozygote and heterozygote for the wild type 
al le le" .  Of whom,  475 (82 .5%) subjects were homozygote for the wild type al le le,  59 
94 
( 1 0 .2%) subjects were heterozygote for CYP1A2*1A1* 1 C  genotype, 33 (5 .8%) were 
heterozygote for CYP1A2*1A1*1K genotype and 1 (0.2%) was heterozygote for 
C YP1A2*1A1*3 genotype. Whereas,  8 ( 1 .4%) subjects were homozygote for the 
mutant al le les.  Of whom , 7 ( 1 .2%) subjects were homozygote for a l lele CYP1A2*1C 
and 1 (0 .2%) subjects was homozygote for a l lele CYP1A2*3 (Table 1 7) .  
Table 1 7 : The  C YP1  A2 genotype frequencies and  distribution 
CYP1 A2 genotype n Frequency 
C YP1A2*1A1"1A 475 0 . 825 
C YP1 A2*1  Al"1 C 59 0. 1 02 
C YP1A2*1A1"1 K 33 0 . 058 
C YP1 A2*1 Al"3 1 0 .002 
C YP1A 2 * 1 CI* 1 C  7 0 .0 1 2  
C YP1A2*31*3 1 0. 002 
The characteristic features and frequencies of the various CYP1 A2 haplotype 
identified among Emiratis, determ ined from TaqMan Real Time peR analysis of 
genomic DNA is shown in table 1 8 . The most common haplotypes by far among our 
popu lation sample belonged to the C YP1A2* 1A (rs206951 4) gene and occurred with 
a frequency of 0 .905. Three d ifferent CYP1A2 a l leles associated with slow activity 
were found .  The frequencies of these slow al le les CYP1A2* 1 C, CYP1A 2 * 1 K  and 
C YP1A2*3 were less common than wild type al le le,  the a l le le belonged to the 
CYP1A2* 1 C  (rs 1 2720461 )  gene occurri ng with a frequency of 0 .0636. Whereas, the 
frequency of C YP1A2*1  K (rs56276455) and CYP1A2*3 (rs7254751 6) genes were 
negl ig ib le 0 .0287 and 0.0027, respectively .  The frequency of CYP1A2*4 
( rs28399424) and C YP1A2*6 (rs20695 1 4) a l le les were absent in  th is population 
(Table 1 8) .  
Whi le examin ing the  deviation from Hardy-Weinberg equi l ibrium,  i t  was also 
found that the observed genotype frequencies were d ifferent from the expected one. 
nonethe less, the data for CYP1 A2*1 K were in accordance with the Hardy-Weinberg 
equ i l ibriu m  since P>0.05.  For CYP1A2* 1 C, the data did not obey the equi l ibrium 
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since P = 0 . 00 1 . C YP1A2*3, CYP1A2*4 and CYP1A2*6 were too rare for the 
equ i l ibr ium to be determined (Table 1 8) .  
Table 1 8 : The  characteristic featu res and  frequencies of the various CYP1 A2 
haplotypes identified among Emiratis 
Haplotype dbSNP Enzyme n Percentage Hardy-Wei nberg Equ i l i brium 
activity 
* 1 A  rs20695 1 4  onna l 1 043 90.5% 
* 1 C  rs 1 2720461 Decreased 73 6 .36% Var. a l lele freq .=  0 .07 ,  P=0.001 
*1 K 
rs56276455 
Decreased 33 2 .87% Var. a l lele freq .=  0 .03, P=0.44 
*3 rs725475 1 6  Decreased 3 0.27% Can't be counted* 
*4 rs28399424 Decreased 0 0% Can't be counted* 
*6 rs20695 1 4  Decreased 0 0% Can't be counted* 
Var. a l le le freq . - Variant a l lele frequency 
*Not accurate if <5 individuals in any genotype group. 
Based on epidemiolog ical stud ies, it has been clearly observed that there is 
a sign ificant ethn ic  variab i l ity in  the d istribution of common and rare CYP1 A2 SNPs 
and haplotypes (Zhou SF et al 2009b). The avai lable data suggested that the 
frequency of C YP1A2*1 C a l le le was 0 .009 in  Brit ish, 0. 008 in  Swedish,  0.23 in 
Japanese, 0 .26 in  Korean, 0 .22 in  Chinese, 0.07 in African American,  0 .07 in 
Tunis ian, 0 . 04 i n  Turkish and 0 .07 in  Egyptian populations (Nakaj ima M et a l  
1 999, Chida M et a l  1 999, Hamdy S I  et a l  2003, Tiwari AK et a l  2005, Bi lgen T et al 
2008) .  In the contrary, based on our study; the Emi rati population was one of the 
lowest frequencies with 0 .06 when compared to most of the mentioned populations. 
Taking in consideration,  the number of the subjects used in  our study was the 
h ig hest in contrast to other stud ies (Figure 27 A) . 
Furthermore, the frequency of CYP1A2*1K al lele was 0.003 in  Swedish, 
0 .005  in  Spanish, 0 .04 in  Saudi  Ara bian and 0 .03 in  Ethiopian populations, whereas 
it was a bsent in  Korean and Japanese populat ions (Akl i l lu E et a l  2003, Ghotbi R et 
a l  2007) .  L ikewise, the genotype frequency of CYP1 A2*1 K haplotype in  Emiratis 
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population was s l ight ly lower than Saudi Arabian and Eth iopian population with 
frequency of 0 .02 (F igure 278) .  
Lastly, the genotype frequencies of CYP1A2*3, C YP1A2*4 and 
C YP1A2*6 a l leles have been identified in  the French population with frequency of 
(0 .005-0.0 1 )  (Cheval ier  0 et al 200 1 , Allorge 0 et a l  2003, Zhou H et al 2004) .  On 
the contrary ,  the frequencies of these haplotypes were lower in  the Emirati 
populat ion specifica l ly  the haplotype C YP1  A2*3 frequency, that was found to be 
0 . 002. S imi lar ly ,  the frequencies of C YP1A2*4 and CYP1A2*6 haplotypes were 
absent in Emiratis population (F igure 27C).  
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Figure 27 :  The frequency of CYP 1 A2 a l leles among Emiratis in  comparison with 
other  populations ,  fig ure (A) shows the CYP1 A2* 1  C haplotype frequencies, figure 
(B)  shows the C YP1A2*1 K haplotype frequencies, figure (C) shows the CYP1A2*3 ,  
CYP1A2*4 and C YP1A2*6 haplotypes frequencies, n = sample size, Emiratis (n = 
576) ,  Japanese (n  = 250) ,  Koreans (n  = 1 50) ,  Chinese (n = 1 68) ,  African Americans 
(n  = 1 1 2) , Tunis ians (n  = 98) ,  Turkish (n = 1 1 0) ,  Egyptians (n = 2 1 2) , Swedish (n = 
1 94) ,  F rench (n  = 1 00) ,  Brit ish (n  = 1 1 4) ,  Spaniards (n = 1 1 7) ,  Saudi Arabians (n  = 
1 36) ,  Ethiopians (n  = 1 73) 
4.4. 1 .2 Caffeine  Meta bol ites Ratio and CYP1 A2 Phenotype Status 
S ince other studies had used " ( 1 7MX + 1 7M U)/1 37MX" molar rat io,  this 
measure was calcu lated and com pared in  th is study (Butler MA et a l  1 992 and , Lang 
NP and Kadlubar  FF  1 99 1 ) . The frequency distribution of ( 1 7MX + 1 7MU)/1 37MX in 
our data ind icated a trimodal d istribution  with specific cut points 2.5 and 6.5 that 
represented s low, intermediate and rapid acetylators (Joshua EM et al 2008) . 
Out of 576 subjects ,  560 showed posit ive resu lts whereas the remain ing 1 6  
d id not comp lete the study.  From those 560 subjects, 8 ( 1 .4%) were s low CYP 1 A2 
enzyme activity " ratio < 2 . 5" ,  9 1  ( 1 6 .3%) were intermediate activity " ratio between 
2 . 5  -2 .6" and 46 1 (82. 3%) were rapid activity for th is enzyme "ratio > 6 .5" (Table 1 9) .  
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Table 1 9 : The classification and the resu lts of the CYP1 A2 enzyme activity based on 
the ratio of ( 1 7MX+ 1 7M U)/1 37MX 
( 1 7MX+ phenotype status No. of Percentage 
1 7M U )/1 37 M X  ratio 
0 .7  2 . 5  
2 . 5 1 -6 .5  
> 6 .5 1  
S low CYP 1 A2 activity 
I ntermediate CYP 1 A2 activity 
Rapid CYP 1 A2 activity 
subjects 
8 1 .4% 
91  1 6 .3% 
461 82 . 3% 
The ratio of ( 1 7MX + 1 7M U)/1 37MX ratio was calcu lated to determine the 
phenotype status of CYP 1 A2 activity in each subject. The frequency distribution 
h istogram of ur inary ( 1 7MX + 1 7M U)/1 37MX molar concentration ratio for 560 UAE 
nationals shows non-normal ly d istri buted result "Median = 5 .05,  Skewness = 1 . 2 1 5  
with Std error = 0 . 1 03, Kutosis = 1 . 239 with Std error = 0.206" (F igure 28) .  
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Figure 28:  The d istri bution of subjects based on CYP 1 A2 activity ( 1 7MX+ 
1 7M U)/1 37MX ratio 
There was clear evidence of a tri-modal distribution of ( 1 7MX + 
1 7MU)/1 37MX ratio with an apparent anti-mode in  the region of 2 . 5  and 6 .5  which 
was in close ag reement to that observed by several studies (Afonina I et al 1 997). 
The mode corresponding to the rapid enzyme activity was not uniformly d istributed 
and may include both heterozygous and homozygous rapid phenotype. The 
frequency distri bution h istog ram suggests the possible existence of a second anti-
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mode (in the region of 6.5) separati ng the heterozygous and homozygous rapid 
phenotype. 
A total of six different genotypes were found,  four associated with rapid 
phenotype and two with slow phenotype . The most common genotype found was 
C YP1A2*1A1*1A with frequencies of 0 .825. Fol lowed by al le les C YP1A2* 1A1* 1 C  and 
C YP1A2*1A1* 1 K with frequency of 0. 1 02 and 0.058 respectively .  The 
C YP1A2*1 CI*1 C  and C YP1A2*31*3 genotypes showed s ign ificantly the lowest 
median values 2 . 06 and 2 .00 respectively (Table 20). 
Table 20: ( 1 7MX + 1 7MU)/1 37MX molar ratios in  subgroups assigned to CYP 1 A2 
a l lele combinat ions 
CYP1 A2 CYP1A2 N Frequency Med ian M i n imum Maximum 
phenotype a l leles 
Rapid  * 1A1*1A 46 1 0.825 7 .58 6 .08 25.25 
I ntermediate * 1A1* 1 C  57 0 . 1 02 4 .98 3. 1 3  6.96 
* 1 A1*1 K  33 0.058 4 .87 2 .53 6 .87 
* 1  Al*3 1 0 .002 6 .85 6.85 6.85 
Slow * 1 C/*1 C  7 0 .0 1 2  2 .06 0 . 1  2 .39 
*31*3 1 0.002 2.00 2.00 2 .00 
Total 560 
The result ing ur inary ( 1 7MX + 1 7MU)/1 37MX ratio and genotypic 
assignments of s low (SIS homozygotes), i ntermediate (RIS heterozygotes) and 
rapid ( R/R homozygotes) are presented in table 21 . .  Using Kruskal-Wal l is test, the 
mean ran k  of these g roups were 4 .5 ,  67. 7 1  and 327.29 respectively, which 
represented strong association between CYP 1 A2 genotype and phenotype (X2 = 
2 1 9 .23 ,  df = 2 and P value < 0 .000 1 ;  95% CI of d ifferences) . 
Table 2 1 : ( 1 7MX + 1 7M U)/1 37MX ratios vs. genotypes. Suggested genotypic state: 
SIS homozygously s low, RIS heterozygotes intermediate , R/R homozygously rapid 
N 
Mean 
SIS homozygotes RlS heterozygotes RlR homozygotes 
8 
1 .8400 




Median 2 .0300 4 .9800 7.5800 
Std. Deviation 0 .743 1 0  1 .362 1 6  3.37762 
Range 2 .29 3.95 1 8.75 
M in imum 0 . 1 0  2 .53 6.08 
Maximum 2.39 6 .98 25.25 
SIS homozygotes slow metabol izers, RlS heterozygotes = intermediate 
metabolizers ,  RlR homozygotes = rapid metabol izers 
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I n  th is study,  the phenotype status of CYP 1 A2 activity in the Emirati 
popu lat ion shows the lowest frequency of poor metabol izers with only 1 .4% s low 
phenotype whi le the percentage in  other populations such as Austra l ians, Japanese, 
Chinese, Americans and I ta l ian were 5%, 1 4%,  5%, 1 2% and 1 3% respectively 
(F igure 29) (Butler et al 1 992, Nakaj ima M et al 1 994, Zhou SF et al  2009b). 
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Figure 29:  The frequency of CYP 1 A2 poor metabolizers among Emiratis in
 
comparison with other populations,  n = sample size, Em iratis (n = 576) , 
Austra l ians 
(n  = 1 7 1 ) , Japanese (n  = 250) ,  Chinese (n = 78),  Americans (n = 1 0 1 ) , 
I tal ians (n = 
95) 
The degree of phenotype/genotype concordance was equal to 
8 1 .6% based 
on the current phenotype classification ( i .e .  rapid/interm
ediate/slow phenotypes) ,  
where those who were homozygotes for the al lele
 CYP1A2*1A genotypes are 
considered to be a rapid metabol iser, those who w
ere heterozygotes for the wild 
type a l le le are considered to be intermediated m
etabol iser and those who had no 
C YP1A2*1A genotype are considered to be a 
slow metaboliser. 
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CYP1A2 and Deg ree of Parent's Relations h ip  
Out  of  8 subjects "homozygote for the  mutant a l leles", 2 (25%) subjects were 
ch i ld ren of th i rd degree re lationship ,  1 ( 1 2 .5%) subject was their parents from the 
same tribe and 5 (62 . 5%) subjects were not re lated.  On the other hand, out of 568 
subjects "homozygote or heterozygote for the wi ld type a l lele", 1 83 (32 .2%) subjects 
were chi ldren of th i rd degree relat ionship,  1 04 ( 1 8 .3%) subjects were parents from 
the same tribe and 281 (49 .%)  subjects were not re lated (Like l ihood Ratio = 0. 552, 
degree of freedom (df) = 2 and P va lue = 0 .759; 95% CI  of differences) which was 
more than 0 . 05 representing a weak evidence of a relat ionship or association 
between genotype and degree of re lationship .  There was no sign ificant corre lation 
between degree of re lationship and genotypes with correlation coefficient 0 .028 
value (P value = 0 . 508; 95% CI of d ifferences using Spearman's rho statistical test). 
C YP1A2 a n d  " Medical  I l l ness" 
With regard to medical i l lness, it was found that out of 56 cases 1 ( 1 .8%) 
subject who had medical i l lness was from those who were homozygote for the 
mutant a l le les compared to 55 (98.2%) subjects from those who were homozygote 
or heterozygote for the wi ld type a l lele (Likel ihood Ratio = 7 .296, degree of freedom 
(df) = 1 0  and P value = 0 .697;  95% CI of d ifferences) which was more than 0.05 
represented a weak evidence of a re lationship or association between genotype and 
medical  i l lness.  There was no sign ificant correlation between medical i l lness and 
genotypes with corre lat ion coefficient 0 .0 1 0 va lue (P va lue = 0 .804; 95% CI  of 
d ifferences using Spearman's  rho stat istical test) . 
Out of 8 subjects "homozygote for the mutant a l leles", 1 ( 1 2 .5%) subject had 
medical i l lness compared to 7 (87 . 5%) subjects who had no medical i l lness .  O
ut of 
568 subjects "homozygote or heterozygote for the wild type al le l
e" 55 (9.9%) 
subjects had medical i l lness compared to 5 1 3  (90 . 1 %) subjects tha
t had no medical 
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i l l ness with OR = 1 .306, re lative risk for those with medical i l lness 1 .268 and relative 
r isk for those with no medical i l lness 0 .971  (L ikel ihood Ratio of X2 = 0 .058, df = 1 
and P value = 0.8 1 ; 95% CI of differences). 
CYP1A2 and Drug Sensit ivity 
With regard to drug sens itivity , it was found that out of 21 cases 1 (4.8%) 
who reported drug sensitivity was from those who were homozygote for the mutant 
a l le les compared to 20 (95.2%) subjects from those who were homozygote or 
heterozygote for the wi ld type a l le le (Likel ihood Ratio of X2 = 1 .339, degree of 
freedom (df) = 3 and P value = 0 .72;  95% C I  of d ifferences) which was more than 
0 .05 represented a weak evidence of a relationship or association between CYP1A2 
genotype and drug sensitivity. There was no s ignificant correlat ion between drug 
sensitivity and genotypes with correlat ion coefficient 0 .056 value (P value = 0. 1 79 ;  
95% C I  of  differences us ing Spearman's rho statistical test) . 
Out of 8 subjects "homozygote for the mutant a l leles", 1 ( 1 2 . 5%) subject was 
having drug sensit ivity compared to 7 (87 . 5%) subjects with no drug sensitivity. Out 
of 568 subjects "homozygote or heterozygote for the wild type a l lele" 20 (3.5%) 
subjects had drug sensitivity compared to 548 (96. 5%) subjects who had no drug 
sensit ivity with OR = 3 .9 1 4 , re lative risk for those with drug sensitivity 3 .55 and 
re lative r isk for those with no  drug sensitivity 0. 907 (Likel ihood ratio of X2= 1 . 1 4, df = 
1 and P value = 0 .286;  95% C I  of d ifferences) .  
Using Kruskal-Wal l is  Test, it was found that there was no d ifference in the 
Mean Rank between the groups which represented a lack of effect of CYP1A2 
genotype on the Drug sensitivity (X2 = 0 .909, df = 3 and P value = 0 .823; 95% C I  of 
differences). 
CYP1A2 a n d  Genotype D istribution with i n  the UAE Emirates 
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Out of the 8 subjects "homozygote for the mutant a l leles" 5 (62 . 5%) were 
from AD Emirate , 3 subjects (37.5%) were from Dubai Emirate and no one was 
found from Northern Emirates. On the other hand, out of 568 subjects "homozygote 
and heterozygote for the wi ld type al le le" 261 (46%) were from AD Emirate, 1 08 
( 1 9%) were from Dubai Emirate and 1 99 (35%) were from Northern Emirate. 
However, th is resu lted in  s ign ificant statistical d ifference between the cities 
(Like l ihood ratio of X2 = 7 .085, df = 2 and P value = 0.029; 95% CI of d ifferences) 
with a posit ive smal l  effect based on the symmetric measures of Phi and Cramer's V 
va lues (Ph i  = 0.09 and Cramer's V= 0.09) with insignificant P value (P value = 
0 .097;  95% C I  of d ifferences). 
4.4.2 NAT2 
4.4.2 . 1  NA T2 Genotype 
Genetica l ly ,  we were able to define 570 subjects us ing PCR-RFLP analysis 
whereas D NA sequencing has been done for the remain ing 6 samples. It was found 
that out of 576 subjects 446 (77 .4%) subjects were carrier of 2 mutant a l leles either 
homozygote or heterozygote ,  1 06 ( 1 8 .4%) were heterozygote for one mutant al lele 
and 24 (4.2%) homozygous for the wi ld type a l le le (F igure 30). 
H omozygote or 
Hete rozygote for 2 
mutnat al le les 
H e terozygote H omozygote 
W i l d  Type 
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Figure 30: The genotype frequencies- 0 .774 of our subjects were homozygote or 
heterozygote for 2 mutant a l leles genotyping,  0 . 1 84 were heterozygote and 0 .042 
were homozygotes for the wild type genotyping 
The overa l l  mutant a l leles' frequency was 0 .866 with a l lele NA T2*5 
frequency = 0.364, a l le le NA T2*6 = 0 . 1 29 ,  a l le le NA T2*7= 0 .274 and a l lele NA T2*14  
= 0.099 whi le the  wild type a l le le frequency was found to  be  0. 1 34 (F igure 3 1 ) . 
F igure 3 1 : Al lele frequencies- a l le le NA T2*5 frequency = 0.364, a l lele NA T2*6 = 
0 . 1 29, a l le le NA T2*7= 0.274 and a l le le NA T2*14 =0.099. The wild type al lele 
frequency was found to be 0. 1 34 
The d ifferent patterns of RFLPs obtained after separate restrict ion enzyme 
d igestion of the PCR product with Msp l ,  Fok l ,  Ode l ,  Kpn l ,  Taq l and BamHI  are 
shown in the fo l lowing figure 3 1 . The presence of a Kpnl site is ind icated by 
fragments of size 424bp and 1 35bp. S imi lar ly ,  the presence of a BamH I  s ite is 
ind icated by the fragments size 5 1 5bp and 44bp. I n  each instance, the presence of 
559bp, ind icates loss of the cutt ing site, and is diagnostic for 481 C> T (Kpn l )  or 
857G>A (BamH I ). 
After d igestion with Taq l ,  s ite was ind icated by fragments of s ize 226bp and 
1 70bp. Fragments size 1 42bp and 21 bp also appeared but were un informative. The 
presence of 396bp frag ment ind icates the loss of the polymorphic Taq l s ite and is 
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diagnostic for the 590G>A mutation .  After d igestion with Mspl , site was ind icated by 
fragments of size 1 8 1 bp and 93bp. Fragments size 1 68bp also appeared but was 
un informative. The presence of 274bp fragment ind icates the loss of the 
polymorphic Mspl site and is  d iagnostic for the 1 9 1 G>A mutation. 
The presence of Fokl s ite is ind icated by fragments of s ize 337bp and 
1 05bp.  the presence of 442bp fragment ind icates the loss of polymorphic Fokl s ite 
and is d iagnostic for the 282C> T mutat ion.  After digestion with Ode l from the first 
PCR (442bp) , s ite was ind icated by fragment size 221 bp. Fragments size 1 63bp and 
58bp also a ppeared but were un informative. The presence of 1 89bp and 32bp 
fragments ind icates the loss of the polymorph ic Odel s ite and is diagnostic for the 
34 1 T>C mutation .  Whereas ,  the d igestion with Odel from the second PCR (559bp), 
s ite was ind icated by fragment size 1 24bp. Fragments size 345bp and 90bp a lso 
appeared but were un informative . The presence of 97bp and 27bp fragments 
ind icates the loss of the polymorphic Odel s ite and is diagnostic for the 803A>G 
mutation .  The presence of wild type (NA T2*4) a l le le in subjects phenotyped as rapid 
acetylators was inferred by exclusion of each of the 1 9 1 G>A,  34 1 T>C , 590G>A and 
857G>A mutat ions. 
The fol lowing figure (32) shows the gel documentation of the ONA fragments after 
ampl ificat ion and restrict ion cleavage. 
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Figure 32 : Representative images of the gel documentation of the DNA fragments 
after ampl ification and restrict ion cleavage. bp = base pairs ,  w = wild type = 
reference sequence (RS) and m = mutant = sequence variation (SV) 
We were able to identify 27 NA T2 diplotypes with the actual genotypes 
identified in the study group shown in Table 29. The ambiguous d iplotypes were 
clarified completely by haplotype reconstruction with a probabi l ity of the 
reconstructed haplotype pairs of P>O.97.  The vast majority of haplotype pairs were 
assigned with a h igh degree of confidence (P= 1 .00) with two having a probabi l ity of 
P�O.99 and two others P�O.98.  
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Out of the 576 subjects ,  1 30 (22.6%) subjects were homozygote and 
heterozygote for the wild type a l le le .  Of whom, 24 (4.2%) subjects were homozygote 
for the wild type a l le le ,  72 ( 1 2 .5%) subjects were heterozygote for NA T2*4/*5 
genotype, 22 (3 .8%) were heterozygote for NA T2*4/*6 genotype, 7 ( 1 .2%) were 
heterozygote for NA T2*41*7 genotype and 5 (0.9%) were heterozygote for 
NA T2*41* 1 4  genotype. Whereas, 446 (77 .4%) subjects were homozygote and 
heterozygote for the mutant a l le les .  Of whom,  36 (6.2%) subjects were homozygote 
for a l le les NA T2*5 cluster, 78 ( 1 3 . 5%) subjects were heterozygote for NA T2*5B/*6A 
genotype, 1 77 (30 . 7%) subjects were heterozygote for NA T2*5/*7 clusters, 20 
(3 .5%) subjects were heterozygote for NA T2*5/*1 4  clusters, 5 (0.9%) subjects were 
homozygote for NA T2*6 cluster, 34 (5 .9%) subjects were heterozygote for 
NA T2*6A/*7B genotype, 5 (0 .9%) subjects were heterozygote for NA T2*6A/*14B 
genotype , 1 4  (2 .4%) subjects were homozygote for NA T2*7B/*7B genotype, 69 
( 1 1 .9%) subjects were heterozygote for NA T2*71*14  clusters and 7 ( 1 .2%) subjects 
were homozygote for NA T2*14A/*14B genotype (Table 22) .  
Table 22:  NAT2 d ip lotypes and genotypes in  the study group. Comparison between 
genotypes reconstructed by PHASE and actual genotypes obta ined by gene 
mapping 
Observed No.  Actual PHASE Probabi l ity 
d i p lotype* genotypes reconstruction 
0000000 24 *41*4 *4/*4 1 .00 
001 1 000 4 *4/*5A *4/*5A 1 .00 
001 1 01 0  52 *4/*58 *4/*58 0.98 
001 001 0 6 *4/*5C *4/*5C 0.98 
001 0000 1 1  *41*50 *41*50 1 .00 
01 001 00 1 9  *4/*6A *4J*6A 1 . 00 
0000 1 00 5 *41*68 *41*68 1 .00 
01 00001 8 *4/*78 *41*78 1 .00 
1 000000 6 *41* 1 4A *41* 1 4A 1 .00 
0022000 2 *5A/*5A *5A/*5A 1 .00 
00220 1 0 9 *5A/*58 *5A/*58 1 .00 
01 1 1 001  1 8  5A/*7 8  *5A/*78 1 .00 
1 01 1 000 4 *5A/*1 4A *5A/*1 4A 0.99 
0022020 1 7  *581*58 *58/*58 1 .00 
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002 1 020 5 *58/*5C *58/*5C 1 .00 
0222220 3 *5U/*5U *5U/*5U 1 .00 
01 1 1 1 1 0  78 *58/*6A *58/*6A 1 .00 
01 1 1 01 1 1 53 *581*78 *58/*78 1 .00 
1 1 1 1 01 0  1 6 *58/*1 48 *58/*1 48 0.99 
0200200 4 *6AJ*6A *6AJ*6A 1 .00 
0200220 1 *6C/*6C *6C/*6C 1 .00 
0200 1 0 1  34 *6A/*78 *6A/*78 1 .00 
1 2001 00 5 *6A/*1 4 8  *6A/*1 48 1 .00 
0200002 1 4  *78/*78 *78/*78 1 .00 
1 1 00001 9 *78/* 1 4A *78/*1 4A 1 .00 
1 200001 61 *78/*1 4 8  *78/*1 48 1 .00 
2 1 00000 7 * 1 4AJ* 1 48 * 1 4AJ* 1 48 1 .00 
Total  576 
* Observed d iplotypes are shown as the number of mutations identified in each 
ind ividua l ,  0: homozygous reference, 1 :  heterozygous, 2: homozygous variant; the 
S N P  order is 1 9 1 ,  282, 34 1 ,  481 , 590, 803 and 857. Ambiguous diplotypes with at 
least two heterozygous loci are h igh l ighted . 
The frequencies of the various haplotypes identified among Emiratis 
determ ined from PCR-RFLP ana lysis of genomic DNA are shown in Table 23. The 
most common haplotypes by far among our population sample belonged to the *58 
gene cluster and occurred with a frequency of 0 .30 1 , which is almost three t imes the 
frequency of the wi ld type al lele (NA T2*4) .  Furthermore, a second slow a l lele 
be longing to the NA T2*78,  was a lso more common than al lele NA T2*4, occurring 
with a frequency of 0. 274. 
Examin ing the deviation from Hardy-Weinberg Equi l ibrium,  it was also found 
that the observed genotype freq uencies were d ifferent from the expected one. 
However, the apparent numbers of alleles NA T2*7 and NA T2* 1 4  were not in strict 
accordance with the Hardy-Weinberg Equi l ibr ium. For a l leles NA T2*5 and NA T2*6 
the data o bey the equ i l ibr ium s ince the result was statistically ins ign ificant (variant 
a l lele frequency for a l le le NA T2*5 = 0 . 55, P value = 0.25;  95% CI of d ifferences and 
for a l le le NA T2*6 = 0 .3 1 , P value = 0 .98;  95% CI of diffe rences) (table 23). 
Table 23: The haplotype frequencies of NAT2 
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Haplotype F requency Percentage Hardy-Weinberg Equ i l i br ium 
GCTCGAG *4 1 54 1 3 .4% 
GCCTGAG *5A 45 3.9% 
GCCTGGG *5B 347 30. 1 %  Var. a l lele freq .=  0.55, P=0.25 
GCCCGGG *5C 1 1  0 .95% 
GCCCGAG *5D 1 0  0 .86% 
GTCTAGG *5U 6 0 .52% 
GTICAAG *6A 1 43 1 2 .4% Var. a l le le freq .=  0.3 1 , P=0.98 
GCTCAAG *6B 4 0 .34% 
GTICAGG *6C 2 0 . 1 7% 
GTICGAA *7B 3 1 6  27 .4% Var. a l lele freq .=  0 .39,  P<0.001 
ACTCGAG * 1 4A 25 2 .2% 
ATICGAG * 1 4B 89 7 .76% Var. a l lele freq. =  0 . 26, P<0.001 
Var. a l le le freq .=  Variant a l lele frequency 
Based on epidemiological stud ies, the frequency of NAT2 slow acetylation 
a l le les in  the Emi rati population shows the h ighest frequency with 86.6% . However, 
in Egyptian ,  I nd ian ,  Omani  and Jordanian populations, the frequency of the s low 
acetylation a l le les ranged between (74% - 79%) whi le in the Moroccan population it 
was 84% (Meyer UA and Zanger U M  1 997 , Guaoua S et al 201 4) .  Moreover, in  
American ,  German ,  Spanish,  Argentin ian and Saudi Arabian populations the 
frequency was between (72%-73%), whereas in  African and Southern Brazil 
populat ions it reached 40%, in Senegalese population 60% and in  Tunisian 
population 69%.  These populations have high frequencies of mutant a l lele NA T2*5 
and NA T2*6 and low freq uencies of mutant a l lele NA T2*7. I n  Asian populations, 
such as Japanese, Chinese, Korean,  and Thai, the frequency of the slow acetylation 
al leles ranged from 1 0  to 30% with high frequency of mutant a l lele NA T2*7 and low 
frequency of mutant al lele NA T2*5 ( Figu re 33) (Meyer UA and Zanger UM 1 997, 
Guaoua S et a l  20 1 4). 
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Figure 33: The frequency of NA T2 slow acetylation a l leles among Emiratis in  
comparison with other populat ions, n = sample size, Emiratis (n = 576), Asians 
"Japanese (n  = 79) , Koreans (n  = 288), Chinese (n = 1 20) ,  Thai (n = 235)" , Africans 
(n  = 97) , Americans (n  = 387), Tunis ians (n = 1 00) , I ndians (n = 250), Egypt ians (n 
= 200),  Germans (n  = 844) ,  Omanis (n = 1 27) ,  Argentineans (n = 1 85) ,  Spaniards (n 
= 258) ,  Saudi Arabians (n = 200), Moroccans (n = 1 63) ,  Jordanians (n = 1 50) 
I dentification of Known Slow Al leles S u btype 
DNA sequencing was performed for 20 samples randomly selected to 
confirm the accuracy of our PCR�RFLP resu lts .  Nevertheless, DNA sequencing was 
a lso performed for the remain ing 6 samples that had not been clearly defined using 
PCR�RFLP.  
Table 24 provided more detai led data of  the 6 samples that had been 
analysed using DNA sequencing .  Whereas, figure 34 i l l ustrated DNA chromatogram 
that showed 5 1 0T>C variant of sample 3 DNA with well �resolved peaks and no 
ambigu it ies. 
1 1 1  
Table 24.: Deta i l s  of the resu lts of the 6 samples that has been ana lysed using DNA 
sequencing 
Sam ple Varia nts Allele1  
N u m ber 
Sample 282C>T 590G>A 282C>T 590G>A 
1 34 1 T>C 803G>A 34 1 T>C 803G>A 
4 8 1 C>T 481 C>T 
Sam ple 34 1 T> C  803G>A 34 1 T>C 803G>A 
2 4 8 1 C>T 481 C>T 
Sample 282C>T 590G>A 282C>T 
3 S 1 0T>C 803G>A 590G>A 
77SA>C 803G>A 
Sample 282C>T 803G>A 282C>T 803G>A 
4 34 1 T> C  77SA>C 34 1 T>C 
4 8 1 C>T 7 3 3A>C 481 C>T 
590G>A 590G>A 
Sample 34 1 T>C 803G>A 34 1 T>C 803G>A 
5 4 8 1 C>T 481 C>T 
Sam ple 34 1 T> C  803G>A 34 1 T>C 803G>A 
6 590G>A 481 C>T 590G>A 481 C>T 
282C>T 282C>T 
The new variants a re highl ighted 
At pos 'on 510, Y represents two peaks of 
m ThYmine & (e) C) osine 
Allele2 Ass ig ned 
Genotype 
282C>T 590G>A Homozygote 
34 1 T>C 803G>A NA T2'5U1*5U 
481 C>T 
34 1 T>C 803G>A Homozygote 
48 1 C>T NA T2'5B1*5B 
282C>T 590G>A Heterozygote 
S 1 0T>C 803G>A NA T2*6CI*6C? 
77SA>C 
282C>T 803G>A Heterozygote 
34 1 T>C 77SA>C NA T2*5UI*5U? 
481 C>T 733A>C 
590G>A 
34 1 T>C 803G>A Homozygote 
48 1 C>T NA T2*5B1*5B 
34 1 T>C 803G>A Homozygote 
590G>A 481 C>T NA T2*5U1*5U 
282C>T 
T C : C .. \7 C T C 
Nucleotides peaks 
Figure 34: An example of DNA chromatogram of T-51 OC variant of sample 3 DNA 
NA T2*58 
Out of these 6 samples, two were homozygote for NA T2*5B, an al lotypic 
variant of NA T2*5, that is characterized by presence of 3 mutations, 
34 1 T>C,481  C> T and 803G>A. I t  differs from NA T2*5 only by the presence of the 
341 T>C and 803G>A mutations and is ind istinguishable from NA T2*4 "wild type 
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al lele" when the criterion for identification of NA T2*4 IS based only upon exclusion of 
the common NA T2 slow al le les .  Al le le carrying 34 1 T>C and 481 C> T mutations were 
presumed to be NA T2*5A in the absence of 803G>A mutation ,  whi le a l leles carrying 
282C>T, 34 1 T>C,  48 1 C>T and 803A>G mutations were presumed to be NA T2*5G. 
Accord ing ly ,  we confirmed the presence of these 3 mutations only by DNA 
sequencing of 2 samples.  
NA T2*5U 
Out of these 6 samples, one sample was heterozygote and two were 
homozygote for NA T2*5U, an a l lotypic variant of NA T2*5, that is characterized by 
presence of 5 mutat ions,  282C>T, 34 1 T>C, 481 C>T, 590G>A and 803>A. I t  differs 
from NA T2*5 only by the presence of the 282C> T, 34 1 T>C, 590G>A and 803G>A 
m utat ions.  Al le les carry ing 34 1 T>C, 481 C>T and 803G>A mutations only were 
presumed to be NA T2*58 in the absence of 282C> T and 590G>A mutations, whi le 
al lele carrying 282C>T, 34 1 T>C, 481 C>T and 803G>A mutations were presumed to 
be NA T2*5G i n  the absence of 590G>A mutation.  Accordingly ,  we confirmed the 
presence of these 5 m utations by DNA sequencing of 3 samples. 
NA T2*6C 
Out of these 6 samples, one sample was heterozygote for NA T2*6C, an 
al lotypic var iant of NA T2*6, that is characterized by presence of 3 mutations, 
282C> T 590G>A and 803G>A. I t  d iffers from NA T2*6 only by the presence of the , 
282C> T and 803G>A mutat ions.  Al leles carrying 590G>A, 282C> T and 1 1 1  T>C 
mutat ions were presumed to be NA T2*60, whi le a l le le carrying 590G>A an
d 
803G>A mutations were presumed to be NA T2*6F in the absence of 282
C> T 
mutation.  According ly ,  we confi rmed the presence of these 3 mutations on
ly by DNA 
sequencing of one sample.  
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U n reported Variants a nd U nknown Slow Al leles S u btype 
After the confi rmation of the presence of two samples that were homozygote 
for NA T2*5B, two samples were homozygote for NA T2*5U, one sample was 
heterozygote for NA T2*6CINat2*6? (Unreported) and one sample who was 
heterozygote for NA T2*5UINA T2*5? (Unreported) .  Three new variants were 
confi rmed us ing DNA sequencing with repetitions. These variants have been 
checked in d ifferent databases l ike Ensembl , ExAC and GlaxC database and were 
found that they were not reported before. The new variants were "51 0T>C, 775A>C 
and 733A>C".  They were presented as heterozygote in NA T2*5 and NA T2*6 
clusters and related to nucleotides changes in the protein  coding regone. 
4.4.2 .2  Caffe i ne Metabol ites Ratio and NAT2 Phenotype Status 
Since other studies had used (AFMU/1 MX) molar rat io, in this study, we 
used s imi lar  measures of calculat ion and comparison. Caffeine phenotype 
categories were defined as slow, intermediate or rapid activators based on the 
d istribution of these values with cut points at 0 .5  and 2 (see aforementioned Table 
1 0) (Grant OM et a l  1 984 and Woolhouse N et al  1 997). 
The rat io of AFMU/1 MX was calcu lated to determine the phenotype status of 
NAT2 activity in  each subject. Out of 576 subjects ,  555 showed posit ive resu lts 
whereas the data from the remain ing 21 were missing. From those 555 subjects, 
436 (78.5%) were slow acetylators for NAT2 activity " ratio < 0 .5" , 1 06 ( 1 9 . 1 %) were 
intermediate "ratio between 0 .5  _2" and 1 3  (2.4%) subjects were rapid acetylators for 
th is enzyme " ratio > 2" (Table 25) .  
Table 25:  The classification a nd the results of the acetylator status of NAT2 activity 
and its sub-classificat ion based on (AFMU/1 MX) ratio 
AFM U/1 MX ratio Acetylator status No. of subjects Percentage 
0 - 0. 5  S low NAT2 acetylator 436 78.5% 
0. 5-2 
2- above 
I nte rmediate NA T2 acetylator 
Rapid NA T2 acetylator 
1 06 
1 3  
1 14 
1 9. 1 %  
2 .4% 
The frequency d istribution h istogram of ur inary AFMU/1 MX molar 
concentration ratio for 555 UAE nationals was non-normally d istributed (Median = 
0 .2535,  Skewness = 3.633 with Std error = 0. 1 04, Kurtosis = 1 8 .4 1 8  with Std error = 
0.207) (F igure 35) .  
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Figure 35: The d istri bution of subjects based on NA T2 activity (AMFU/1 MX) ratio 
There was a clear evidence of a bi-modal d istribution of AFMU/1 MX ratio 
with an  apparent anti-mode in  the reg ion of 0.5.  The mode corresponding to the 
slow acetylator phenotype was un iformly d istributed and was assumed to be made 
up of ind iv iduals who possess various combinations of several d iffe rent a l leles, 
known to determ ine s low acetylation. 
The mode corresponding to the rapid acetylator phenotype was not un iform ly 
d istributed and is assumed to include both heterozygous and homozygous rapid 
acety lators. The frequency d istribution h istogram suggests the possible existence of 
a second anti-mode (in the region of 2) that separates the heterozygous and 
homozygous rapid acetylators. 
Table 26 and figu re 36 shows the acetylation capacity of the 25 subgroups 
assigned to NAT2 a l lele combinations. The NA T2*6A/*6A, NA T2*6A1*7B, 
1 1 5  
NA T2*7BI"7B, NA T2*5A/*5B and  NA T2*5A/*5A genotypes showed sign ificantly the 
lowest median values 0 .006, 0 .01 8, 0 .029 , 0 .095 and 0. 1 32 respectively. N ine 
different genotypes associated with rapid acetylation and sixteen with slow 
acetylation ,  the most common genotypes found were NA T2*5B/*7B heterozygotes, 
NA T2* 5BI*6A heterozygotes , NA T2*7B/*14B heterozygotes and NA T2*4/*5B 
heterozygotes with frequencies of 0 .255,  0 . 1 35 ,  0. 1 05 and 0 .09, respectively. 
Table 26: AFMU/1 X molar ratios in  subgroups assigned to NAT2 al lele combinations 
Phenotype N AT2 al leles or 
pos ib le al lele 
combination 
Rapid *4/*4 
Intemlediate *4/* 5A 
low 






*4/* 1 4A 
* 5A/* 5A 
*5A/* 5B  
5A/*7B 
* 5A/* 1 4A 
* 5 B/* 5B  
* 5 B/* 5C 
* 5 B/*6A 
* 5 B/* 7B 
* 5 B/* 1 4B 
*6A/*6A 
*6A/* 7B 
*6A/* 1 4B 
* 7B/* 7B 
* 7 B/* 1 4A 
* 7 B/* 1 4B 
* 1 4A/* 1 4B 
Total 
N Median 
1 3  2 . 5430 
4 0 .5788 
52  0 .7955 
6 0 .9055 
1 0  0 .8665 
1 8  0 . 8435 
4 1 .6562 
7 0 .7326 
5 0 . 7645 
2 0 . 1 323 
9 0 .0956 
24 0.2670 
4 0 .4 1 5 1  
1 7  0 .2455 
3 0 .2422 
78 0 .2058 
1 49 0 .2 1 52 
1 6  0 .3586 
4 0 .006 1 
34 0 .0 1 88 
5 0 . 3 803 
1 4  0.0298 
9 0 .2453 
6 1  0 . 336 1  
7 0 .2037 
555  
Min imum Maximum 
2 .0634 
0.5249 
0 . 5200 
0.6 1 02 




0 . 5382 
0 . 1 2 1 0  
0.028 1 
0 .0979 
0.08 1 5  
0 .0087 
0 . 1 32 1  
0 .0 1 46 
0 .0 1 20 




0 .005 1 
0 . 1 726 
0 .0 1 34 
0 .0 1 47 
4 .332 1 
0 .7992 
1 . 8045 
1 .6078 
1 . 7049 
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0 .5269 
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Figure 36: Comparison of NAT2 phenotype and genotype i n  555 subjects. It 
i l lustrates the acetylat ion capacity of the 25 subgroups assigned to NAT2 al lele 
com binations .  Those who are homozygotes for NAT2*4 al leles show the h ighest 
AFMU/1 MX ratios, those who a re heterozygotes for NAT2*4 al lele show intermediate 
AFMU/1 MX ratios and those who are homozygotes or heterozygotes for the derived 
al le les show the s lowest AFMU/1 MX ratios 
The result ing urinary AFMU/1 X ratios and genotypic assignments of slow 
(SIS homozygotes) ,  intermediate (RIS heterozygotes) and rapid acetylators (RIR 
homozygotes) are presented in  Table 27. Us ing Kruskal-Wal l is test, the mean rank 
of these groups were 2 1 7 .8 ,  487 . 2  and 549 respectively ,  which represented strong 
association between NAT2 genotype and phenotype (X2 = 282.01 , df = 2 and P 
value < 0 . 000 1 ; 95% C I  of differences) .  
Table 27 :  AFMU/1 X ratios vs. genotypes, based on the last update of NAT 
nomenclature scheme publ ished by The Ary lamine N-acetyltransferase Gene 
Nomenclature Committee accord ing to consensus gu ide l ines (Hein OW et al 2008). 
Genotypic acetylator state: SIS homozygously s low, RIS heterozygotes ,  RlR 
homozygously rapid 
SIS RlS RlR 
homozygotes heterozygotes homozygotes 
N 436 1 06 1 3  
Mean 0 .25 0.89 2 . 76 
S O  0 . 1 6  0 .35 2.62 
Median 0 .22 0.79 2 .54 
Range 0 . 53 1 .28 2 .27 
M in imum 0 .01  0 . 52 2 .06 
Max imum 0 .53 1 .8 4.33 
1 1 7  
SIS homozygotes slow acetylators, RlS heterozygotes = i ntermediate 
acetylators, R/R homozygotes = rapid acetylators 
I n  th is study, the phenotype status of NAT2 activity in the Emirati population 
shows the h ighest frequency of poor metabol izers with 78 .5% s low phenotype whi le 
the percentage i n  other popu lations such as Americans,  Turkish,  Egyptians and 
Saudi Arabians were 58 . 1  %,  57 .4%,  60. 5% and 72.3% respectively (Figure 37) 
(Hamdy et al 2003, Ojordjevic N et al  201 2) .  
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Figure 37:  The frequency NAT2 poor metabolizers among Emiratis in  comparison 
with other populat ions, n = sample size , Emiratis (n = 576), Americans (n = 255) ,  
Turkish (n  = 1 1 3) ,  Egyptians (n = 200) ,  Saudi Arabians (n = 200) 
The degree of phenotype/genotype concordance was ca lcu lated by 
measuring the agreement between the genotype and phenotype methods based on 
the traditiona l  phenotype classification ( i .e .  rapid/slow phenotypes) ,  where non 
conta in ing a l le le 4 genotypes, are considered to be a slow phenotype, and was 
equal  to 96.2%.  
NA T2 a n d  Deg ree of  Parent's Relationsh ip  
Out of  446 subjects "homozygote or  heterozygote for the mutant a l leles", 1 4 1 
(31 .6%) subjects were chi ldren of th i rd degree re latives, 84 ( 1 8. 8%) subjects had 
parents from the same tribe and 221 (49. 5%) subjects were not related. On the 
other hand,  out of 1 30 subjects of the "homozygote or heterozygote for the wild type 
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al le le" ,  44 (33.8%) subjects were chi ldren of third degree relatives, 2 1  ( 1 6.2%) 
subjects had parents were from the same tribe and 65 (50%) subjects were not 
related (Pearson Ch i-Square = 0 .567 ,  degree of freedom (df) = 2 and P value = 
0 .753 ;  95% CI  of d ifferences) which was more than 0 .05 representing a weak 
evidence of a relat ionship or association between genotype and degree of 
relationship .  There was no s ignificant correlation between degree of relationship and 
genotypes with corre lat ion coefficient 0 .0 1 4 value (P value = 0 .729;  95% CI  of 
differences using Spearman's  rho statistical test) .  
In addit ion ,  i t  was found that 78. 1 % of the subjects from those whose parents 
were relatives were homozygote or heterozygote for the mutant a l le les whereas, 
77 .4% from those whose parents were not re latives were homozygote or 
heterozygote for the wild type al le le with OR = 1 . 04 1 , relative risk for those whose 
parents were relatives was 1 .02 and relative risk for those whose parents were not 
relatives was 0 .98 (X2 = 0 .040, df = 1 and P value = 0 .84 1 ; 95% CI  of d ifferences) .  
Us ing Kruskal-Wa l l is  Test, out 576 subjects ,  1 85 subjects were classified as 
chi ldren with th i rd degree relat ionship,  1 05 subjects were classified as relatives from 
the same tribe and 286 subjects with no relationship. There was no d ifference in the 
Mean Rank between the 3 g roups which represented no effect on the NA T2 
genotype (X2 = 0. 566, df = 2 and P value = 0 .753;  95% CI  of d ifferences) .  
NAT2 and " Medical  I l l ness" 
To determ ine whether  medical i l lness was corre lated with genotypes, we 
found out of 57 cases, 40 (70.2%) who had medical i l lness were from those who 
were homozygote or heterozygote for the mutant a l leles compared to 1 7  (29.8%) 
from those who were homozygote or heterozygote for the wild type a l le le (L ikel ihood 
Ratio = 7 . 488, degree of freedom (df) = 1 0  and P value = 0.679; 95% CI of 
differences) which was more than 0 .05 representing a weak evidence of a 
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re latIonsh ip or association between genotype and medical i l lness. There was no 
sIgn Ificant corre lat ion between medical i l l ness and genotypes with correlation 
coefficient of 0 .007 (P value = 0 .957;  95% CI  of d ifferences using Spearman's rho 
statIstical test). 
Out of 446 subjects " homozygote or heterozygote for the mutant a l leles" , 40 
(8 .93%) subjects had medical i l lness compared to 406 (91 .07%) subjects were with 
no medical i l l ness. Out of 1 30 subjects "homozygote or heterozygote for the wild 
type a l le le" 1 7  ( 1 3 .28%) subjects were having medical i l l ness compared to 1 1 3 
(86 .72%) who had no medical i l lness with OR = 0.64, re lative risk for those with 
medical i l lness 0.672 and relative risk for those with no medical i l lness 1 .05 (X2 = 
2. 1 1 5 , df = 1 and P value = 0 . 1 46; 95% CI  of differences) .  
Us ing Kruskal-Wal l is  Test, i t  was found that there were no d ifferences in  the 
mean rank between the groups which represented no effect of NAT2 genotype on 
PMH (X2 = 4.909, df = 1 0  and P value = 0 .897; 95% C I  of d ifferences). 
NA T2 a n d  Drug Sensitiv i ty 
With regard to d rug sensitivity , it was found that out of 2 1  cases 1 7  (81 %) 
who had drug sensitivity were from those who were homozygote or heterozygote for 
the m utant a l le les compared to 4 ( 1 9%) from those who were homozygote or 
heterozygote for the wi ld type a l le le (Likel ihood Ratio = 1 .840, degree of freedom 
(df) = 3 and P value = 0.606;  95% CI of d ifferences) which was more than 0.05 
representing a weak  evidence of a re lationship or association between NA T2 
genotype and drug sensit ivity. There was no s ignificant correlation between drug 
sensit ivity and genotypes with corre lation coefficient of 0 .022 (P value = 0 .925; 95% 
CI of differences using Spearman's rho statistical test) . 
1 20 
Out of 446 subjects "homozygote or heterozygote for the mutant a l leles" , 1 7  
(3 79%) subjects had drug sensitivity compared to 431 (96 .21  %) subjects with no 
drug sensit ivity. Out of 1 28 subjects "homozygote or heterozygote for the wild type 
a l lele" 4 (3 . 1 3%) subjects were having drug sensitivity compared to 1 24 (96.88%) 
who had no drug sensitivity with OR = 1 . 223, relative risk for those with drug 
sensit ivity 1 .2 1 4  and re lative risk for those with no drug sensitivity 0 .993 (Like l ihood 
ratio = 0 . 1 32 ,  df = 1 and P value = 0 .7 1 7 ; 95% CI of differences) .  
Us ing Kruskal-Wal l is  Test , i t  was found that no d ifferences in the Mean Rank 
between the g roups which represented no effect of NA T2 genotype on the Drug 
sensitivity (X2 = 1 .658, df = 3 and P value = 0.646 ; 95% CI of differences) .  
NA T2 and Genotype d istribution with in  the UAE Emirates 
Out of the 446 subjects who were homozygote or heterozygote for the 
mutant a l le les 2 1 0  (46. 69%) were from AD emirate, 90 subjects (20.09%) were from 
Dubai emi rate and 1 46 (33. 04%) were from Northern Emirates with no significant 
statistica l  d ifference between the cities (X2 = 2 .247, df = 2 and P value = 0 .325;  
95% C I  of differences) .  
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Chapter 5 :  Discussions 
This study of 576 subjects of Emiratis is considered to be the first complete 
and comprehensive report on C YP1A2 and NA T2 phenotyping and genotyping on 
UAE populat ion in which a l l  known or common mutations or polymorph isms of these 
genes have been fu l ly  and thoroughly tested using H PLC and TaqMan Real Time 
PCR techniques for C YP1A2 gene and HPLC,  PCR-RFLP techniques and DNA 
sequencing for NA T2 gene. 
The d istri bution of samples were based on the d istribution of population 
between emirates wh ich was again based on the data provided by UAE National 
Bureau of Statistics of Emiratis which represented proper sample d istribution a l l  over 
UAE . 
I n  the past, acetylator phenotypes were determined using different 
substances. Traditional ly ,  ison iazid has often been used for acetylator phenotype 
determ inat ion. However, ison iazid undergoes complex metabol ism and requires 
serial blood sampl ing and wou ld not be convenient to use as a screening too l .  Other 
substances contain ing su lfonamide l ike su lfad imid ine ,  su lfapyrid ine,  su lfasalazine or 
su lfamethazine ,  and based on the classical Bratton-Marshal l  procedures, which 
involve the admin istration of a s ing le oral dose and col lection of multiple samples or 
a s ing le sample of serum or u rine,  have been used as wel l .  Dapsone has a lso been 
used with a s ing le sample of plasma being col lected 2-72 hours after administration. 
The ratio of N-acety lprocainam ide to proca inamide in plasma has been used to 
determ ine acetylator phenotype . In the present study,  caffe ine was used because it 
is u biquitous and present in popular d ri nks l ike co las, coffees and teas and can be 
used in school going chi ldren .  It is a lso easier to co l lect urine samples than blood 
samples.  I n  th is  study, u rine samples were col lected two hours after a d rink  of cola 
or coffee. 
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5 . 1  C YP1A2 
The variabi l ity in  l iver expression of the C YP1A2 gene reached almost 40% 
and 60% variabi l ity in caffeine metabol ism;  the most often used probe drug for 
C YP1A2 (Gunes A and Dahl ML .  2008) .  Only few variants explain the phenotypic 
variabi l ity in C YP1A2 gene expression, contra ri ly ,  it was much more with other drug­
metabol izi ng CYPs (Ghotbi R et a l  2007) .  Ghotbi R et a l  in  2007 observed a very 
low frequency of the coding sequence variants in White and Asian populations 
(Ghotbi R et a l  2007) .  Browning et a l  in  201 0  examined CYP1A2 variation in 
Eth iopians,  suggested that because of the overal l  g reater incidence of variation 
there could be some indiv iduals freed from any CYP 1 A2 activity in that population 
(Browning SL et a l  20 1 0) .  
General ly ,  i t  has  been d iscussed previously that the exact posit ioning of the 
cut-off point (anti mode) between phenotypical ly slow and rapid activities seems 
laboratory-dependent and attributed to differences in chromatographic condit ions 
(Bolt HM et a l  2005). In this particu lar  population sample, the frequency d istribution 
of the ( 1 7MX + 1 7MU)/1 37MX ratio is clear trimodal .  
C YP1 A2*1  A has been the reference (or  "wi ld type") a l lele for the respective 
gene that associated with rapid phenotype status .  The other variant a l le les have 
been class ified from this by one or more s ingle nucleotide polymorph isms (SNPs) .  
Based on many studies i n  many ethnic groups, a l le le *1  A was the most common 
al le le (Zhou SF et a l  2009b, Browning SL et al  201 0) .  Mutant a l leles CYP1A2*1C 
"G-3860A (rs206951 4)" , C YP1A2* 1 K  "T-739G (rs2069526), C-729T (rs 1 272046 1 )  
and C-1 63A ( rs762551 )" ,  C YP1A2*3 "21 1 6G>A and 5347T>C (rs56276455)", 
C YP1A2*4 "2499A>T (rs725475 1 6)" and C YP1A2*6 "5090C>T (rs28399424)" had 
low catalytic activ ity associated with the s low phenotype (Zhou SF et al 2009a, 
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Brown ing SL e t  a l  201 0) and  were less common than the wild type al lele (Cheval ier 
o et al  200 1 , Zhou H et a l  2004) .  
C YP1 A 2  genotypes have been classified into three d ifferent phenotypes: 
"slow" (two s low a l le les) ,  " intermediate" (1 slow and 1 rapid al le le) ,  and "rapid" (2 
rapid a l le les) . In our study we found that 1 .4% of our subjects were homozygote for 
mutant a l le les ,  1 6. 1  % were heterozygote and 82.5% were homozygote for the wild 
type a l le le .  
As a matter of  fact, some reports suggest that many influential factors may 
play an impo rtant role in  corre lating C YP1 A2 genotype to CYP 1 A2 phenotype. For 
instance, the drugs which cause induction or inh ibition of CYP 1 A2 enzyme may 
affect the corre lat ion between C YP1 A2 genotype and phenotype. Simi larly, the 
environmental factors such as  cigarette smoking can affect CYP 1 A2 enzymatic 
activity as wel l .  With regard to our study, all of the participants were non-smokers 
and the majority of them were aged between 1 6- 1 9 years of age. Additional ly ,  90% 
of them were with no medical i l lness and not on any concomitant drugs. Thus, we 
found the h igh degree of concordance between phenotype and genotypes of 
C YP1A2 gene.  I nterest ingly ,  we found that those with mutant a l leles have shown 
s low phenotype status.  Furthermore, those who were homozygote for al leles 
C YP1A 2 * 1 C  and C YP1A2*3 were associated with the slowest enzyme activity. 
Hence,  when Hardy-Weinberg equation was appl ied ,  the apparent numbers 
of homozygous and heterozygous slow activity were not in strict accordance with the 
Hardy-Weinberg equ i l ibr ium which is a clear ind ication that individual genotypes 
cannot be pred icted. For a l le le C YP1A2*1 C  the result was inconsistent with Hardy­
Weinberg Equi l ibrium which may be due to an unexpectedly large number of 
C YP1 A2*1  C homozygotes. For a l le le C YP1 A2*1  K the result was consistent with 
Hardy-Weinberg Equi l ibrium.  This finding may be due to the evolutionary influences, 
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l i ke mate choice,  mutation ,  select ion, genetic d rift, gene flow and meiotic drive as 
one or more of these i nfluences are typica l ly present in real populations. The level of 
consangu in ity in  the UAE is  very h igh with more than 50% of marriages being 
consangu ineous. I ndeed, about 50% of the sample g roup reported consanguin ity of 
their parents. This clearly influences the genotype frequencies and their deviation 
from Hardy-Weinberg . 
Our study samples included few numbers with PMH and drug sensitivity and 
when tested for their re lation and effect on genotype we found few significant 
association .  Although ,  we found a clear associated of CYP1 A2 polymorphism and 
epi lepsy with strong statistical evidence of correlation compared to wild type carriers 
however, the low numbe r  of our subjects with epi lepsy could be a concern and the 
need for another study in  this regard is important . 
Nevertheless,  we found the results were statist ical ly sign ificant and 
d ifferences have been found between cities in regards to genotype and a l leles 
d istribution between Emirates .  We found C YP1A2 polymorphisms in  AD and Dubai 
Emi rates whereas they were absent in  Northern Emirates. 
5.2 NA T2 
I n  th is study, we use the ratio of AFMU/1 MX to determine the acetylat ion 
status or NA T2 activity. Phenotypica l ly ,  the d ifferences in NAT2 activity (as 
measured by AFMU/1 MX ratio) between variable populations have been 
documented and it was markedly h igh in Koreans compared to Swedes, and this 
may be due to a h igher  proport ion of the NA T2*4 rapid a l le le in  Koreans and the 
higher frequency of s low acety lator genotype in  Swedes ( Djordjevic N et a l  201 2) .  I n  
other  studies,  58. 1 % of Americans,  57 .4% of Turkish, 60. 50% of Egyptians and 
72 .3% of Saudi  Arabians were of s low acetylator phenotype. In our study, NAT2 
activ ity showed a h igh percentage of slow acetylators (78.5%) .  
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General ly ,  i t  has been d iscussed previously that the exact posit ioning of the 
cut-off point (antimode) between phenotypica l ly slow and rapid acetylators seems 
laboratory-dependent and attributed to d ifferences in chromatographic conditions 
(Bolt HM et a l  2005). In this part icu lar population sample, the frequency distribution 
of the AFMU/1 MX ratio is clearly trimodal .  
Some studies have reported good corre lation between acetylator phenotype 
measured by caffeine metabol ite ratio and NA T2 genotype (Jetter A et al  2004, Rihs 
HP et a l  2007);  contrari ly  other studies have showed no correlation (Cascorbi I et a l  
1 995,  O'Nei l  WM et a l  1 997 ,  Zhao B et al  2000, Wolkenste in P et a l  2000, Bol t  HM 
et a l  2005, Ojordjevic N et a l  201 1 ) . I n  our study we found a strong statistical 
evidence of corre lat ion between acetylation-phenotypes and genotypes of NA T2 
gene. 
The high overa l l  degree of concordance between NA T2 genotype and 
phenotype thus confi rms the val id ity of genotyping tests to predict NAT2 phenotypes 
with in  the UAE population .  Genotyping offers several advantages over phenotyping 
methods; it is a s imple and a re l iable procedure, obviating the need for the use of 
probe drugs and is not subject to physiolog ica l ly  or patholog ical ly determined 
variat ion .  In this part icu lar population sample,  the frequency d istribution of the 
AFMU/1 MX ratio is clear trimodal s ince those who were identified as NA T2*4/*4 
(wi ld type) homozygotes, proved to have the highest ratios. Those who were 
heterozygotes proved to have intermediate ratios and those who were homozygotes 
for the mutant al le les proved to have the slowest ratios thus provid ing a strong 
evidence of gene dosage effect. 
Studies on NAT2 are obstructed by issues with unclear haplotype 
assig nment as unphased genotypes of the NAT2 gene SNPs resulted in more than 
one possible haplotype pair particularly if more than one of these SNPs is 
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heterozygous.  Because of  th is ,  PHASE v2. 1 . 1 program was used to enable a rapid 
and accurate haplotype predict ion .  However, h igher precision of the estimates and 
more unam biguous information may be obtained by increasing the sample size 
(Aqundez JA et al 2008 and Sel inski  S et al 201 3a) .  
NA T2 i s  a polymorphic gene with a round 1 1 0 NA T2 al leles being assigned 
offic ia l  symbols by the Arylamine N-acetyltransferase Gene Nomenclature 
Committee, accord ing to consensus gu idel ines (Hein OW et al 2008). Based on 
many studies in  many ethnic groups, haplotype NA T2*4 carries the wild type a l le le 
at a l l  the variable sites (polymorph isms) reported in  the NA T2 l iterature that 
associated with rapid acetylator phenotype and is not the most common a l lele (Hein 
OW et a l  1 994, Hein et a l  1 995,  O'Nei l  WM et al  2000) .  Mutant a l lele at positions 
1 9 1 ,  34 1 ,  560 and 857 that represent mutant a l lele NA T2* 1 4, NA T2*5, NA T2*6 and 
NA T2*7 respectively ,  have low catalyt ic activ ity associated with the s low acetylator 
phenotype and are more common than the wild type a l le le (NA T2*4) (Hein OW et al 
1 994 , Hein et al 1 995 ,  O'Nei l  WM et al  2000) .  I n  our study, the frequency of the wi ld 
type a l le le (NA T2*4) among Emiratis was markedly low (0. 1 34) which is s imi lar  to 
many ethn ic  populat ions including Caucasians,  Egyptians,  Omanis ,  Saudi Arabians, 
I nd ians and Moroccans.  However, it is markedly considerably lower in  comparison 
to Asians and H ispanics. 
The NA T2 gene has a h igh frequency of functional variat ion, d istinguishing 
among st populat ions that are ethn ical ly d ifferent, and has high levels of haplotype 
variat ion (Pat in E et al 2006a, Mortensen HM et al  201 1 ) . The d istribution of 
polymorph isms in our studied population showed h igh percentage of those with 
m utant a l le les either homozygote or heterozygote (77.4%) . 
NA T2 genotypes have been classified into three d ifferent phenotypes: "slow 
acetylator" (two s low al le les) ,  " intermediate acetylator" ( 1  slow and 1 rapid a l le le) ,  
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and "rapid acetylator" (2 rapid al leles) (Stanley LA and Sim E 2008). Some papers 
used to report rapid as any genotype conta in ing a l le le NA T2*4 and slow as any non­
carriers of allele NA T2*4 acety lators (Soej ima M et al  2007) .  In addit ion, within the 
slow acetylator genotype group there is heterogeneity in  phenotype due to variation 
in  enzyme activity conferred by d ifferent a l leles (Hein OW et a l  1 995, Cascorbi I et al 
1 999, He in  OW 2009, Ru iz JO et al 201 2) which may affect the abi l ity to identify 
s ign ificant associations (Sel inski  S et al 201 3b) .  
Cartwright RA et a l  ( 1 982) d ivided the ratio that was used to measure the 
phenotype status into 4 g roups, (0 .3  and greater) corresponded to rapid acetylators, 
and the other three (0 .01 -0 .09;  0. 1 -0. 1 9; and 0 .2-0.29) corresponded to different 
leve ls  of s low acetylator phenotype. Urinary bladder cancer risk was markedly 
e levated as NAT2 phenotype reduced, part icular ly with the slowest NAT2 phenotype 
(Cartwright RA et al 1 982) .  S imi lar  conclusion has been reported by d ifferent studies 
(Brockmol ler J et a l 1 996, Okkels H et a l 1 997, F i l iadis IF et a I 1 999). 
I nterest ingly ,  we observed that the NA T2*6A/*6A , NA T2*6A1*7B, 
NA T2*7BI*7B, NA T2*5A1*5B and NA T2*5A1*5A genotypes were having the lowest 
enzyme activity, respectively. This resu lt was supported by Sel i nski et al 201 3b who 
identified the u ltra-slow genotypes. This 'u ltra-slow' genotype is defined by a 
combination of NA T2*6A1*6A, NA T2*6A1*7B, NA T2*7B/*7B haplotype pairs (Ru iz JO 
et  a l  20 1 2, Se l insk i  et  a l  201 3b).  Th is  provided a clear picture that NA T2 slow 
acetylator phenotype was not homogeneous, but rather mu lt iple s low acetylator 
phenotypes that exist result ing from different SNPs and mechanisms. 
I n  addition ,  a lot of the therapeutic agents have been found to be 
polymorphical ly acetylated in humans due to the genetic polymorphism in N­
acetyltransferase activity l i ke hydralazine,  phenelzine, phenylenediamine, 
su lphamethazine ,  isoniazid , su lphasalazine, amonafide, endralazine, procainamide, 
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a number  of su lphonamides, n itrazepam and dapsone. Although , the possibi l ity of 
fa i led or less effective c l in ical response as a result of acetylation polyphorphism is 
very low because of the wide therapeutic window of the drugs as acetylation is a 
minor metabol ic pathway (Yamasaki Y et al 2008, Ma JJ et a l  2009) (Kuhn UO et a l  
20 1 0) .  In  another study on Japanese patients who were treated with co-trimoxazole 
found indiv iduals to have h igher risk of adverse events with slow acety lator status 
(NA T2 genotypes *6A1*6A, *6A/*78, *781*78) compared to rapid acetylators (NA T2 
genotypes *41*4, *41*58, *41*5E, *4/*6A, *4/*78) (Soej ima M et a l  2007) .  
NA T2 al le les conta in ing the 1 9 1 G>A (rs 1 80 1 279), 34 1 T>C (rs 1 801 280), 
590G>A (rs 1 799930), and/or 857G>A (rs 1 799931 )  m issense substitutions are 
associated with s low acetylator phenotypes. Striking ethn ic d ifferences in  the 
frequencies of these missense substitutions (Grant OM et a l  1 997) play an important 
role in  ethn ic  differences in  frequency of s low acetylator a l leles and phenotypes 
(Cascorbi I and Roots I 1 999). For example, the 1 9 1  G>A substitution commonly 
represents the NA T2* 1 4  gene cluster that is avai lable in  greater extent in  African 
Americans and native Africans,  but it is virtual ly absent in  Caucasian populat ions. 
In our study, the most common mutation associated with slow acetylation 
(34 1 T>C) occurs with a s ign ificantly h igher frequency (0 .364) than other mutant 
variants and it was s imi lar  to what had been reported in  other ethnic groups. 
Moroccan ,  Egyptian ,  Spanish , Omani ,  Saudi Arabian,  American and German 
populat ions reported h igh frequencies of a l lele NA T2*5 between (42% - 53%), 
whereas Argent ine,  African ,  I nd ian ,  Senegalese, Tunis ian and Southern Brazil 
populat ions reported (28% - 37%). However, it was at a very low frequency in  Asian 
populat ions « 7%) (Meyer U and Zanger U 1 997, Guaoua S et a I 201 4). 
I nd ian popu lation reported the hig hest frequency of a l lele NA T2*6 (38%) 
whereas ,  German ,  Omani ,  American,  Egyptian ,  Argentina,  Moroccan, Spanish, 
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Japanese and Southern Korean populations have frequencies ranging between 22% 
- 28 .5%.  However, in  Senegalese, Tunisian ,  African and Southern Brazil populations 
it was at a very low frequency ( 1 0% - 1 8%) (Meyer U and Zanger U 1 997, Guaoua S 
et a l  201 4) .  
In  regard to a l le le NA T2*7 the frequency was the h ighest in Tunisian and 
Southern Korean populations 1 5% and 1 3 .2%,  respectively. However, it marked ly 
decl ined with Argent ine ,  African ,  Omani ,  I ndian , Egypt ian,  Southern Brazil and 
Moroccan populat ions to (2% - 8%), a lthough it was found to be negl igible in 
American ,  German ,  Japanese, Spanish and Senegalese populations « 1  %) (Meyer 
U and Zanger U 1 997, Guaoua S et aI 20 1 4) .  
African ,  Senegalese, Tunis ian and  Moroccan populations reported the 
h ighest frequency of a l le le NA T2* 1 4  between (4% - 1 0 . 3%) where it was found to be 
at low level with other populat ions « 2%) (Meyer U and Zanger U 1 997, Guaoua S 
et a l  20 1 4) .  
Moreover, in  one  of  our previous studies conducted by  Wool house e t  a l  
( 1 997) we had  determined the  polymorphic N-acetyltransferase (NA T2) genotypes 
in 1 06 unre lated Emiratis from Eastern reg ion of Abu Dhabi by PCR-RFLP analysis 
(Wool house et a l  1 997) .  We found more than 1 3  d ifferent genotypes , 4 associated 
with the rapid acetylator phenotype and 9 with the slow acetylator phenotype. The 
prevalence of s low acetylation a l leles were 8 1 .6%. In  our study, we reported 27 
d ifferent genotypes ,  9 associated with the rapid acetylator phenotype and 1 8  with 
the s low acetylator phenotypes and the prevalence of s low acetylation al leles were 
86.6%. The most common a l le le was NA T2*5. 
I nterest ingly ,  we were able to report the presence of 3 new variants 
"5 1 0T>C,  775A>C and 733A>C" that have been confirmed by DNA sequencing and 
were associated with slow acetylation activity. These nucleotide changes represent 
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new al le le NA T2*5 subtype and new al lele NA T2*6 subtype as fo l lowing:  NA T2*5 
new subtype : 282C>T, 34 1 T>C,  481 C>T, 590G>A, 803G>A, 775A>C and 733A>C 
variants and NA T2*6 sUbtype: contains 282C> T, 775A>C, 590G>A, 51 0T>C and 
803G>A variants. 
Hence ,  when Hardy-Weinberg equation was applied, the apparent numbers 
of homozygous and heterozygous slow acetylators were not in strict accordance 
with the Hardy-Weinberg equi l ibrium for a l lele NA T2*7 and NA T2*14 ,  which is a 
clear ind ication that indiv idual genotypes cannot be predicted,  a lthough ,  for a l lele 
NA T2*5 and NA T2*6 the result was consistent with Hardy-Weinberg Equi l ibrium.  
This find ing may be due to the evolut ionary influences, such as mate choice , 
mutation ,  select ion,  genetic drift , gene flow and meiotic d rive, since one or more of 
these influences are typica l ly present in rea l populations. The level of consanguin ity 
in the UAE is very h igh where more than 50% of marriages are consanguineous. 
I ndeed, about 50% of the sample g roup reported consanguin ity of their parents. This 
clearly infl uences the genotypes frequencies and their deviation from Hardy­
Weinberg . 
Our samples have represented few numbers of those with PMH and drug 
sens itivity and when they have been tested for their re lation and effect on genotype 
we found that the resu lts were not supported by statistical evidence. Nevertheless, 
we also found  the results were not statistical ly sig nificant and no d ifferences have 
been found  between cities in regard to genotype and al le les d istribution between the 
d ifferent Emirates. 
1 3 1  
Chapter 6 :  Conclusions 
6 . 1  C YP1A2 
The frequency of s low activity CYP 1 A2 enzyme al leles is very low among 
Emi ratis which correlates with the presence of low frequencies of mutant a l leles in 
C YP1A2 gene. The genotype frequency of the wild type a l lele is the h ighest in this 
population , fo l lowed by C YP1 A2*1 Al"1 C and CYP1 A2*1 A/*1 K genotypes, 
respectively .  
Those who are homozygote for a l leles CYP1A2*1 C and CYP1A2*3 might be 
at h igh risk of toxicity with some d rugs and some diseases as these a l leles are 
associated with the slowest phenotype status. Consequently, genetic testing is 
recommended pr ior to prescrib ing medications that are largely metabol ized by 
CYP 1 A2 .  
6 . 2  NA T2 
There is a h igh percentage of s low acetylators among Emiratis which 
correlates with the presence of high frequencies of mutant a l leles in  NA T2 gene. 
The genotype frequency of the a l lele NA T2*5 was the h ighest in this population. 
Moreover, the genotype frequency of NA T2*58/*78, NA T2*58/*6A, NA T2*781*1 48 
and NA T2*41*58 were the h ighest in th is population. 
I ndividuals who carried NAT2*6AJ*6A, NAT2*6AJ*7B,  NAT2*7B/*7B, 
NAT2*5AJ*5B or NAT2*5AJ*5A genotypes mig ht be at h igher r isk of toxicity with 
drugs and some d iseases compared to others as these genotypes are associated 
with the slowest acetylat ion status. Conseq uently, genetic testi ng is recommended 
prior to prescribing medications that are largely metabolized by NAT2. 
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Appendix 8 :  Data col lection form 
Acetylation Phenotyp ing  and Genotyp ing  Study 
Name:  10 no :  --------------------------------------- -----------
Nationa l ity: 
Are father and mother re lated? LJ LJ  
I f  the answer to above is yes what is the re lation? 
1 .  Father's father and mother's father are brothers .  
2 .  Father's father and mother's mother are brother and sister. 
3 .  Father's father and mother's mother are sisters. 
4 .  Father's father and mother's father are sister and brother. 
5 .  Father's father and mother's grandfather are brothers. 
6. Father's father and mother's grandmother are brother and sister. 
7 .  Father's father a n d  mother's g randmother are sisters. 
8 .  Father's father and mother's grandfather are sister and brother. 
9 .  Other close relation -----------------------
1 0. Same tribe 
Emi rate 
Age Sex EJ I Female I 
Smoker 
1 65 
Append ix  8 :  Data col lection form- conti n ue 
Existence of any medical condit ion 
If  answer to above is yes ,  what is  (are) the medical condition (s)? 
Any mi ld ,  moderate or severe reaction to any drug? 
If the answer to the above q uestion is yes ,  what is the name of the drug? 
If the answer to the above q uestion is yes, what was the reaction that occurred? 
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